{"questions": [{"id": "5a75eb6483b0d9ea66000004", "body": "What is Blount's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31651748", "http://www.ncbi.nlm.nih.gov/pubmed/15481748", "http://www.ncbi.nlm.nih.gov/pubmed/34209445", "http://www.ncbi.nlm.nih.gov/pubmed/25932193", "http://www.ncbi.nlm.nih.gov/pubmed/27583129", "http://www.ncbi.nlm.nih.gov/pubmed/23610758", "http://www.ncbi.nlm.nih.gov/pubmed/30104937", "http://www.ncbi.nlm.nih.gov/pubmed/880738", "http://www.ncbi.nlm.nih.gov/pubmed/19370370", "http://www.ncbi.nlm.nih.gov/pubmed/7670990"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370", "text": "BACKGROUND Blount's disease is a multi-planar deformity affecting the pediatric population which leads to varus alignment of the lower extremities.", "offsetInBeginSection": 0, "offsetInEndSection": 147, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20609637", "text": "INTRODUCTION In stage\u00a01 of all currently accepted classifications for infantile tibia vara, the diagnosis is difficult between physiological bowing and true Blount's disease.", "offsetInBeginSection": 0, "offsetInEndSection": 175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25932193", "text": "Blount's disease is an uncommon disorder of postero-medial proximal tibial physis.", "offsetInBeginSection": 0, "offsetInEndSection": 82, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15481748", "text": "Blount's disease or congenital tibia vara is a clinical entity characterized by tibia bowing, tibia torsion, and beaking of the medial tibia metaphysis on plain radiograph.", "offsetInBeginSection": 0, "offsetInEndSection": 172, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27583129", "text": "Blount's disease is a progressive form of genu varum due to asymmetrical inhibition of the postero medial portion of the proximal tibial epiphysis.", "offsetInBeginSection": 0, "offsetInEndSection": 147, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12077670", "text": "This report is the first known case of SCFE associated with infantile Blount's disease.", "offsetInBeginSection": 328, "offsetInEndSection": 415, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8657465", "text": "In view of the spontaneous recovery of all investigated patients, it must be doubted whether a diagnosis of infantile tibia vara can be made in early infancy, and whether infantile Blount's disease is a diagnosis in its own right.", "offsetInBeginSection": 672, "offsetInEndSection": 902, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7670990", "text": "We postulate the hypothesis of the etiopathogenesis of the infantile type of Blount's disease as a disease related to a dysplastic linkage between epiphysis and metaphysis.", "offsetInBeginSection": 95, "offsetInEndSection": 267, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23610758", "text": "Infantile Blount's disease is a condition that causes genu varum and internal tibial torsion.", "offsetInBeginSection": 0, "offsetInEndSection": 93, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23610758", "text": "Treatment options include observation, orthotics, corrective osteotomy, elevation of the medial tibial plateau, resection of a physeal bar, lateral hemi-epiphysiodesis, and guided growth of the proximal tibial physis.", "offsetInBeginSection": 94, "offsetInEndSection": 311, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6a2dcab750ff4455000023", "body": "Which are the constitutive parts of a Genomic Regulatory Block (GRB)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19374772", "http://www.ncbi.nlm.nih.gov/pubmed/22666536", "http://www.ncbi.nlm.nih.gov/pubmed/19698106", "http://www.ncbi.nlm.nih.gov/pubmed/32421818", "http://www.ncbi.nlm.nih.gov/pubmed/21619633", "http://www.ncbi.nlm.nih.gov/pubmed/31616042", "http://www.ncbi.nlm.nih.gov/pubmed/11696597", "http://www.ncbi.nlm.nih.gov/pubmed/26830472", "http://www.ncbi.nlm.nih.gov/pubmed/22962458", "http://www.ncbi.nlm.nih.gov/pubmed/10961894"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22666536", "text": "The Sonic Hedgehog (Shh) genomic regulatory block (GRB) is one of the best functionally characterized examples, with several discrete enhancers reported within its introns, vast upstream gene-free region and neighboring genes (Lmbr1 and Rnf32).", "offsetInBeginSection": 192, "offsetInEndSection": 436, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144", "text": "We termed these chromosomal segments genomic regulatory blocks (GRBs).", "offsetInBeginSection": 916, "offsetInEndSection": 986, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144", "text": "Reporter insertions distal to zebrafish developmental regulatory genes pax6.1/2, rx3, id1, and fgf8 and miRNA genes mirn9-1 and mirn9-5 recapitulate the expression patterns of these genes even if located inside or beyond bystander genes, suggesting that the regulatory domain of a developmental regulatory gene can extend into and beyond adjacent transcriptional units.", "offsetInBeginSection": 546, "offsetInEndSection": 915, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144", "text": "Bystander genes are not specifically under the control of the regulatory elements that drive the target genes and are expressed in patterns that are different from those of the target genes.", "offsetInBeginSection": 355, "offsetInEndSection": 545, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19374772", "text": "BACKGROUND Genomic regulatory blocks (GRBs) are chromosomal regions spanned by highly conserved non-coding elements (HCNEs), most of which serve as regulatory inputs of one target gene in the region.", "offsetInBeginSection": 0, "offsetInEndSection": 199, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22962458", "text": "These elements are organized as large clusters, so-called gene regulatory blocks (GRBs) around key developmental genes.", "offsetInBeginSection": 315, "offsetInEndSection": 434, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21619633", "text": "They are therefore functionally related to a number of key protein coding developmental genes, that form genomic regulatory blocks (GRBs) with arrays of highly conserved non-coding elements (HCNEs) functioning as long-range enhancers that collaboratively regulate the expression of their target genes.", "offsetInBeginSection": 256, "offsetInEndSection": 557, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21619633", "text": "Furthermore these predictions include miRNAs of the miR-9 family, which are the only experimentally verified GRB target miRNAs.", "offsetInBeginSection": 1937, "offsetInEndSection": 2064, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22234889", "text": "Developmental genes are regulated by complex, distantly located cis-regulatory modules (CRMs), often forming genomic regulatory blocks (GRBs) that are conserved among vertebrates and among insects.", "offsetInBeginSection": 0, "offsetInEndSection": 197, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17989259", "text": "These arrays span key developmental regulatory genes, forming genomic regulatory blocks (GRBs).", "offsetInBeginSection": 286, "offsetInEndSection": 381, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a735cdc3b9d13c708000004", "body": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24025752", "http://www.ncbi.nlm.nih.gov/pubmed/29184043", "http://www.ncbi.nlm.nih.gov/pubmed/29046284", "http://www.ncbi.nlm.nih.gov/pubmed/33883402", "http://www.ncbi.nlm.nih.gov/pubmed/26506607", "http://www.ncbi.nlm.nih.gov/pubmed/11105172", "http://www.ncbi.nlm.nih.gov/pubmed/11105174", "http://www.ncbi.nlm.nih.gov/pubmed/5197001", "http://www.ncbi.nlm.nih.gov/pubmed/5723184", "http://www.ncbi.nlm.nih.gov/pubmed/26933069"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752", "text": "The objective of this study was to evaluate ocular tolerance, safety, and effect on intraocular pressure (IOP) of a topically administered small interfering RNA; SYL040012, on healthy volunteers.", "offsetInBeginSection": 0, "offsetInEndSection": 195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707", "text": "The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3).", "offsetInBeginSection": 582, "offsetInEndSection": 727, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28760727", "text": "RESULTS Recruitment for the first phase of this project commenced in November 2016, and the phase will run from February to November 2017.", "offsetInBeginSection": 2157, "offsetInEndSection": 2295, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28760727", "text": "TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12616001243404p; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371422 (Archived by WebCite at http://www.webcitation.org/ 6rmlEiM1L).", "offsetInBeginSection": 2590, "offsetInEndSection": 2823, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28493171", "text": "Atezolizumab, approved in May 2016, and nivolumab, approved in February 2017, are the first Food and Drug Administration (FDA)-approved immune-checkpoint inhibitors in bladder cancer for platinum-pretreated patients based on phase II data.", "offsetInBeginSection": 1282, "offsetInEndSection": 1521, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208", "text": "In November 2013, landiolol hydrochloride (Onoact(\u00ae) 50 for Injection, Ono Pharamaceutical, Osaka, Japan) was approved with the indication for \"tachyarrhythmia (AF/AFL) in patients with cardiac dysfunction.\"", "offsetInBeginSection": 309, "offsetInEndSection": 517, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17621880", "text": "A phase I/II clinical trial in CTCL and CBCL was recently completed, and in November 2006 Transgene initiated a phase II clinical trial in CBCL.", "offsetInBeginSection": 209, "offsetInEndSection": 353, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28671135", "text": "METHODS All HD clinical trials registered in the WHO International Clinical Trials Search Portal, from inception to May 2017, were analyzed.", "offsetInBeginSection": 488, "offsetInEndSection": 628, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12020052", "text": "Following a meeting with the FDA, La Jolla planned a phase III trial of abetimus and expected this to begin in the second half of 2000 [364916].", "offsetInBeginSection": 452, "offsetInEndSection": 596, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12020052", "text": "In September 2000, phase III trials were initiated [382931].", "offsetInBeginSection": 149, "offsetInEndSection": 209, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a777ab9faa1ab7d2e00000a", "body": "What is the drug target(s) for Belsomra?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32259095", "http://www.ncbi.nlm.nih.gov/pubmed/28279667", "http://www.ncbi.nlm.nih.gov/pubmed/27825624", "http://www.ncbi.nlm.nih.gov/pubmed/32473525", "http://www.ncbi.nlm.nih.gov/pubmed/25227290", "http://www.ncbi.nlm.nih.gov/pubmed/30552562", "http://www.ncbi.nlm.nih.gov/pubmed/26864332", "http://www.ncbi.nlm.nih.gov/pubmed/25336862", "http://www.ncbi.nlm.nih.gov/pubmed/18083776", "http://www.ncbi.nlm.nih.gov/pubmed/15283135"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25336862", "text": "Idelalisib (Zydelig) for certain types of leukemia and lymphoma, peginterferon beta-1a (Plegridy) for relapsing forms of multiple sclerosis, and suvorexant (Belsomra) for insomnia.", "offsetInBeginSection": 0, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419", "text": "Dual orexin receptor antagonists represent a new class of medications for the treatment of insomnia, which block the binding of wakefulness-promoting neuropeptides orexin A and orexin B to their respective receptor sites.", "offsetInBeginSection": 557, "offsetInEndSection": 778, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419", "text": "Suvorexant (Belsomra) is the first dual orexin receptor antagonist to be approved in the US and Japan and has demonstrated efficacy in decreasing time to sleep onset and increasing total sleep time.", "offsetInBeginSection": 779, "offsetInEndSection": 977, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419", "text": "Historically, insomnia has been treated with agents such as benzodiazepines, nonbenzodiazepine receptor agonists, and melatonin agonists.", "offsetInBeginSection": 419, "offsetInEndSection": 556, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419", "text": "Suvorexant is not likely to replace benzodiazepines or nonbenzodiazepine receptor antagonists as a first-line sleep agent but does represent a novel option for the treatment of patients with chronic insomnia.", "offsetInBeginSection": 1622, "offsetInEndSection": 1830, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27390287", "text": "Starting from suvorexant (trade name Belsomra), we successfully identified interesting templates leading to potent dual orexin receptor antagonists (DORAs) via a scaffold-hopping approach.", "offsetInBeginSection": 0, "offsetInEndSection": 188, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17883836", "text": "In the current study, based on the properties of known drug targets, we have developed a sequence-based drug target prediction method for fast identification of novel drug targets.", "offsetInBeginSection": 657, "offsetInEndSection": 837, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17883836", "text": "Identifying potential drug targets is the first step in the process of modern drug discovery for developing novel therapeutic agents.", "offsetInBeginSection": 193, "offsetInEndSection": 326, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17016423", "text": "What is a drug target?", "offsetInBeginSection": 0, "offsetInEndSection": 22, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23317822", "text": "In apicomplexan parasites, the apicoplast is a suitable target for established and novel drugs.", "offsetInBeginSection": 724, "offsetInEndSection": 819, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8861eb8cb19eca6b000001", "body": "List the two most important synaptic markers.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8269086", "http://www.ncbi.nlm.nih.gov/pubmed/22767246", "http://www.ncbi.nlm.nih.gov/pubmed/9700660", "http://www.ncbi.nlm.nih.gov/pubmed/9646253", "http://www.ncbi.nlm.nih.gov/pubmed/32147725", "http://www.ncbi.nlm.nih.gov/pubmed/10888735", "http://www.ncbi.nlm.nih.gov/pubmed/21074556", "http://www.ncbi.nlm.nih.gov/pubmed/22319471", "http://www.ncbi.nlm.nih.gov/pubmed/8783274", "http://www.ncbi.nlm.nih.gov/pubmed/7622570"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847", "text": "The protein and messenger RNA (mRNA) levels of 7 synaptic markers (complexin-1, complexin-2, synaptophysin, synaptobrevin, syntaxin, synaptosomal-associated protein 25 (SNAP-25), and septin-5) were compared in the brains of nondemented and demented individuals ranging from 70 to 103 years of age.", "offsetInBeginSection": 660, "offsetInEndSection": 957, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24205365", "text": "GluA2-containing AMPA receptors and their association with protein kinase M zeta (PKM\u03b6) and post-synaptic density-95 (PSD-95) are important for learning, memory and synaptic plasticity processes.", "offsetInBeginSection": 0, "offsetInEndSection": 196, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27906174", "text": "Alzheimer's disease (AD) is characterized by synaptic and neuronal loss, which occurs at least partially through oxidative stress induced by oligomeric amyloid-\u03b2 (A\u03b2)-peptide.", "offsetInBeginSection": 0, "offsetInEndSection": 177, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27906174", "text": "Histologically, CA increased dendritic and synaptic markers, and decreased astrogliosis, A\u03b2 plaque number, and phospho-tau staining in the hippocampus.", "offsetInBeginSection": 1180, "offsetInEndSection": 1332, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25755633", "text": "Synaptic failure and neurofibrillary degeneration are two major neuropathological substrates of cognitive dysfunction in Alzheimer's disease (AD).", "offsetInBeginSection": 0, "offsetInEndSection": 146, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22609570", "text": "Insulin-like growth factor-1 (IGF1) and its active peptide (1-3)IGF1 modulate brain growth and plasticity and are candidate molecules for treatment of brain disorders.", "offsetInBeginSection": 0, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7783952", "text": "Of these latter proteins, one is integral (synaptophysin) the other peripheral (synapsin I) to the synaptic vesicle membranes.", "offsetInBeginSection": 294, "offsetInEndSection": 420, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20540992", "text": "Orexin (Orx or hypocretin) is critically important for maintaining wakefulness, since in its absence, narcolepsy with cataplexy occurs.", "offsetInBeginSection": 0, "offsetInEndSection": 135, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20540992", "text": "None were immunostained for vesicular glutamate transporter 1 (VGluT1) or VGluT3 or for the vesicular transporter for GABA, vesicular GABA transporter (VGAT).", "offsetInBeginSection": 861, "offsetInEndSection": 1019, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20540992", "text": "A similar proportion of the large Orx+ varicosities contained synaptophysin (Syp), a presynaptic marker for synaptic vesicles.", "offsetInBeginSection": 1107, "offsetInEndSection": 1233, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a75ee7e83b0d9ea66000005", "body": "List symptoms of the Zieve's syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8819039", "http://www.ncbi.nlm.nih.gov/pubmed/464793", "http://www.ncbi.nlm.nih.gov/pubmed/7110955", "http://www.ncbi.nlm.nih.gov/pubmed/31620530", "http://www.ncbi.nlm.nih.gov/pubmed/11761804", "http://www.ncbi.nlm.nih.gov/pubmed/34158930", "http://www.ncbi.nlm.nih.gov/pubmed/1217221", "http://www.ncbi.nlm.nih.gov/pubmed/2616809", "http://www.ncbi.nlm.nih.gov/pubmed/871409", "http://www.ncbi.nlm.nih.gov/pubmed/8645520"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955", "text": "Zieve's syndrome therefore is not benign but precedes acute alcoholic hepatitis episodes on a normal, fibrotic or cirrhotic liver.", "offsetInBeginSection": 508, "offsetInEndSection": 638, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955", "text": "Zieve's syndrome, characterized by jaundice, hyperlipaemia and haemolytic anaemia, usually develops in young, chronically alcoholic subjects with enlarged fatty liver.", "offsetInBeginSection": 0, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809", "text": "The clinical manifestations of the syndrome contains no pathognomonic symptoms and suggests rather cholecystopathy.", "offsetInBeginSection": 132, "offsetInEndSection": 247, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809", "text": "This is possibly the cause of rare recognition of the syndrome.", "offsetInBeginSection": 248, "offsetInEndSection": 311, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/464793", "text": "The Zieve's syndrome consists of the transient association of cholestatic jaundice, hemolytic anemia, hyperlipemia, in a chronic alcoholic.", "offsetInBeginSection": 0, "offsetInEndSection": 139, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11761804", "text": "We report a case of recurrent Zieve's syndrome, consisting of jaundice, hemolytic anemia and hyperlipoproteinemia, initiated by alcohol abuse.", "offsetInBeginSection": 0, "offsetInEndSection": 142, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/548954", "text": "A patient with Zieve's syndrome is described.", "offsetInBeginSection": 0, "offsetInEndSection": 45, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8819039", "text": "Zieve's syndrome consists of transient haemolytic anaemic, jaundice, hyperlipidaemia and alcohol-induced liver disease.", "offsetInBeginSection": 0, "offsetInEndSection": 119, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8645520", "text": "Jaundice, hyperlipidemia and haemolytic anemia define Zieve's Syndrome (Z.S.)", "offsetInBeginSection": 692, "offsetInEndSection": 769, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8645520", "text": "There is a pathogenetic relationship among the clinical and biological phenomena in this syndrome, whose starter is an acute alcohol intake.", "offsetInBeginSection": 770, "offsetInEndSection": 910, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7636d39e632bc066000004", "body": "Which R packages have been developed for the discovery of mutational signatures in cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35157026", "http://www.ncbi.nlm.nih.gov/pubmed/35575002", "http://www.ncbi.nlm.nih.gov/pubmed/29898651", "http://www.ncbi.nlm.nih.gov/pubmed/26163694", "http://www.ncbi.nlm.nih.gov/pubmed/33782531", "http://www.ncbi.nlm.nih.gov/pubmed/33222322", "http://www.ncbi.nlm.nih.gov/pubmed/27591080", "http://www.ncbi.nlm.nih.gov/pubmed/29145625", "http://www.ncbi.nlm.nih.gov/pubmed/34625425", "http://www.ncbi.nlm.nih.gov/pubmed/27091472"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472", "text": "RESULTS MutSpec includes a set of tools that perform variant annotation and use advanced statistics for the identification of mutation signatures present in cancer genomes and for comparing the obtained signatures with those published in the COSMIC database and other sources.", "offsetInBeginSection": 699, "offsetInEndSection": 975, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923", "text": "Results We proposed two complementary ways of measuring confidence and stability of decomposition results and applied them to analyze mutational signatures in breast cancer genomes.", "offsetInBeginSection": 882, "offsetInEndSection": 1063, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29145625", "text": "Deciphering mutational signatures in cancer is a new topic in cancer research.", "offsetInBeginSection": 256, "offsetInEndSection": 334, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29145625", "text": "mSignatureDB (http://tardis.cgu.edu.tw/msignaturedb) integrates R packages and in-house scripts to determine the contributions of the published signatures in 15 780 individual tumors from 73 TCGA/ICGC cancer projects, making comparison of signature patterns within and between projects become possible.", "offsetInBeginSection": 875, "offsetInEndSection": 1177, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080", "text": "RESULTS Here we present a new method for the statistical estimation of mutational signatures based on an empirical Bayesian treatment of the NMF model.", "offsetInBeginSection": 749, "offsetInEndSection": 900, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080", "text": "These signatures have been identified from high throughput sequencing data generated from cancer genomes by using non-negative matrix factorisation (NMF) techniques.", "offsetInBeginSection": 191, "offsetInEndSection": 356, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28968631", "text": "The study of these DNA fingerprints, termed mutational signatures, holds important potential for furthering our understanding of the causes and evolution of cancer, and can provide insights of relevance for cancer prevention and treatment.", "offsetInBeginSection": 154, "offsetInEndSection": 393, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15059910", "text": "iFLP allows the high-throughput discovery and tracing of mutational signatures in human cells, precancerous lesions, and primary or metastatic tumors and the assessment of the number and heterogeneity of low-level mutations in surgical samples.", "offsetInBeginSection": 1491, "offsetInEndSection": 1735, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28912133", "text": "We developed a strategy that can be used to explore the origin of cancer-associated mutational signatures.", "offsetInBeginSection": 189, "offsetInEndSection": 295, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28912133", "text": "Application of this strategy to the cancer predisposition gene NTHL1, which encodes a base excision repair protein, revealed a mutational footprint (signature 30) previously observed in a breast cancer cohort.", "offsetInBeginSection": 670, "offsetInEndSection": 879, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8dc57ffcd1d6a10c000025", "body": "Are the human bombesin receptors, GRPR and NMBR, frequently overexpressed G-protein-coupled-receptors by lung-cancers?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29410320", "http://www.ncbi.nlm.nih.gov/pubmed/19694578", "http://www.ncbi.nlm.nih.gov/pubmed/21729729", "http://www.ncbi.nlm.nih.gov/pubmed/22080443", "http://www.ncbi.nlm.nih.gov/pubmed/35744904", "http://www.ncbi.nlm.nih.gov/pubmed/30775647", "http://www.ncbi.nlm.nih.gov/pubmed/15016826", "http://www.ncbi.nlm.nih.gov/pubmed/25146125", "http://www.ncbi.nlm.nih.gov/pubmed/27670095", "http://www.ncbi.nlm.nih.gov/pubmed/24349381"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496", "text": "In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines.", "offsetInBeginSection": 305, "offsetInEndSection": 668, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238", "text": "Mammalian bombesin-like peptides neuromedin B (NMB) and gastrin-releasing peptide (GRP) act by activating NMB receptors (NMBR, BBl) and GRP receptors (GRPR,BB2), respectively.", "offsetInBeginSection": 0, "offsetInEndSection": 175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238", "text": "These two bombesin receptors are members of the G-protein-coupled receptor (GPCR) superfamily.In the brain, NMBR and GRPR are highly expressed in the brain areas involved in memory processing and emotional responses, such as the hippocampus and the amygdaloid nuclei.", "offsetInBeginSection": 176, "offsetInEndSection": 443, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12959933", "text": "Dexamethasone and bombesin increased GRPR mRNA, bombesin downregulated NMBR, and neither agent affected BRS-3.", "offsetInBeginSection": 1077, "offsetInEndSection": 1187, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12959933", "text": "To test the hypothesis that such effects are mediated by known mammalian bombesin receptors [gastrin-releasing peptide (GRP)/bombesin-preferring receptor (GRPR), neuromedin B (NMB) receptor (NMBR), and the orphan bombesin receptor subtype-3 (BRS-3)], we analyzed the ontogeny of GRPR, NMBR, and BRS-3 gene expression in mouse lung.", "offsetInBeginSection": 148, "offsetInEndSection": 479, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8018339", "text": "Three receptors have been identified for bombesin and its analogs, namely gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3).", "offsetInBeginSection": 261, "offsetInEndSection": 448, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19628633", "text": "The mammalian bombesin (Bn) peptides, neuromedin B (NMB) and gastrin-releasing peptide (GRP), have widespread actions in many tissues, and their effects are mediated by two closely related G-protein-coupled receptors, the NMBR and GRPR.", "offsetInBeginSection": 0, "offsetInEndSection": 236, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10679759", "text": "Three bombesin receptor subtypes, termed gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), have been identified in rodents and humans.", "offsetInBeginSection": 168, "offsetInEndSection": 366, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23826298", "text": "receptors for gastrin-releasing peptide (GRPr) and neuromedin B (NMBr) differentially regulate itch scratching.", "offsetInBeginSection": 194, "offsetInEndSection": 305, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26030739", "text": "We purified peptide E as a low-affinity ligand for hBRS3, which was also found to be an agonist for the other two mammalian bombesin receptors such as gastrin-releasing peptide receptor (GRPR) and neuromedin B receptor (NMBR).", "offsetInBeginSection": 1361, "offsetInEndSection": 1587, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7602be83b0d9ea6600000f", "body": "Describe King\u2013Kopetzky syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10997453", "http://www.ncbi.nlm.nih.gov/pubmed/8738633", "http://www.ncbi.nlm.nih.gov/pubmed/14570238", "http://www.ncbi.nlm.nih.gov/pubmed/11603771", "http://www.ncbi.nlm.nih.gov/pubmed/14558893", "http://www.ncbi.nlm.nih.gov/pubmed/8985564", "http://www.ncbi.nlm.nih.gov/pubmed/20500033", "http://www.ncbi.nlm.nih.gov/pubmed/9677061", "http://www.ncbi.nlm.nih.gov/pubmed/11345752", "http://www.ncbi.nlm.nih.gov/pubmed/21514828"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737", "text": "Goldberg-Shprintzen syndrome is a rare autosomal recessive condition that describes the association of Hirschsprung disease with microcephaly, developmental delay and characteristic facies.", "offsetInBeginSection": 0, "offsetInEndSection": 189, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737", "text": "We describe two brothers from a non-consanguineous family who have classical features of Goldberg-Shprintzen syndrome.", "offsetInBeginSection": 190, "offsetInEndSection": 308, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/835533", "text": "It is suggested that this syndrome is inherited as an autosomal-recessive condition.", "offsetInBeginSection": 265, "offsetInEndSection": 349, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281", "text": "Syndrome) the Aase Syndrome and Diamond-Blackfan Anemia.", "offsetInBeginSection": 211, "offsetInEndSection": 267, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281", "text": "), Thrombocytopenia Absent Radii Syndrome (T.A.R.", "offsetInBeginSection": 161, "offsetInEndSection": 210, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6703533", "text": "Authors describe the phenotype and review the literature on this syndrome.", "offsetInBeginSection": 159, "offsetInEndSection": 233, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6703533", "text": "A new case of Robinow dwarfism syndrome, in a 26 month old child is described.", "offsetInBeginSection": 0, "offsetInEndSection": 78, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116", "text": "Although there is considerable variability, most individuals with Down syndrome have mental retardation and speech and language deficits, particularly in language production and syntax and poor speech intelligibility.", "offsetInBeginSection": 0, "offsetInEndSection": 217, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23565480", "text": "BACKGROUND Wolfram syndrome is a rare hereditary or sporadic neurodegenerative disorder also known as DIDMOAD.", "offsetInBeginSection": 0, "offsetInEndSection": 110, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/112864", "text": "The oculocerebrofacial syndrome was described from siblings of both sexes in 1971 by Kaufman.", "offsetInBeginSection": 0, "offsetInEndSection": 93, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a67c284b750ff4455000011", "body": "What is GenomeVIP?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28522612", "http://www.ncbi.nlm.nih.gov/pubmed/19702537", "http://www.ncbi.nlm.nih.gov/pubmed/30656893", "http://www.ncbi.nlm.nih.gov/pubmed/6683883", "http://www.ncbi.nlm.nih.gov/pubmed/15734663", "http://www.ncbi.nlm.nih.gov/pubmed/32603623", "http://www.ncbi.nlm.nih.gov/pubmed/11326518", "http://www.ncbi.nlm.nih.gov/pubmed/6359612", "http://www.ncbi.nlm.nih.gov/pubmed/34534728", "http://www.ncbi.nlm.nih.gov/pubmed/31798210"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612", "text": "GenomeVIP orchestrates the analysis of whole-genome and exome sequence data using a set of robust and popular task-specific tools, including VarScan, GATK, Pindel, BreakDancer, Strelka, and Genome STRiP, through a web interface.", "offsetInBeginSection": 790, "offsetInEndSection": 1018, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612", "text": "GenomeVIP has been used for genomic analysis in large-data projects such as the TCGA PanCanAtlas and in other projects, such as the ICGC Pilots, CPTAC, ICGC-TCGA DREAM Challenges, and the 1000 Genomes SV Project.", "offsetInBeginSection": 1019, "offsetInEndSection": 1231, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612", "text": "Here, we introduce the Genome Variant Investigation Platform (GenomeVIP), an open-source framework for performing genomics variant discovery and annotation using cloud- or local high-performance computing infrastructure.", "offsetInBeginSection": 569, "offsetInEndSection": 789, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612", "text": "Identifying genomic variants is a fundamental first step toward the understanding of the role of inherited and acquired variation in disease.", "offsetInBeginSection": 0, "offsetInEndSection": 141, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612", "text": "The accelerating growth in the corpus of sequencing data that underpins such analysis is making the data-download bottleneck more evident, placing substantial burdens on the research community to keep pace.", "offsetInBeginSection": 142, "offsetInEndSection": 348, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612", "text": "Here, we demonstrate GenomeVIP's ability to provide high-confidence annotated somatic, germline, and de novo variants of potential biological significance using publicly available data sets.", "offsetInBeginSection": 1232, "offsetInEndSection": 1422, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612", "text": "As a result, the search for alternative approaches to the traditional \"download and analyze\" paradigm on local computing resources has led to a rapidly growing demand for cloud-computing solutions for genomics analysis.", "offsetInBeginSection": 349, "offsetInEndSection": 568, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a981e66fcd1d6a10c00002f", "body": "According to guidelines, insulin resistance is one risk factor in the diagnosis of metabolic syndrome, name 3 more risk factors.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11276389", "http://www.ncbi.nlm.nih.gov/pubmed/18497723", "http://www.ncbi.nlm.nih.gov/pubmed/16599068", "http://www.ncbi.nlm.nih.gov/pubmed/14689101", "http://www.ncbi.nlm.nih.gov/pubmed/15547646", "http://www.ncbi.nlm.nih.gov/pubmed/15529616", "http://www.ncbi.nlm.nih.gov/pubmed/23535629", "http://www.ncbi.nlm.nih.gov/pubmed/30743769", "http://www.ncbi.nlm.nih.gov/pubmed/15940204", "http://www.ncbi.nlm.nih.gov/pubmed/18370749"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15547646", "text": "Insulin resistance is the key factor for the clustering of risk factors characterizing the metabolic syndrome.", "offsetInBeginSection": 272, "offsetInEndSection": 382, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16505579", "text": "Soon, metabolic syndrome will overtake cigarette smoking as the number one risk factor for heart disease among the US population.", "offsetInBeginSection": 1182, "offsetInEndSection": 1311, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16505579", "text": "The syndrome has been given several names, including- the metabolic syndrome, the insulin resistance syndrome, the plurimetabolic syndrome, and the deadly quartet.", "offsetInBeginSection": 75, "offsetInEndSection": 238, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12643148", "text": "Also, there is new and better understanding of the complex dyslipidemias and other risk factors strongly associated with the metabolic syndrome, which greatly increase the risk of clinical atherosclerotic events.", "offsetInBeginSection": 394, "offsetInEndSection": 606, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447", "text": "Abdominal adiposity is considered high-risk fat, and it is associated with insulin resistance, hyperglycemia, dyslipidemia, hypertension, and prothrombotic and/or proinflammatory states.", "offsetInBeginSection": 905, "offsetInEndSection": 1091, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447", "text": "First-line therapy for individuals with metabolic syndrome should be directed to the major CVD risk factors, namely, elevated low-density lipoprotein cholesterol levels, hypertension, and diabetes, and it should emphasize lifestyle modification.", "offsetInBeginSection": 1226, "offsetInEndSection": 1471, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447", "text": "Until additional research better defines the most appropriate therapies, conventional cardiovascular risk factors, such as lipid levels, blood pressure, and diabetes, should be managed in individuals with metabolic syndrome according to nationally accepted clinical guidelines.", "offsetInBeginSection": 1472, "offsetInEndSection": 1749, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19108808", "text": "The metabolic syndrome has 5 criteria: central obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) levels, fasting hyperglycemia, and hypertension.", "offsetInBeginSection": 1021, "offsetInEndSection": 1182, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15529616", "text": "Pathogenesis of metabolic syndrome implies 3 potential etiological mechanisms: obesity and adipose tissue disorders, insulin resistance, and a constellation of independent factors.", "offsetInBeginSection": 64, "offsetInEndSection": 244, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15529616", "text": "In addition, other components commonly aggregate with the major components: elevated apolipoprotein B, small LDL particles, insulin resistance and hyperinsulinemia, impaired glucose tolerance (IGT), elevated C-reactive protein (CRP), and variation in coagulation factors (plasminogen activator inhibitor [PAI]-I and fibrinogen).", "offsetInBeginSection": 484, "offsetInEndSection": 812, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a76080683b0d9ea66000015", "body": "Is cilengitide effective for treatment of glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24014381", "http://www.ncbi.nlm.nih.gov/pubmed/21739168", "http://www.ncbi.nlm.nih.gov/pubmed/23667810", "http://www.ncbi.nlm.nih.gov/pubmed/21269250", "http://www.ncbi.nlm.nih.gov/pubmed/19221171", "http://www.ncbi.nlm.nih.gov/pubmed/22517399", "http://www.ncbi.nlm.nih.gov/pubmed/25163906", "http://www.ncbi.nlm.nih.gov/pubmed/12901235", "http://www.ncbi.nlm.nih.gov/pubmed/23354807", "http://www.ncbi.nlm.nih.gov/pubmed/20439646"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168", "text": "Cilengitide is a cyclic pentapeptide that is a specific inhibitor of the \u03b1v\u03b23 and \u03b1v\u03b25 integrins.", "offsetInBeginSection": 0, "offsetInEndSection": 101, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24014381", "text": "BACKGROUND Cilengitide, an \u03b1v integrin antagonist, has demonstrated activity in recurrent adult glioblastoma (GBM).", "offsetInBeginSection": 0, "offsetInEndSection": 116, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24014381", "text": "CONCLUSIONS We conclude that cilengitide is not effective as a single agent for refractory pediatric HGG.", "offsetInBeginSection": 1417, "offsetInEndSection": 1522, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24442484", "text": "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT \u2192 TMZ) in newly diagnosed glioblastoma.", "offsetInBeginSection": 0, "offsetInEndSection": 200, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22866207", "text": "A foundation of encouraging preclinical studies led to a well-designed clinical development plan that culminated in a pivotal phase III study of cilengitide in combination with radiation therapy and temozolomide chemotherapy for newly diagnosed glioblastoma patients.", "offsetInBeginSection": 545, "offsetInEndSection": 812, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22866207", "text": "Although several integrin inhibitors are under clinical evaluation, cilengitide is the most clinically advanced and is emerging as a prototype for this class of anticancer therapy.", "offsetInBeginSection": 364, "offsetInEndSection": 544, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22976135", "text": "Among them, cilengitide is a novel integrin antagonist for the treatment of glioblastoma.", "offsetInBeginSection": 648, "offsetInEndSection": 737, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22976135", "text": "Cilengitide is currently being assessed in phase III trials for patients with glioblastoma multiforme and in phase II trials for other types of cancers, demonstrating promising therapeutic outcomes to date.", "offsetInBeginSection": 1016, "offsetInEndSection": 1222, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21417900", "text": "Cilengitide is currently under evaluation in a pivotal, randomized Phase III study (Cilengitide in Combination With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Phase III Randomized Clinical Trial [CENTRIC]) for newly diagnosed GBM.", "offsetInBeginSection": 734, "offsetInEndSection": 983, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21417900", "text": "Cilengitide and other integrin-targeting therapeutics have preclinical activity against many cancer subtypes including glioblastoma (GBM), the most common and deadliest CNS tumor.", "offsetInBeginSection": 243, "offsetInEndSection": 422, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6a3464b750ff4455000026", "body": "Which algorithm has been developed in order to improve multiple circular sequence alignment using refined sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28821841", "http://www.ncbi.nlm.nih.gov/pubmed/28088189", "http://www.ncbi.nlm.nih.gov/pubmed/7804875", "http://www.ncbi.nlm.nih.gov/pubmed/15130542", "http://www.ncbi.nlm.nih.gov/pubmed/7796270", "http://www.ncbi.nlm.nih.gov/pubmed/18662101", "http://www.ncbi.nlm.nih.gov/pubmed/19627599", "http://www.ncbi.nlm.nih.gov/pubmed/16707662", "http://www.ncbi.nlm.nih.gov/pubmed/18616828", "http://www.ncbi.nlm.nih.gov/pubmed/16452808"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189", "text": "RESULTS We present MARS, a new heuristic method for improving Multiple circular sequence Alignment using Refined Sequences.", "offsetInBeginSection": 917, "offsetInEndSection": 1040, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189", "text": "A solution for these inconsistencies would be to identify a suitable rotation (cyclic shift) for each sequence; these refined sequences may in turn lead to improved multiple sequence alignments using the preferred multiple sequence alignment program.", "offsetInBeginSection": 664, "offsetInEndSection": 914, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599", "text": "RESULTS In this paper we propose an efficient algorithm that identifies the most interesting region to cut circular genomes in order to improve phylogenetic analysis when using standard multiple sequence alignment algorithms.", "offsetInBeginSection": 876, "offsetInEndSection": 1101, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599", "text": "Researchers interested in aligning circular DNA sequences must first rotate them to the \"right\" place using an essentially manual process, before they can use multiple sequence alignment tools.", "offsetInBeginSection": 680, "offsetInEndSection": 873, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599", "text": "CONCLUSION The results show that a circularization and rotation pre-processing step significantly improves the efficiency of public available multiple sequence alignment algorithms when used in the alignment of circular DNA sequences.", "offsetInBeginSection": 1796, "offsetInEndSection": 2030, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16086841", "text": "CONCLUSION We have implemented a genetic algorithm in parallel mode to optimize multiple genomic sequence alignments initially generated by various alignment tools.", "offsetInBeginSection": 2174, "offsetInEndSection": 2338, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16086841", "text": "We describe a new program, GenAlignRefine, which improves the overall quality of global multiple alignments by using a genetic algorithm to improve local regions of alignment.", "offsetInBeginSection": 846, "offsetInEndSection": 1021, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7796270", "text": "To date, most multiple alignment systems have employed a tree-based algorithm, which combines the results of two-way dynamic programming in a tree-like order of sequence similarity.", "offsetInBeginSection": 72, "offsetInEndSection": 253, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18616828", "text": "RESULTS The performance of the proposed algorithm is validated via comparison to popular progressive multiple alignment approaches, ClustalW and T-Coffee, and to the more recently developed algorithms MAFFT, MUSCLE, Kalign, and PSAlign using the BAliBASE 3.0 database of amino acid alignment files and a set of longer sequences generated by Rose software.", "offsetInBeginSection": 469, "offsetInEndSection": 824, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7804875", "text": "An algorithm called Multiple Sequence Alignment using Simulated Annealing (MSASA) has been developed.", "offsetInBeginSection": 543, "offsetInEndSection": 644, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a74e9ad0384be955100000a", "body": "What is a SERM?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11332210", "http://www.ncbi.nlm.nih.gov/pubmed/12106639", "http://www.ncbi.nlm.nih.gov/pubmed/16951470", "http://www.ncbi.nlm.nih.gov/pubmed/16972673", "http://www.ncbi.nlm.nih.gov/pubmed/16263696", "http://www.ncbi.nlm.nih.gov/pubmed/11910661", "http://www.ncbi.nlm.nih.gov/pubmed/10569450", "http://www.ncbi.nlm.nih.gov/pubmed/15500393", "http://www.ncbi.nlm.nih.gov/pubmed/28185712", "http://www.ncbi.nlm.nih.gov/pubmed/28098599"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24667357", "text": "One such example is the tissue selective estrogen complex, which partners a SERM with 1 or more estrogens, with the aim of blending the desired estrogen-receptor agonist activities of estrogens on vasomotor symptoms, vulvar-vaginal atrophy, and loss of bone mass with the tissue selectivity of a SERM.", "offsetInBeginSection": 1065, "offsetInEndSection": 1366, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12036407", "text": "Tamoxifen is a SERM that acts as an oestrogen antagonist in breast tissue and is currently being used for the treatment and prevention of breast cancer.", "offsetInBeginSection": 486, "offsetInEndSection": 638, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12036407", "text": "Oestrogen and another SERM, raloxifene, have been shown to prevent osteoporosis.", "offsetInBeginSection": 759, "offsetInEndSection": 839, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24930824", "text": "Tamoxifen, a pioneering selective estrogen receptor modulator (SERM), has long been a therapeutic choice for all stages of estrogen receptor (ER)-positive breast cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 169, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043", "text": "A new target in treating postmenopausal osteoporosis is the tissue estrogen complex or the pairing of a SERM with a conjugated estrogen known as a tissue selective estrogen complex (TSEC).", "offsetInBeginSection": 1528, "offsetInEndSection": 1716, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043", "text": "Several agents are available in the U.S., including bisphosphonates, hormone therapy, calcitonin, parathyroid hormone and the selective estrogen receptor modulator (SERM) raloxifene.", "offsetInBeginSection": 675, "offsetInEndSection": 857, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23925896", "text": "Estrogen and selective estrogen receptor modulator (SERM) treatments for acromegaly have received limited attention since the development of newer pharmacologic therapies.", "offsetInBeginSection": 0, "offsetInEndSection": 171, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18279543", "text": "Other SERMs have entered clinical development more recently, including benzothiophenes (raloxifene and arzoxifene), benzopyrans (ormeloxifene, levormeloxifene, and EM-800), lasofoxifene, pipendoxifene, bazedoxifene, HMR-3339, and fulvestrant, an anti-estrogen which is approved for breast cancer treatment.", "offsetInBeginSection": 1049, "offsetInEndSection": 1355, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15500393", "text": "An ideal SERM is a compound with an oestrogen antagonist effect on the breast and uterus but oestrogen agonist effect on bone.", "offsetInBeginSection": 127, "offsetInEndSection": 253, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15500393", "text": "Recently, raloxifene, a second-generation SERM, has been used in the treatment of familial adenomatous polyposis patients affected by desmoid tumour.", "offsetInBeginSection": 469, "offsetInEndSection": 618, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7610ca83b0d9ea6600001b", "body": "What is the role of nimotuzumab in treatment of pontine glioma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23926436", "http://www.ncbi.nlm.nih.gov/pubmed/24696052", "http://www.ncbi.nlm.nih.gov/pubmed/19903064", "http://www.ncbi.nlm.nih.gov/pubmed/36181764", "http://www.ncbi.nlm.nih.gov/pubmed/25926743", "http://www.ncbi.nlm.nih.gov/pubmed/30417211", "http://www.ncbi.nlm.nih.gov/pubmed/23754473", "http://www.ncbi.nlm.nih.gov/pubmed/35191733", "http://www.ncbi.nlm.nih.gov/pubmed/23782513", "http://www.ncbi.nlm.nih.gov/pubmed/20046573"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052", "text": "Findings on the role of EGFR signaling in the onset of childhood DIPG prompted the use of nimotuzumab, an anti-EGFR monoclonal antibody.", "offsetInBeginSection": 92, "offsetInEndSection": 228, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052", "text": "Radiotherapy is the only treatment definitely indicated for diffuse pontine gliomas (DIPG).", "offsetInBeginSection": 0, "offsetInEndSection": 91, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052", "text": "Assuming a potential synergy with both radiotherapy and vinorelbine, a pilot phase 2 protocol was launched that combined nimotuzumab with concomitant radiation and vinorelbine.", "offsetInBeginSection": 229, "offsetInEndSection": 405, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743", "text": "We found that nimotuzumab with or without radiotherapy, chemotherapy in newly diagnosed or recurrent HGG, such as glioblastoma multiforme (GBM), anaplastic astrocytomas (AA), and diffuse intrinsic pontine glioma (DIPG), might improve the response rate or the survival time.", "offsetInBeginSection": 499, "offsetInEndSection": 772, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743", "text": "We review the humanized epidermal growth factor receptor (EGFR) and the major EGFR target drugs in HGG treatments, focusing on the EGFR antibody nimotuzumab as a new therapeutic strategy in HGG.", "offsetInBeginSection": 304, "offsetInEndSection": 498, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24847085", "text": "CONCLUSIONS Modest activity of nimotuzumab in DIPG, which has been shown previously, was confirmed: A small subset of DIPG patients appeared to benefit from anti-EGFR antibody treatment.", "offsetInBeginSection": 1499, "offsetInEndSection": 1685, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23754473", "text": "Primary metastatic diffuse intrinsic pontine glioma (DIPG) is relatively rare and associated with a dismal prognosis.", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21171927", "text": "The activity of nimotuzumab, a humanized anti-EGFR monoclonal antibody, was therefore studied within a Phase II trial in 47 relapsing pediatric patients with DIPG and high-grade gliomas, showing an interesting, persistent response, especially in the first group treated.", "offsetInBeginSection": 571, "offsetInEndSection": 841, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19903064", "text": "Emerging trials suggest a promising role for nimotuzumab as a therapeutic agent in patients with high-grade gliomas.", "offsetInBeginSection": 537, "offsetInEndSection": 653, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27379495", "text": "Targeted therapy protocols included radiation therapy along with treatment by erlotinib, cilengitide, or an association of nimotuzumab and vinblastine.", "offsetInBeginSection": 864, "offsetInEndSection": 1015, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6a35b7b750ff4455000027", "body": "What is libgapmis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24564250", "http://www.ncbi.nlm.nih.gov/pubmed/6683883", "http://www.ncbi.nlm.nih.gov/pubmed/19702537", "http://www.ncbi.nlm.nih.gov/pubmed/30656893", "http://www.ncbi.nlm.nih.gov/pubmed/15734663", "http://www.ncbi.nlm.nih.gov/pubmed/24119119", "http://www.ncbi.nlm.nih.gov/pubmed/11326518", "http://www.ncbi.nlm.nih.gov/pubmed/31798210", "http://www.ncbi.nlm.nih.gov/pubmed/6359612", "http://www.ncbi.nlm.nih.gov/pubmed/34534728"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250", "text": "libgapmis is based on an algorithm computing a modified version of the traditional dynamic-programming matrix for sequence alignment.", "offsetInBeginSection": 1240, "offsetInEndSection": 1373, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250", "text": "The open-source code of libgapmis is available at http://www.exelixis-lab.org/gapmis.", "offsetInBeginSection": 2289, "offsetInEndSection": 2374, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250", "text": "CONCLUSIONS We present libgapmis, a library for extending pairwise short-read alignments.", "offsetInBeginSection": 1942, "offsetInEndSection": 2031, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250", "text": "RESULTS In this article, we present libgapmis, a library for extending pairwise short-read alignments.", "offsetInBeginSection": 1042, "offsetInEndSection": 1144, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250", "text": "We show that libgapmis is better-suited and more efficient than existing algorithms for this task.", "offsetInBeginSection": 2032, "offsetInEndSection": 2130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250", "text": "The fact that the reads are rather short and that the gap occurrence frequency observed in various studies is rather low suggest that aligning (parts of) those reads with a single gap is in fact desirable.", "offsetInBeginSection": 834, "offsetInEndSection": 1039, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250", "text": "After aligning a substring of the reference sequence against the high-quality prefix of a short read--the seed--an important problem is to find the best possible alignment between a substring of the reference sequence succeeding and the remaining suffix of low quality of the read--extend.", "offsetInBeginSection": 544, "offsetInEndSection": 833, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250", "text": "BACKGROUND A wide variety of short-read alignment programmes have been published recently to tackle the problem of mapping millions of short reads to a reference genome, focusing on different aspects of the procedure such as time and memory efficiency, sensitivity, and accuracy.", "offsetInBeginSection": 0, "offsetInEndSection": 279, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250", "text": "The seed-and-extend strategy is applied in most short-read alignment programmes.", "offsetInBeginSection": 463, "offsetInEndSection": 543, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250", "text": "The library also provides the user the flexibility to split the read into fragments, based on the observed gap occurrence frequency and the length of the read, thereby allowing for a variable, but bounded, number of gaps in the alignment.", "offsetInBeginSection": 1701, "offsetInEndSection": 1939, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a76016683b0d9ea6600000d", "body": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19212162", "http://www.ncbi.nlm.nih.gov/pubmed/30714014", "http://www.ncbi.nlm.nih.gov/pubmed/26243569", "http://www.ncbi.nlm.nih.gov/pubmed/25738006", "http://www.ncbi.nlm.nih.gov/pubmed/34321946", "http://www.ncbi.nlm.nih.gov/pubmed/33707583", "http://www.ncbi.nlm.nih.gov/pubmed/26599319", "http://www.ncbi.nlm.nih.gov/pubmed/23754950", "http://www.ncbi.nlm.nih.gov/pubmed/21081842", "http://www.ncbi.nlm.nih.gov/pubmed/33412332"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618", "text": "Furthermore, we show that the modest increase in expression afforded by a single extra transgenic copy of Dscr1 is sufficient to confer significant suppression of tumour growth in mice, and that such resistance is a consequence of a deficit in tumour angiogenesis arising from suppression of the calcineurin pathway.", "offsetInBeginSection": 600, "offsetInEndSection": 916, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25738006", "text": "Downs syndrome (DS) occurs due to an extra copy of chromosome 21.", "offsetInBeginSection": 0, "offsetInEndSection": 65, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097", "text": "Analysis of individual distribution of satellite between homologues of chromosome 21 provides new possibilities for determination of the origin of extra chromosome in the patients with trisomy 21.", "offsetInBeginSection": 802, "offsetInEndSection": 998, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097", "text": "The difference in the copy number between two homologues chromosomes, 13 and 21 reaches up to 5 times.", "offsetInBeginSection": 602, "offsetInEndSection": 704, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19212162", "text": "Down syndrome is a genetic disorder, occurring when an individual has all or part of an extra copy of chromosome 21.", "offsetInBeginSection": 0, "offsetInEndSection": 116, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11399108", "text": "The augmented antioxidant protection resulting from an extra copy of chromosome 21 may, with time, selectively protect human oocytes from apoptosis, increasing their proportion with age, explaining the higher incidence of this disease.", "offsetInBeginSection": 872, "offsetInEndSection": 1107, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26243569", "text": "Down syndrome, which arises in individuals carrying an extra copy of chromosome 21, is associated with a greatly increased risk of early-onset Alzheimer disease.", "offsetInBeginSection": 0, "offsetInEndSection": 161, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2880544", "text": "An extra copy of human chromosome 21 has been known for over twenty years to be the chromosomal abnormality in Down's syndrome; however, the biochemical and molecular basis governing expression of the phenotype is still poorly understood.", "offsetInBeginSection": 0, "offsetInEndSection": 238, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7763760", "text": "The extra copy of chromosome 21 could alter growth regulation and biochemical mechanisms, so we examined quantitatively some DS phenotypical aspects to detect possible differences from those of controls.", "offsetInBeginSection": 224, "offsetInEndSection": 427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9050924", "text": "On analysis of 34 cases of Down's syndrome, including two cases of unbalanced translocation 46, XY, der (14; 21) (q10; q10), + 21, and 100 normal individuals, the relative ratio of the PFKM-CH1/PFKL-CH21 product was 1.33 +/- 0.323 (mean +/- SD) and 0.40 +/- 0.16 (mean +/- SD) for disomy DNA and trisomy DNA, respectively.", "offsetInBeginSection": 547, "offsetInEndSection": 869, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7615af83b0d9ea6600001f", "body": "Is vorinostat effective for glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22090453", "http://www.ncbi.nlm.nih.gov/pubmed/30561869", "http://www.ncbi.nlm.nih.gov/pubmed/29016887", "http://www.ncbi.nlm.nih.gov/pubmed/22086447", "http://www.ncbi.nlm.nih.gov/pubmed/19307505", "http://www.ncbi.nlm.nih.gov/pubmed/24576944", "http://www.ncbi.nlm.nih.gov/pubmed/33457098", "http://www.ncbi.nlm.nih.gov/pubmed/29133513", "http://www.ncbi.nlm.nih.gov/pubmed/32166308", "http://www.ncbi.nlm.nih.gov/pubmed/30302275"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194", "text": "Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents that are actively being evaluated in the context of clinical trials in solid tumors, including glioblastoma.", "offsetInBeginSection": 0, "offsetInEndSection": 196, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194", "text": "The effects of the HDAC inhibitor vorinostat and SN38, which is the active metabolite of the topoisomerase I inhibitor CPT-11, was evaluated using the clonogenic assay.", "offsetInBeginSection": 694, "offsetInEndSection": 862, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944", "text": "We present two patients with glioblastoma multiforme who developed severe hemolytic anemia shortly after initiating therapy with vorinostat, a pan-active histone deacetylase inhibitor, while on prophylactic dapsone.", "offsetInBeginSection": 827, "offsetInEndSection": 1042, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944", "text": "Patients undergoing treatment for glioblastoma multiforme are routinely placed on prophylactic treatment for Pneumocystis jirovecii pneumonia because of significant therapy-induced lymphopenia.", "offsetInBeginSection": 0, "offsetInEndSection": 193, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19307505", "text": "PURPOSE Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM).", "offsetInBeginSection": 0, "offsetInEndSection": 127, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22086447", "text": "Histone deacetylase inhibitors (HDACIs) represent a class of agents that can modulate gene expression to reduce tumor growth, and we and others have noted some antiglioma activity from HDACIs, such as vorinostat, although insufficient to warrant use as monotherapy.", "offsetInBeginSection": 81, "offsetInEndSection": 346, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24838514", "text": "Multiple phase II trials with vorinostat in combination with targeted agents, temozolomide and radiotherapy are currently recruiting.", "offsetInBeginSection": 1155, "offsetInEndSection": 1288, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24838514", "text": "Vorinostat is the most advanced HDAC inhibitor that entered clinical trials in glioblastoma, showing activity in recurrent disease.", "offsetInBeginSection": 1023, "offsetInEndSection": 1154, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22090453", "text": "Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown evidence of single-agent activity in glioblastoma (GBM), and in preclinical studies, we have demonstrated significant synergistic cytotoxicity between HDAC inhibitors and proteasome inhibitors in GBM cell lines.", "offsetInBeginSection": 0, "offsetInEndSection": 273, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22923449", "text": "A phase I/II trial of vorinostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway.", "offsetInBeginSection": 1527, "offsetInEndSection": 1642, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6a7869b750ff4455000028", "body": "Describe SNP2TFBS", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27899579", "http://www.ncbi.nlm.nih.gov/pubmed/35158151", "http://www.ncbi.nlm.nih.gov/pubmed/31969149", "http://www.ncbi.nlm.nih.gov/pubmed/33841080", "http://www.ncbi.nlm.nih.gov/pubmed/36164436", "http://www.ncbi.nlm.nih.gov/pubmed/33506367", "http://www.ncbi.nlm.nih.gov/pubmed/15162768", "http://www.ncbi.nlm.nih.gov/pubmed/28433298", "http://www.ncbi.nlm.nih.gov/pubmed/25346200", "http://www.ncbi.nlm.nih.gov/pubmed/27269376"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15861591", "text": "Experience of SA-RPE using the simplified technique described by Pogrel et al is describe.", "offsetInBeginSection": 585, "offsetInEndSection": 675, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825", "text": "We describe first a field deployable mass spectrometer, based on an ion trap analyzer, and variants of that system.", "offsetInBeginSection": 375, "offsetInEndSection": 490, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825", "text": "We describe four sensing and characterization technologies recently developed at Los Alamos National Laboratory; a select set of mass spectral and optical techniques is emphasized.", "offsetInBeginSection": 0, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825", "text": "We then describe a hand-held, battery-operated optical spectrometer, usable in either absorption, or fluorescence excitation mode.", "offsetInBeginSection": 491, "offsetInEndSection": 621, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11441785", "text": "In this paper, we describe \"Clerambault's syndrome\" and \"Kandinsky-Clerambault's syndrome\" and discuss and clarify the confusion surrounding these different syndromes.", "offsetInBeginSection": 216, "offsetInEndSection": 383, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11441785", "text": "Using a similar term to describe different forms of pathology leads to a muddle.", "offsetInBeginSection": 135, "offsetInEndSection": 215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498", "text": "We propose describing a manipulative technique using 6 characteristics: Rate of force application: Describe the rate at which the force was applied.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498", "text": "Relative structural movement: Describe which structure or region was intended to remain stable and which structure or region was intended to move, with the moving structure or region being named first and the stable segment named second, separated by the word \"on.\"", "offsetInBeginSection": 581, "offsetInEndSection": 846, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26579876", "text": "As anatomists we owe it to the medical and research community to correct the nomenclature to minimize confusion, and to describe the heart properly in respect to its surrounding structures.", "offsetInBeginSection": 692, "offsetInEndSection": 881, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18301504", "text": "The Babinet principle is used to separate components that describe the data signal, servo signals, and three types of cross talk.", "offsetInBeginSection": 166, "offsetInEndSection": 295, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7706b79e632bc066000009", "body": "What is trismus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2090084", "http://www.ncbi.nlm.nih.gov/pubmed/25303582", "http://www.ncbi.nlm.nih.gov/pubmed/34031281", "http://www.ncbi.nlm.nih.gov/pubmed/10765845", "http://www.ncbi.nlm.nih.gov/pubmed/27255150", "http://www.ncbi.nlm.nih.gov/pubmed/32766081", "http://www.ncbi.nlm.nih.gov/pubmed/33456691", "http://www.ncbi.nlm.nih.gov/pubmed/30271636", "http://www.ncbi.nlm.nih.gov/pubmed/34895786", "http://www.ncbi.nlm.nih.gov/pubmed/16154654"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26058916", "text": "Trismus is characterized by a reduced ability to open the mouth, directly affecting many aspects of daily life, such as chewing, swallowing, speaking and maintaining oral hygiene.", "offsetInBeginSection": 0, "offsetInEndSection": 179, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26058916", "text": "Radiotherapy in the head and neck area is identified as one of the most frequent causes of trismus in head and neck cancer (HNC) patients.", "offsetInBeginSection": 260, "offsetInEndSection": 398, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23193958", "text": "Trismus severely impairs HRQL and negatively affects daily life activities in patients with H&N cancer.", "offsetInBeginSection": 1632, "offsetInEndSection": 1735, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20236743", "text": "Trismus is a serious problem for some patients after oral and oropharyngeal cancer, and it has a detrimental impact on quality of life and function.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22632890", "text": "Trismus is frequently a sequel of temporomandibular joint (TMJ) involvement in a zygomaticomaxillary complex (ZMC) fracture.", "offsetInBeginSection": 0, "offsetInEndSection": 124, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28122104", "text": "In conclusion, exercise with TheraBite improved MIO and trismus-related symptoms in patients with trismus secondary to head and neck cancer.", "offsetInBeginSection": 1050, "offsetInEndSection": 1190, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28122104", "text": "Trismus is a common symptom in patients with head and neck cancer that affects many aspects of daily life negatively.", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27627138", "text": "BACKGROUND Trismus, a restricted mouth opening in head and neck cancer patients may be caused by tumor infiltration in masticatory muscles, radiation-induced fibrosis or scarring after surgery.", "offsetInBeginSection": 0, "offsetInEndSection": 193, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23154328", "text": "In conclusion, involvement of buccal region, ablative surgery, radiotherapy, and recurrence are provocative factors of trismus.", "offsetInBeginSection": 797, "offsetInEndSection": 924, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23154328", "text": "Trismus is a common problem among oral cancer patients.", "offsetInBeginSection": 0, "offsetInEndSection": 55, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a67ab79b750ff445500000b", "body": "CURB65 score is used for stratification of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16928720", "http://www.ncbi.nlm.nih.gov/pubmed/32923449", "http://www.ncbi.nlm.nih.gov/pubmed/21539743", "http://www.ncbi.nlm.nih.gov/pubmed/20920140", "http://www.ncbi.nlm.nih.gov/pubmed/20529344", "http://www.ncbi.nlm.nih.gov/pubmed/31258921", "http://www.ncbi.nlm.nih.gov/pubmed/34686088", "http://www.ncbi.nlm.nih.gov/pubmed/18991510", "http://www.ncbi.nlm.nih.gov/pubmed/22118182", "http://www.ncbi.nlm.nih.gov/pubmed/26186637"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344", "text": "METHODS We assessed clinical parameters and five biomarkers, the precursor levels of adrenomedullin (ADM), endothelin-1 (ET1), atrial-natriuretic peptide (ANP), anti-diuretic hormone (copeptin), and procalcitonin in patients with LRTI and CAP enrolled in the multicenter ProHOSP study.", "offsetInBeginSection": 232, "offsetInEndSection": 517, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140", "text": "The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia.", "offsetInBeginSection": 1509, "offsetInEndSection": 1679, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140", "text": "The CURB65 score was developed to predict mortality risk in community acquired pneumonia.", "offsetInBeginSection": 228, "offsetInEndSection": 317, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743", "text": "CONCLUSIONS The new CURB65-A risk score combining CURB65 risk classes with ProADM cut-off values accurately predicts adverse events and mortality in patients with CAP and non-CAP-LRTI.", "offsetInBeginSection": 1744, "offsetInEndSection": 1928, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743", "text": "We aimed to derive a practical algorithm combining the CURB65 score with ProADM-levels in patients with community-acquired pneumonia (CAP) and non-CAP-LRTI.", "offsetInBeginSection": 162, "offsetInEndSection": 318, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743", "text": "RESULTS CURB65 and ProADM predicted both adverse events and mortality similarly well in CAP and non-CAP-LRTI.", "offsetInBeginSection": 658, "offsetInEndSection": 767, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743", "text": "The combined CURB65-A risk score provided better prediction of death and adverse events than the CURB65 score in the entire cohort and in CAP and non-CAP-LRTI patients.", "offsetInBeginSection": 768, "offsetInEndSection": 936, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743", "text": "A composite score (CURB65-A) was created combining CURB65 classes with ProADM cut-offs to further risk-stratify patients.", "offsetInBeginSection": 534, "offsetInEndSection": 655, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24931899", "text": "CONCLUSION Presepsin is a valuable biomarker in predicting severity and outcome in CAP patients in the ED and Presepsin in combination with CURB65 score significantly enhanced the predictive accuracy.", "offsetInBeginSection": 1704, "offsetInEndSection": 1904, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26237261", "text": "BACKGROUND An intervention trial found a trend for shorter length of stay (LOS) in patients with community-acquired pneumonia (CAP) when the CURB65 score was combined with the prognostic biomarker proadrenomedullin (ProADM) (CURB65-A).", "offsetInBeginSection": 0, "offsetInEndSection": 235, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6cfe27b750ff4455000029", "body": "What is SMiLE-seq?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28092692", "http://www.ncbi.nlm.nih.gov/pubmed/35858192", "http://www.ncbi.nlm.nih.gov/pubmed/36267955", "http://www.ncbi.nlm.nih.gov/pubmed/34249793", "http://www.ncbi.nlm.nih.gov/pubmed/32243424", "http://www.ncbi.nlm.nih.gov/pubmed/24389415", "http://www.ncbi.nlm.nih.gov/pubmed/35947004", "http://www.ncbi.nlm.nih.gov/pubmed/35909114", "http://www.ncbi.nlm.nih.gov/pubmed/35536712", "http://www.ncbi.nlm.nih.gov/pubmed/26058022"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692", "text": "Here, we present a novel, semiautomated protein-DNA interaction characterization technology, selective microfluidics-based ligand enrichment followed by sequencing (SMiLE-seq).", "offsetInBeginSection": 127, "offsetInEndSection": 303, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692", "text": "We validated SMiLE-seq by analyzing 58 full-length human, mouse, and Drosophila TFs from distinct structural classes.", "offsetInBeginSection": 504, "offsetInEndSection": 621, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692", "text": "SMiLE-seq is neither limited by DNA bait length nor biased toward strong affinity binders; it probes the DNA-binding properties of TFs over a wide affinity range in a fast and cost-effective fashion.", "offsetInBeginSection": 304, "offsetInEndSection": 503, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25195479", "text": "CLINICAL RELEVANCE Smile analysis is an essential part of smile diagnosis.", "offsetInBeginSection": 346, "offsetInEndSection": 420, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19429690", "text": "Moreover, SMILE interacts with specific HDACs (histone deacetylases) and SMILE-mediated repression is released by HDAC inhibitor trichostatin A, in a NR-specific manner.", "offsetInBeginSection": 836, "offsetInEndSection": 1005, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19429690", "text": "SMILE (small heterodimer partner interacting leucine zipper protein) has been identified as a coregulator in ER signaling.", "offsetInBeginSection": 0, "offsetInEndSection": 122, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19429690", "text": "Adenoviral overexpression of SMILE represses GR-, CAR- and HNF4 alpha-mediated target gene expression.", "offsetInBeginSection": 1131, "offsetInEndSection": 1233, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19690166", "text": "SMILE (small heterodimer partner interacting leucine zipper protein) has been identified as a corepressor of the glucocorticoid receptor, constitutive androstane receptor, and hepatocyte nuclear factor 4alpha.", "offsetInBeginSection": 0, "offsetInEndSection": 209, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19690166", "text": "Interestingly, the repression of SMILE on ERRgamma is released by SIRT1 inhibitors, a catalytically inactive SIRT1 mutant, and SIRT1 small interfering RNA but not by histone protein deacetylase inhibitor.", "offsetInBeginSection": 645, "offsetInEndSection": 849, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19690166", "text": "Overall, these findings implicate SMILE as a novel corepressor of ERRgamma and recruitment of SIRT1 as a novel repressive mechanism for SMILE and ERRgamma inverse agonist.", "offsetInBeginSection": 1641, "offsetInEndSection": 1812, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a77072c9e632bc06600000a", "body": "What is craniosynostosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17980312", "http://www.ncbi.nlm.nih.gov/pubmed/35451466", "http://www.ncbi.nlm.nih.gov/pubmed/30976281", "http://www.ncbi.nlm.nih.gov/pubmed/34161690", "http://www.ncbi.nlm.nih.gov/pubmed/27622416", "http://www.ncbi.nlm.nih.gov/pubmed/29610183", "http://www.ncbi.nlm.nih.gov/pubmed/28740400", "http://www.ncbi.nlm.nih.gov/pubmed/27226847", "http://www.ncbi.nlm.nih.gov/pubmed/22038757", "http://www.ncbi.nlm.nih.gov/pubmed/29093661"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29093661", "text": "Syndromic forms of craniosynostosis arise from mutations in genes belonging to the Fibroblast Growth Factor Receptor (FGFR) family and the interconnected molecular pathways in most cases.", "offsetInBeginSection": 361, "offsetInEndSection": 548, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27622416", "text": "Prenatal ultrasound`s detection rate of craniosynostosis is low.", "offsetInBeginSection": 735, "offsetInEndSection": 799, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27226847", "text": "FGFR2, FGFR3, FGFR1, TWIST1 and EFNB1 genes are major causative genes of genetic syndromes associated with craniosynostosis.", "offsetInBeginSection": 632, "offsetInEndSection": 756, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26910679", "text": "Among various craniosynostosis forms, sagittal nonsyndromic craniosynostosis is the most prevalent.", "offsetInBeginSection": 114, "offsetInEndSection": 213, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26910679", "text": "FGFR1-3 mutational hotspots and the entire TWIST1, RAB23, and BMP2 coding regions were screened because of their known roles in human nonsyndromic or syndromic sagittal craniosynostosis, expression patterns, and/or animal model studies.", "offsetInBeginSection": 615, "offsetInEndSection": 851, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24071792", "text": "RESULTS The incidence rate of craniosynostosis was highest for first-degree relatives of probands with metopic craniosynostosis (6.4%), followed by those with complex craniosynostosis (4.9%), sagittal craniosynostosis (3.8%), lambdoid craniosynostosis (3.9%), and coronal craniosynostosis (0.7%).", "offsetInBeginSection": 457, "offsetInEndSection": 753, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20108486", "text": "Mutations in the genes encoding fibroblast growth factor receptors 1, 2 and 3 (FGFR-1, FGFR-2, FGFR-3), TWIST and MSX2 (muscle segment homebox 2) have been identified in certain syndromic craniosynostosis.", "offsetInBeginSection": 814, "offsetInEndSection": 1019, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28623672", "text": "Craniosynostosis is a developmental craniofacial anomaly, resulting in impairment of brain development and abnormally shaped skull.", "offsetInBeginSection": 0, "offsetInEndSection": 131, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28654618", "text": "When anomalies outside the skull are present, craniosynostosis is often part of a syndrome and usually involves multiple sutures (syndromic craniosynostosis).", "offsetInBeginSection": 1017, "offsetInEndSection": 1175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28654618", "text": "Understand the craniofacial dysmorphology associated with nonsyndromic craniosynostosis.", "offsetInBeginSection": 86, "offsetInEndSection": 174, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a67b152b750ff445500000e", "body": "Describe nursemaid's elbow injury.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21317693", "http://www.ncbi.nlm.nih.gov/pubmed/31687997", "http://www.ncbi.nlm.nih.gov/pubmed/19657259", "http://www.ncbi.nlm.nih.gov/pubmed/31695989", "http://www.ncbi.nlm.nih.gov/pubmed/28503271", "http://www.ncbi.nlm.nih.gov/pubmed/7560033", "http://www.ncbi.nlm.nih.gov/pubmed/19821438", "http://www.ncbi.nlm.nih.gov/pubmed/7773660", "http://www.ncbi.nlm.nih.gov/pubmed/27294496", "http://www.ncbi.nlm.nih.gov/pubmed/35319578"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259", "text": "Nursemaid's elbow is a common injury in young children that can often be prevented.", "offsetInBeginSection": 144, "offsetInEndSection": 227, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259", "text": "Activities such as swinging a child by the hands or pulling on the pronated upper extremity can cause nursemaid's elbow.", "offsetInBeginSection": 324, "offsetInEndSection": 444, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496", "text": "This article also reviews successful reduction maneuvers for nursemaid's elbow.", "offsetInBeginSection": 803, "offsetInEndSection": 882, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496", "text": "Nursemaid's elbow and elbow fractures are both common causes of acute elbow pain, but the mechanism of injury is quite different.", "offsetInBeginSection": 0, "offsetInEndSection": 129, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21317693", "text": "Nursemaid's elbow (subluxation of the radial head) is a common pediatric upper extremity injury encountered in the emergency and urgent care settings.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11153321", "text": "Nursemaid's elbow, also known as a pulled elbow or a subluxated radial head, may result from the specific activities described above and is the most common dislocation injury handled by pediatricians.", "offsetInBeginSection": 520, "offsetInEndSection": 720, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7773660", "text": "Subluxation of the radial head, or \"nursemaid's elbow,\" is a common injury among children aged 1 to 4 years.", "offsetInBeginSection": 0, "offsetInEndSection": 108, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7560033", "text": "Acute annular ligament interposition into the radiocapitellar joint (\"nursemaid's elbow\") is a common injury in children younger than 5 years.", "offsetInBeginSection": 0, "offsetInEndSection": 142, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27836316", "text": "CONCLUSIONS Hyperpronation was more effective in terms of success rate and seems to be less painful compared to the supination-flexion maneuver in children with nursemaid's elbow.", "offsetInBeginSection": 1582, "offsetInEndSection": 1761, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27836316", "text": "The aim of this systematic review and meta-analysis was to compare the two most commonly performed maneuvers (supination-flexion and hyperpronation) in the treatment of nursemaid's elbow.", "offsetInBeginSection": 232, "offsetInEndSection": 419, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6d08d5b750ff445500002c", "body": "Which stapled peptide has been designed to target Ctf4?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28815832", "http://www.ncbi.nlm.nih.gov/pubmed/32104498", "http://www.ncbi.nlm.nih.gov/pubmed/32220493", "http://www.ncbi.nlm.nih.gov/pubmed/26159518", "http://www.ncbi.nlm.nih.gov/pubmed/34311259", "http://www.ncbi.nlm.nih.gov/pubmed/24336354", "http://www.ncbi.nlm.nih.gov/pubmed/35492160", "http://www.ncbi.nlm.nih.gov/pubmed/29598901", "http://www.ncbi.nlm.nih.gov/pubmed/35731722", "http://www.ncbi.nlm.nih.gov/pubmed/32226843"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832", "text": "Herein, we report the design, optimization, and validation of double-click stapled peptides encoding the Ctf4-interacting peptide (CIP) of the replicative helicase subunit Sld5.", "offsetInBeginSection": 313, "offsetInEndSection": 490, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832", "text": "By screening stapling positions in the Sld5 CIP, we identified an unorthodox i,i+6 stapled peptide with improved, submicromolar binding to Ctf4.", "offsetInBeginSection": 491, "offsetInEndSection": 635, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832", "text": "The mode of interaction with Ctf4 was confirmed by a crystal structure of the stapled Sld5 peptide bound to Ctf4.", "offsetInBeginSection": 636, "offsetInEndSection": 749, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832", "text": "The stapled Sld5 peptide was able to displace the Ctf4 partner DNA polymerase\u2005\u03b1 from the replisome in yeast extracts.", "offsetInBeginSection": 750, "offsetInEndSection": 870, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832", "text": "The Ctf4/AND-1 protein hub, which links DNA replication, repair, and chromosome segregation, represents a novel target for the synthetic lethality approach.", "offsetInBeginSection": 156, "offsetInEndSection": 312, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27397685", "text": "Here, we identify new Ctf4 partners in\u00a0addition to Pol \u03b1 and helicase, all of which contain a \"Ctf4-interacting-peptide\" or CIP-box.", "offsetInBeginSection": 266, "offsetInEndSection": 400, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27057630", "text": "Our results demonstrate both the high level of structural p53 mimicry employed by PM2 to engage HDM2, and the potential resilience of stapled peptide antagonists to mutations in target proteins.", "offsetInBeginSection": 1038, "offsetInEndSection": 1232, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27057630", "text": "Interrogation of a large collection of randomly mutated HDM2 proteins failed to identify point mutations that could selectively abrogate binding by a stapled peptide inhibitor (PM2).", "offsetInBeginSection": 671, "offsetInEndSection": 853, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27057630", "text": "Stapled peptides represent a novel class of antagonists capable of inhibiting therapeutically relevant protein-protein interactions.", "offsetInBeginSection": 321, "offsetInEndSection": 453, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22230563", "text": "One type that has shown promise in early-stage studies is hydrocarbon-stapled \u03b1-helical peptides, a novel class of synthetic miniproteins locked into their bioactive \u03b1-helical fold through the site-specific introduction of a chemical brace, an all-hydrocarbon staple.", "offsetInBeginSection": 667, "offsetInEndSection": 936, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a773c50faa1ab7d2e000002", "body": "Has ATF4 transcription factor been linked to cancer and neoplastic transformation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22102693", "http://www.ncbi.nlm.nih.gov/pubmed/33628101", "http://www.ncbi.nlm.nih.gov/pubmed/28797581", "http://www.ncbi.nlm.nih.gov/pubmed/25690730", "http://www.ncbi.nlm.nih.gov/pubmed/28843961", "http://www.ncbi.nlm.nih.gov/pubmed/31534554", "http://www.ncbi.nlm.nih.gov/pubmed/20696107", "http://www.ncbi.nlm.nih.gov/pubmed/19823771", "http://www.ncbi.nlm.nih.gov/pubmed/17466566", "http://www.ncbi.nlm.nih.gov/pubmed/17957143"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693", "text": "Here, we report that ATF4 promotes oncogene-induced neoplastic transformation by suppressing the expression of cellular senescence-associated genes.", "offsetInBeginSection": 261, "offsetInEndSection": 409, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693", "text": "Many cancers overexpress ATF4, a stress-induced transcription factor that promotes cell survival under hypoxic conditions and other stresses of the tumor microenvironment, but the potential contributions of ATF4 to oncogenesis itself have been little explored.", "offsetInBeginSection": 0, "offsetInEndSection": 260, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441", "text": "These include mitogen-activated protein kinase kinase (MAPKK), CCAAT/enhancer-binding protein (C/EBP), activating transcription factor 4 (ATF4) and C/EBP-homologous protein (CHOP).", "offsetInBeginSection": 234, "offsetInEndSection": 414, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26961881", "text": "In Per2 mutant and Cry1/2-null cells, the introduction of oncogenes induced expression of ATF4, a potent repressor of cell senescence-associated proteins p16INK4a and p19ARF.", "offsetInBeginSection": 1001, "offsetInEndSection": 1175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12213216", "text": "H-ras transformation of MCF-10a cells resulted in upregulation of MAP kinase and PI 3-kinase signals, upregulation of sterol regulatory element binding protein 1 (SREBP-1) transcription factor levels, and upregulation of FAS expression and FA synthesis.", "offsetInBeginSection": 659, "offsetInEndSection": 912, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17297441", "text": "We have previously reported that activating transcription factor 4 (ATF4) is upregulated in cisplatin-resistant cells and plays a role in cisplatin resistance.", "offsetInBeginSection": 124, "offsetInEndSection": 283, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17466566", "text": "ATF4 expression is upregulated in cancer.", "offsetInBeginSection": 971, "offsetInEndSection": 1012, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17466566", "text": "Activating transcription factor 4 (ATF4) belongs to the ATF/CREB (activating transcription factor/cyclic AMP response element binding protein) family of basic region-leucine zipper (bZip) transcription factors, which have the consensus binding site cAMP responsive element (CRE).", "offsetInBeginSection": 0, "offsetInEndSection": 279, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28843961", "text": "Activating transcription factor 4 (ATF4), an endoplasmic reticulum stress-inducible transcription factor, plays important roles in cancer progression and resistance to therapy.", "offsetInBeginSection": 0, "offsetInEndSection": 176, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28797581", "text": "Activating transcription factor 4 (ATF4) is a stress-induced transcription factor that is frequently upregulated in cancer cells.", "offsetInBeginSection": 0, "offsetInEndSection": 129, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a68eabab750ff4455000015", "body": "Is there an association between Klinefelter syndrome and breast cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8491916", "http://www.ncbi.nlm.nih.gov/pubmed/3111653", "http://www.ncbi.nlm.nih.gov/pubmed/15626018", "http://www.ncbi.nlm.nih.gov/pubmed/7841064", "http://www.ncbi.nlm.nih.gov/pubmed/21246928", "http://www.ncbi.nlm.nih.gov/pubmed/215842", "http://www.ncbi.nlm.nih.gov/pubmed/9283592", "http://www.ncbi.nlm.nih.gov/pubmed/11976824", "http://www.ncbi.nlm.nih.gov/pubmed/16564924", "http://www.ncbi.nlm.nih.gov/pubmed/3002597"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025", "text": "CONCLUSIONS These results support a hormonal etiology for breast cancer in men and for prostate cancer and suggest that men with Klinefelter syndrome may be at substantially elevated risks for non-Hodgkin lymphoma, breast cancer, and, perhaps, lung cancer.", "offsetInBeginSection": 1368, "offsetInEndSection": 1624, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025", "text": "Compared with the general population, men with Klinefelter syndrome had higher mortality from lung cancer (SMR = 1.5, 95% CI = 1.0 to 2.0), breast cancer (SMR = 57.8, 95% CI = 18.8 to 135.0), and non-Hodgkin lymphoma (SMR = 3.5, 95% CI = 1.6 to 6.6) and lower mortality from prostate cancer (SMR = 0, 95% CI = 0 to 0.7).", "offsetInBeginSection": 737, "offsetInEndSection": 1057, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1690312", "text": "While the association of Klinefelter's syndrome and breast cancer is well known, only recently an increased incidence of mediastinal germ cell tumors in this syndrome has been established, which again is demonstrated in this case report.", "offsetInBeginSection": 285, "offsetInEndSection": 522, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7841064", "text": "Many case reports have suggested an association between Klinefelter syndrome (KS) and cancer, but studies of the cancer incidence in larger groups of men with KS are lacking.", "offsetInBeginSection": 0, "offsetInEndSection": 174, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9283592", "text": "Patients with a 47,XXY karyotype (Klinefelter syndrome) appear to have an increased risk of developing cancer, especially male breast cancer and germ cell tumors, but rarely malignant hematologic disorders.", "offsetInBeginSection": 0, "offsetInEndSection": 206, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21246928", "text": "Klinefelter syndrome has been consistently associated with breast cancer in men (MBC).", "offsetInBeginSection": 109, "offsetInEndSection": 195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21246928", "text": "Klinefelter syndrome, in which patients carry XXY chromosome, may be present in men with breast cancer for this reason they often develop gynecomastia.", "offsetInBeginSection": 1285, "offsetInEndSection": 1436, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11976824", "text": "Since the early 1960s, numerous reports have appeared of an increased risk of malignant neoplasms among patients with Klinefelter syndrome.", "offsetInBeginSection": 439, "offsetInEndSection": 578, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20698148", "text": "Patients with 47, XXY karyotype (Klinefelter syndrome) appear to have increased risk of developing cancer, especially male breast cancer, germ cell tumours and non Hodgkin lymphomas, but rarely acute myeloid leukaemia.", "offsetInBeginSection": 0, "offsetInEndSection": 218, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23464700", "text": "Male breast cancer risk factors show strong association with BRCA2 mutations, as well as Klinefelter syndrome.", "offsetInBeginSection": 418, "offsetInEndSection": 528, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6d1733b750ff4455000030", "body": "Which resource contains accurate enhancer predictions in the developing limb?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28827824", "http://www.ncbi.nlm.nih.gov/pubmed/25984238", "http://www.ncbi.nlm.nih.gov/pubmed/30905748", "http://www.ncbi.nlm.nih.gov/pubmed/34252960", "http://www.ncbi.nlm.nih.gov/pubmed/27929098", "http://www.ncbi.nlm.nih.gov/pubmed/21307091", "http://www.ncbi.nlm.nih.gov/pubmed/26460939", "http://www.ncbi.nlm.nih.gov/pubmed/21655898", "http://www.ncbi.nlm.nih.gov/pubmed/30372441", "http://www.ncbi.nlm.nih.gov/pubmed/32142172"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824", "text": "Here we present the Limb-Enhancer Genie (LEG), a collection of highly accurate, genome-wide predictions of enhancers in the developing limb, available through a user-friendly online interface.", "offsetInBeginSection": 415, "offsetInEndSection": 607, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824", "text": "We predict limb enhancers using a combination of >50 published limb-specific datasets and clusters of evolutionarily conserved transcription factor binding sites, taking advantage of the patterns observed at previously in vivo validated elements.", "offsetInBeginSection": 608, "offsetInEndSection": 854, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824", "text": "Moreover, we describe general features that can guide the type of datasets to include when predicting tissue-specific enhancers genome-wide, while providing an accessible resource to the general biological community and facilitating the functional interpretation of genetic studies of limb malformations.", "offsetInBeginSection": 1285, "offsetInEndSection": 1589, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824", "text": "Epigenomic mapping of enhancer-associated chromatin modifications facilitates the genome-wide discovery of tissue-specific enhancers in vivo.", "offsetInBeginSection": 0, "offsetInEndSection": 141, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21637758", "text": "The pipeline combines both the accurate computational genome-wide prediction of neuronal specific cis-regulatory modules (CRMs) and a newly developed experimental setup to rapidly obtain transgenic lines in a cost-effective and highly reproducible manner.", "offsetInBeginSection": 585, "offsetInEndSection": 840, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15212693", "text": "CONCLUSION Phospho.ELM will be a valuable tool both for molecular biologists working on protein phosphorylation sites and for bioinformaticians developing computational predictions on the specificity of phosphorylation reactions.", "offsetInBeginSection": 1247, "offsetInEndSection": 1476, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29092931", "text": "The results include reconstruction of functional enhancer profiles, \"super-enhancer\" target genes, as well as predictions of active transcription factors and their target genes for each TCGA cancer type.", "offsetInBeginSection": 559, "offsetInEndSection": 762, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26091399", "text": "Integrating shape features with a machine-learning algorithm AdaBoost, we developed an enhancer predicting method, DELTA (Distal Enhancer Locating Tool based on AdaBoost).", "offsetInBeginSection": 721, "offsetInEndSection": 892, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26091399", "text": "We show that DELTA significantly outperforms current enhancer prediction methods in prediction accuracy on different datasets and can predict enhancers in one cell type using models trained in other cell types without loss of accuracy.", "offsetInBeginSection": 893, "offsetInEndSection": 1128, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29159193", "text": "While further work is needed to potentially incorporate sensory and cognitive factors, the algorithm can be used within days of stroke to provide accurate predictions of upper limb functional outcomes at 3\u00a0months after stroke.", "offsetInBeginSection": 1451, "offsetInEndSection": 1678, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7877c0faa1ab7d2e00000c", "body": "What is the first line treatment for sarcoidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28696638", "http://www.ncbi.nlm.nih.gov/pubmed/26204816", "http://www.ncbi.nlm.nih.gov/pubmed/35660263", "http://www.ncbi.nlm.nih.gov/pubmed/16536004", "http://www.ncbi.nlm.nih.gov/pubmed/10598414", "http://www.ncbi.nlm.nih.gov/pubmed/34569301", "http://www.ncbi.nlm.nih.gov/pubmed/23880702", "http://www.ncbi.nlm.nih.gov/pubmed/28056473", "http://www.ncbi.nlm.nih.gov/pubmed/26478443", "http://www.ncbi.nlm.nih.gov/pubmed/26120005"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609", "text": "For symptomatic patients, the first line treatment includes corticosteroids or ursodeoxycholic acid.", "offsetInBeginSection": 892, "offsetInEndSection": 992, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28696638", "text": "Systemic corticosteroids are the first line treatment in sarcoidosis.", "offsetInBeginSection": 323, "offsetInEndSection": 392, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26419478", "text": "While corticosteroids remain the first line of treatment, tumour necrosis factor alpha (TNF-\u03b1) inhibitors have been investigated as one potential steroid sparing treatment for sarcoidosis.", "offsetInBeginSection": 122, "offsetInEndSection": 311, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26419478", "text": "Paradoxically, in some patients treated with biologic TNF-\u03b1 inhibitors for other diseases, treatment can induce the development of sarcoidosis.", "offsetInBeginSection": 541, "offsetInEndSection": 685, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26120005", "text": "This case reports a rare presentation of preschool sarcoidosis as well as the novel and successful use of pulse methylprednisolone in paediatric pulmonary sarcoidosis.", "offsetInBeginSection": 505, "offsetInEndSection": 672, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26330764", "text": "Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases.", "offsetInBeginSection": 329, "offsetInEndSection": 474, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26330764", "text": "Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management.", "offsetInBeginSection": 118, "offsetInEndSection": 272, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23196575", "text": "For patients who are refractory to or intolerant of corticosteroid therapy, second-line agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, and mycophenolate mofetil (MMF).", "offsetInBeginSection": 1008, "offsetInEndSection": 1203, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27598883", "text": "Oral corticosteroids are the first line of treatment.", "offsetInBeginSection": 1211, "offsetInEndSection": 1264, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10719453", "text": "TREATMENT Corticosteroid therapy is given as first line treatment with a satisfactory effect in most cases.", "offsetInBeginSection": 817, "offsetInEndSection": 924, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a68f005b750ff4455000016", "body": "Which personality disorder is treated using dialectical behavior therapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20975829", "http://www.ncbi.nlm.nih.gov/pubmed/11177762", "http://www.ncbi.nlm.nih.gov/pubmed/29955449", "http://www.ncbi.nlm.nih.gov/pubmed/18186120", "http://www.ncbi.nlm.nih.gov/pubmed/26160623", "http://www.ncbi.nlm.nih.gov/pubmed/32535985", "http://www.ncbi.nlm.nih.gov/pubmed/35913768", "http://www.ncbi.nlm.nih.gov/pubmed/24000870", "http://www.ncbi.nlm.nih.gov/pubmed/8010153", "http://www.ncbi.nlm.nih.gov/pubmed/11697073"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357", "text": "Treatment outcome data for Dialectical Behavior Therapy of borderline personality disorder and Trauma Model Therapy of dissociative identity disorder are reviewed.", "offsetInBeginSection": 177, "offsetInEndSection": 340, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179", "text": "OBJECTIVE The authors describe the use of dialectical behavior therapy (DBT) in treating borderline personality disorder during psychiatry residency, and assess the status of DBT education within psychiatry residencies in the United States.", "offsetInBeginSection": 0, "offsetInEndSection": 240, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9603574", "text": "Dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "offsetInBeginSection": 0, "offsetInEndSection": 201, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7977884", "text": "CONCLUSIONS These results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "offsetInBeginSection": 882, "offsetInEndSection": 1106, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15930077", "text": "OBJECTIVE The aim of this study was to determine the efficacy and safety of dialectical behavior therapy plus olanzapine compared with dialectical behavior therapy plus placebo in patients with borderline personality disorder.", "offsetInBeginSection": 0, "offsetInEndSection": 226, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19755574", "text": "CONCLUSIONS These results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder.", "offsetInBeginSection": 1458, "offsetInEndSection": 1723, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20579633", "text": "A central component of Dialectical Behavior Therapy (DBT) is the teaching of specific behavioral skills with the aim of helping individuals with Borderline Personality Disorder (BPD) replace maladaptive behaviors with skillful behavior.", "offsetInBeginSection": 0, "offsetInEndSection": 236, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27642799", "text": "Dialectical behavior therapy (DBT) was originally developed by Marsha Linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, DBT is also increasingly being recommended for the treatment of CD and APD.", "offsetInBeginSection": 343, "offsetInEndSection": 646, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18186120", "text": "Dialectical behavior therapy (DBT) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "offsetInBeginSection": 0, "offsetInEndSection": 220, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25373068", "text": "CONTEXT Dialectical Behavior Therapy (DBT) is an evidence-based therapy developed for the treatment of suicidal behaviors and disorders characterized by emotional and behavioral dyscontrol that is effective in veteran populations.", "offsetInBeginSection": 0, "offsetInEndSection": 230, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6d186db750ff4455000031", "body": "Is there any role of Dlx1 and Dlx2 transcription factors in cortical interneurons?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29028947", "http://www.ncbi.nlm.nih.gov/pubmed/17582322", "http://www.ncbi.nlm.nih.gov/pubmed/17582329", "http://www.ncbi.nlm.nih.gov/pubmed/16007083", "http://www.ncbi.nlm.nih.gov/pubmed/24236816", "http://www.ncbi.nlm.nih.gov/pubmed/26620267", "http://www.ncbi.nlm.nih.gov/pubmed/18562615", "http://www.ncbi.nlm.nih.gov/pubmed/28276447", "http://www.ncbi.nlm.nih.gov/pubmed/17259176", "http://www.ncbi.nlm.nih.gov/pubmed/27983964"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947", "text": "The postnatal functions of the Dlx1&2 transcription factors in cortical interneurons (CINs) are unknown.", "offsetInBeginSection": 0, "offsetInEndSection": 104, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176", "text": "Dlx1/Dlx2 null mice die at birth with an abnormal cortical phenotype, including impaired differentiation and migration of GABAergic interneurons to the neocortex.", "offsetInBeginSection": 79, "offsetInEndSection": 241, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176", "text": "This is the first report that DLX1 or DLX2 can function as transcriptional repressors.", "offsetInBeginSection": 967, "offsetInEndSection": 1053, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176", "text": "Of importance, there is up-regulated and aberrant expression of NRP-2 in the forebrains of Dlx1/Dlx2 null mice.", "offsetInBeginSection": 855, "offsetInEndSection": 966, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17582322", "text": "In this issue of Neuron, Rubenstein and colleagues demonstrate that the homeobox proteins Dlx1 and Dlx2 promote interneuron migration in part by preventing the premature expression of PAK3, a serine/threonine kinase that is later involved in neurite outgrowth and other aspects of interneuron maturation.", "offsetInBeginSection": 172, "offsetInEndSection": 476, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28821666", "text": "DLX1 and/or DLX2 activated the transcription of both Gad genes, and defects in Dlx function disrupted the differentiation of GABAergic interneurons with global reduction in GABA levels in the forebrains of the Dlx1/Dlx2 double knock-out mouse in vivo Identification of Gad genes as direct Dlx transcriptional targets is significant; it extends our understanding of Dlx gene function in the developing forebrain beyond the regulation of tangential interneuron migration to the differentiation of GABAergic interneurons arising from the basal telencephalon, and may help to unravel the pathogenesis of several developmental brain disorders.SIGNIFICANCE STATEMENT GABA is the major inhibitory neurotransmitter in the brain.", "offsetInBeginSection": 1014, "offsetInEndSection": 1734, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28821666", "text": "We have discovered that specific promoter regulatory elements of glutamic acid decarboxylase isoforms (Gad1 and Gad2), which regulate GABA synthesis from the excitatory neurotransmitter glutamate, are direct transcriptional targets of both DLX1 and DLX2 homeoproteins in vivo Further gain- and loss-of-function studies in vitro and in vivo demonstrated that both DLX1 and DLX2 are necessary and sufficient for Gad gene expression.", "offsetInBeginSection": 583, "offsetInEndSection": 1013, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28821666", "text": "We show that Dlx1/Dlx2 homeobox genes regulate GABA synthesis during forebrain development through direct activation of glutamic acid decarboxylase enzyme isoforms that convert glutamate to GABA.", "offsetInBeginSection": 1735, "offsetInEndSection": 1930, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16766712", "text": "Toward elucidating the mechanisms underlying the generation of interneuron diversity, we have studied in mice the expression patterns in differentiating and mature neocortical interneurons of 8 transcription factors, including 6 homeobox (Dlx1, Dlx2, Dlx5, Arx, Lhx6, Cux2), 1 basic helix-loop-helix, (NPAS1), and 1 bZIP (MafB).", "offsetInBeginSection": 261, "offsetInEndSection": 589, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19026749", "text": "DLX1 and DLX2 transcription factors are necessary for forebrain GABAergic neuron differentiation, migration, and survival.", "offsetInBeginSection": 0, "offsetInEndSection": 122, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a79d0b8faa1ab7d2e00000d", "body": "What cellular process are okazaki fragments associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35879148", "http://www.ncbi.nlm.nih.gov/pubmed/33157085", "http://www.ncbi.nlm.nih.gov/pubmed/21278448", "http://www.ncbi.nlm.nih.gov/pubmed/25814667", "http://www.ncbi.nlm.nih.gov/pubmed/20178844", "http://www.ncbi.nlm.nih.gov/pubmed/11676941", "http://www.ncbi.nlm.nih.gov/pubmed/23451868", "http://www.ncbi.nlm.nih.gov/pubmed/18635534", "http://www.ncbi.nlm.nih.gov/pubmed/16935873", "http://www.ncbi.nlm.nih.gov/pubmed/10636085"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448", "text": "Therefore, efficient processing of Okazaki fragments is vital for DNA replication and cell proliferation.", "offsetInBeginSection": 263, "offsetInEndSection": 368, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448", "text": "During this process, primase-synthesized RNA/DNA primers are removed, and Okazaki fragments are joined into an intact lagging strand DNA.", "offsetInBeginSection": 369, "offsetInEndSection": 506, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28159842", "text": "During DNA replication in eukaryotic cells, short single-stranded DNA segments known as Okazaki fragments are first synthesized on the lagging strand.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28159842", "text": "The Okazaki fragments originate from \u223c35-nucleotide-long RNA-DNA primers.", "offsetInBeginSection": 151, "offsetInEndSection": 226, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23451868", "text": "Substrate specificity allows FEN1 to process intermediates of Okazaki fragment maturation, long-patch base excision repair, telomere maintenance, and stalled replication fork rescue.", "offsetInBeginSection": 206, "offsetInEndSection": 388, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25814667", "text": "During replication, Okazaki fragment maturation is a fundamental process that joins discontinuously synthesized DNA fragments into a contiguous lagging strand.", "offsetInBeginSection": 0, "offsetInEndSection": 159, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19779567", "text": "We propose that TbPIF5 unwinds RNA primers after lagging strand synthesis, thus facilitating processing of Okazaki fragments.", "offsetInBeginSection": 1315, "offsetInEndSection": 1440, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24035200", "text": "Lagging strand DNA replication requires the concerted actions of DNA polymerase \u03b4, Fen1 and DNA ligase I for the removal of the RNA/DNA primers before ligation of Okazaki fragments.", "offsetInBeginSection": 0, "offsetInEndSection": 182, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/227871", "text": "These intermediates accumulated during excision of RNA primers in the presence of adenine 9-beta-D-arabinoside 5'-triphosphate, and those Okazaki fragments blocked by RNA primers (class III) were found to have originated the farthest from the 5' ends of long nascent DNA strands.", "offsetInBeginSection": 2359, "offsetInEndSection": 2638, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/227871", "text": "However, when washed nuclei were incubated in the abscence of cytosol, both class I and class II Okazaki fragments accumulated despite the excision of RNA primers: class III Okazaki fragments and RNA-DNA covalent linkages both disappeared at similar rates.", "offsetInBeginSection": 1172, "offsetInEndSection": 1428, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a68f633b750ff4455000019", "body": "Is creatinine assessment included in the MELD score?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24119148", "http://www.ncbi.nlm.nih.gov/pubmed/17692661", "http://www.ncbi.nlm.nih.gov/pubmed/29404491", "http://www.ncbi.nlm.nih.gov/pubmed/35014073", "http://www.ncbi.nlm.nih.gov/pubmed/22380485", "http://www.ncbi.nlm.nih.gov/pubmed/15482344", "http://www.ncbi.nlm.nih.gov/pubmed/24696621", "http://www.ncbi.nlm.nih.gov/pubmed/23717537", "http://www.ncbi.nlm.nih.gov/pubmed/20346070", "http://www.ncbi.nlm.nih.gov/pubmed/27480755"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344", "text": "The MELD score has a short-term prognostic yield that is better than what is provided by both the CTP and CTP creatinine-modified scores, even in cirrhotic patients who are not critically ill.", "offsetInBeginSection": 1912, "offsetInEndSection": 2104, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344", "text": "However, the MELD score proved to be better at defining patients' prognosis in the short-term as compared with both the traditional CTP score (P=0.012) and the creatinine-modified CTP (P=0.047).", "offsetInBeginSection": 1404, "offsetInEndSection": 1598, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714", "text": "CONCLUSION Incorporating eGFR obtained by the 6-variable MDRD equation into the MELD score showed an equal predictive performance in in-hospital mortality compared to a creatinine-based MELD score.", "offsetInBeginSection": 3159, "offsetInEndSection": 3356, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714", "text": "MELD-MDRD-6 included 6-variable MDRD eGFR as one of the variables and showed an improvement over MELD score, as suggested by an increase in chi-square (2293.82 vs 2198.32) and a decrease in -2 log (likelihood) (2810.77 vs 2664.79).", "offsetInBeginSection": 2353, "offsetInEndSection": 2584, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714", "text": "Finally, when serum creatinine was replaced by CKD-EPI eGFR, it showed a slight improvement compared to the original MELD score (chi-square: 2199.16, -2 log (likelihood): 2773.07).", "offsetInBeginSection": 2585, "offsetInEndSection": 2765, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714", "text": "MELD-MDRD-4 excluded serum creatinine, with the coefficients refit among the remaining 3 variables, i.e., total bilirubin, INR and 4-variable MDRD eGFR.", "offsetInBeginSection": 2014, "offsetInEndSection": 2166, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24601755", "text": "The MELD-Bicarbonate equation, which included three variables (international normalized ratio, creatinine level, and HCO3 level), showed better prognostic value than the original MELD score in critically ill patients with cirrhosis.", "offsetInBeginSection": 1362, "offsetInEndSection": 1594, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20827408", "text": "Changes in MELD score simple during the admission, which were calculated by CRE and TBI [3.8 \u00d7 log (bilirubin (mg/dl)] + 9.6 \u00d7 log [Creatinine (mg/dl) + 6.43], were significant predictor for patients with type 1 HRS.", "offsetInBeginSection": 1423, "offsetInEndSection": 1641, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17370333", "text": "Univariate analysis showed that age, duration of jaundice, jaundice-encephalopathy interval (JEI), grade of encephalopathy, presence of cerebral edema, bilirubin, prothrombin time, creatinine, and MELD score were significantly different between survivors and nonsurvivors.", "offsetInBeginSection": 787, "offsetInEndSection": 1059, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22178107", "text": "MELD score, CKD-EPI formula creatinine-based eGFR and cystatin C-based eGFR were evaluated in 100 cirrhotic patients.", "offsetInBeginSection": 466, "offsetInEndSection": 583, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6d196db750ff4455000032", "body": "Which resource has been developed in order to study the transcriptional regulation of GABAergic cell fate?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27710791", "http://www.ncbi.nlm.nih.gov/pubmed/26843111", "http://www.ncbi.nlm.nih.gov/pubmed/24470343", "http://www.ncbi.nlm.nih.gov/pubmed/28912684", "http://www.ncbi.nlm.nih.gov/pubmed/17910758", "http://www.ncbi.nlm.nih.gov/pubmed/25556833", "http://www.ncbi.nlm.nih.gov/pubmed/24370451", "http://www.ncbi.nlm.nih.gov/pubmed/33130411", "http://www.ncbi.nlm.nih.gov/pubmed/23567272", "http://www.ncbi.nlm.nih.gov/pubmed/34730112"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791", "text": "Thus, these subpallial enhancer transgenic lines are data and tool\u00a0resources to study transcriptional regulation of GABAergic cell fate.", "offsetInBeginSection": 896, "offsetInEndSection": 1033, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24370451", "text": "The basic helix-loop-helix (bHLH) transcriptional activator Ptf1a determines inhibitory GABAergic over excitatory glutamatergic neuronal cell fate in progenitors of the vertebrate dorsal spinal cord, cerebellum and retina.", "offsetInBeginSection": 0, "offsetInEndSection": 222, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24370451", "text": "Thus, Prdm13 is a novel crucial component of the Ptf1a regulatory pathway that, by modulating the transcriptional activity of bHLH factors such as Neurog2, controls the balance between GABAergic and glutamatergic neuronal fate in the dorsal and caudal part of the vertebrate neural tube.", "offsetInBeginSection": 1328, "offsetInEndSection": 1615, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24643195", "text": "Our data show that GABAergic inducing activity of Ascl1 requires the direct transcriptional regulation of Ptf1a, providing therefore a new piece of the network governing neurotransmitter subtype specification during retinogenesis.", "offsetInBeginSection": 1219, "offsetInEndSection": 1449, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24643195", "text": "We showed that it is necessary for retinal GABAergic cell genesis and sufficient in overexpression experiments to bias a subset of retinal precursor cells towards a GABAergic fate.", "offsetInBeginSection": 510, "offsetInEndSection": 690, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28912684", "text": "To explore the transcriptional regulation of the development of cerebellar inhibitory neurons, we examined the role of Tfap2A and Tfap2B in the specification of GABAergic neuronal subtypes in mice.", "offsetInBeginSection": 230, "offsetInEndSection": 427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28912684", "text": "The onset of their expression follows Ptf1a and Olig2, key determinants of GABAergic neuronal fate in the cerebellum; and, their expression precedes Pax2, an interneuron-specific factor.", "offsetInBeginSection": 578, "offsetInEndSection": 764, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25556833", "text": "This multifaceted study generates a powerful resource and informs understanding of the transcriptional regulation underlying pyramidal neuron diversity in the neocortex.", "offsetInBeginSection": 953, "offsetInEndSection": 1122, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26843111", "text": "In order to study its role in the regulation of vestibulo-motor development, we investigated a transgenic mouse expressing Isl1 under the Pax2 promoter control (Tg +/- ).", "offsetInBeginSection": 282, "offsetInEndSection": 452, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17678855", "text": "We show that Dlx homeobox transcription factors, required for GABAergic interneuron production, repress oligodendrocyte precursor cell (OPC) formation by acting on a common progenitor to determine neuronal versus oligodendroglial cell fate acquisition.", "offsetInBeginSection": 300, "offsetInEndSection": 552, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a79d195faa1ab7d2e00000e", "body": "Is celiac disease caused by gliadin-induced transglutaminase-2 (TG2)-dependent events ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27613408", "http://www.ncbi.nlm.nih.gov/pubmed/18793760", "http://www.ncbi.nlm.nih.gov/pubmed/22198767", "http://www.ncbi.nlm.nih.gov/pubmed/32059410", "http://www.ncbi.nlm.nih.gov/pubmed/34059947", "http://www.ncbi.nlm.nih.gov/pubmed/28250436", "http://www.ncbi.nlm.nih.gov/pubmed/26503953", "http://www.ncbi.nlm.nih.gov/pubmed/24391952", "http://www.ncbi.nlm.nih.gov/pubmed/15290344", "http://www.ncbi.nlm.nih.gov/pubmed/24240659"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659", "text": "The present study examined the capability of different oat cultivars of activating the gliadin-induced transglutaminase-2 (TG2)-dependent events in some in vitro models of CD.", "offsetInBeginSection": 275, "offsetInEndSection": 450, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22878839", "text": "Gluten-derived gliadin peptides are deamidated by transglutaminase 2 (TG2), leading to an immune response in the small-intestinal mucosa.", "offsetInBeginSection": 198, "offsetInEndSection": 335, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22878839", "text": "TG2 inhibitors have therefore been suggested as putative drugs for celiac disease.", "offsetInBeginSection": 336, "offsetInEndSection": 418, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27613408", "text": "Type 2 transglutaminase (TG2) has an important pathogenic role in celiac disease (CD), an inflammatory intestinal disease that is caused by the ingestion of gluten-containing cereals.", "offsetInBeginSection": 0, "offsetInEndSection": 183, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15290344", "text": "The discovery that type 2 transglutaminase (TG2) is the main, if not the sole, target of the endomysium CD-specific autoantibodies assigned to this enzyme a master regulator role of CD.", "offsetInBeginSection": 222, "offsetInEndSection": 407, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27263022", "text": "A key player in the pathogenetic process leading to the enteropathy is played by a protein called transglutaminase 2 (TG2), which is able to enzymatically modify gluten-derived gliadin peptides.", "offsetInBeginSection": 382, "offsetInEndSection": 576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15511629", "text": "Deamidation may be catalysed by intestinal tissue transglutaminase (TG2), a protein which is also the main autoantigen in celiac disease.", "offsetInBeginSection": 195, "offsetInEndSection": 332, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18793760", "text": "The in vivo deamidation of gliadin peptides plays an important role in the immunopathogenesis of celiac disease (CD).", "offsetInBeginSection": 112, "offsetInEndSection": 229, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18793760", "text": "Transglutaminase 2 (TG2) catalyzes cross-linking or deamidation of glutamine residues in peptides and proteins.", "offsetInBeginSection": 0, "offsetInEndSection": 111, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23966323", "text": "Celiac disease (CD) is an autoimmune enteropathy triggered by gluten ingestion and characterized by circulating anti-transglutaminase type 2 (anti-TG2) autoantibodies.", "offsetInBeginSection": 0, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a68f965b750ff445500001a", "body": "Clue cells are characteristics to which causative bacteria of vaginitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2668431", "http://www.ncbi.nlm.nih.gov/pubmed/35719334", "http://www.ncbi.nlm.nih.gov/pubmed/32628346", "http://www.ncbi.nlm.nih.gov/pubmed/8017578", "http://www.ncbi.nlm.nih.gov/pubmed/2091736", "http://www.ncbi.nlm.nih.gov/pubmed/21524046", "http://www.ncbi.nlm.nih.gov/pubmed/2576032", "http://www.ncbi.nlm.nih.gov/pubmed/3497132", "http://www.ncbi.nlm.nih.gov/pubmed/16021494", "http://www.ncbi.nlm.nih.gov/pubmed/6610607"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132", "text": "The specific aetiologies of vaginitis are many.", "offsetInBeginSection": 111, "offsetInEndSection": 158, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132", "text": "Vaginitis of undetermined aetiology is more complex and is characterized by a purulent vaginal discharge, a pH of 4.0-4.6, numerous WBC's, and a high concentration of bacteria.", "offsetInBeginSection": 823, "offsetInEndSection": 999, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132", "text": "One of the most common entities, however, is \"non-specific vaginitis\" which can be subdivided into: Gardnerella vaginitis, anaerobic vaginosis, and vaginitis of undetermined aetiology.", "offsetInBeginSection": 159, "offsetInEndSection": 343, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10932748", "text": "Lactobacillus populations, which are usually dominant in healthy women, are replaced by a polymicrobial group of organisms that includes G. vaginalis, anaerobic Gram-negative rods such as Prevotella species, Peptostreptococcus species, Mycoplasma hominis, Ureaplasma urealyticum, and often Mobiluncus species.", "offsetInBeginSection": 479, "offsetInEndSection": 788, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12838684", "text": "Gardnerella vaginalis is found in vaginal flora of women with bacterial vaginitis as well as in healthy women, while anaerobic bacteria such as Mobiluncus and Prevotella are the causative agents for bacterial vaginosis.", "offsetInBeginSection": 257, "offsetInEndSection": 476, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21524046", "text": "Bacterial vaginosis, trichomoniasis, and vulvovaginal candidiasis are the most common infectious causes of vaginitis.", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6336135", "text": "Examination of Gram-stained vaginal smears obtained from infected pig-tailed macaques failed to demonstrate clue cells, a feature which is pathognomonic of non-specific vaginitis in humans.", "offsetInBeginSection": 209, "offsetInEndSection": 398, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11845812", "text": "Aerobic vaginitis was diagnosed if smears were deficient in lactobacilli, positive for cocci or coarse bacilli, positive for parabasal epithelial cells, and/or positive for vaginal leucocytes (plus their granular aspect).", "offsetInBeginSection": 549, "offsetInEndSection": 770, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6607525", "text": "Gardnerella-associated vaginosis (Hemophilus vaginalis vaginitis, nonspecific vaginitis) is the most common cause of vaginal discharge and odor.", "offsetInBeginSection": 0, "offsetInEndSection": 144, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6607525", "text": "The diagnosis is further confirmed when a microscopic examination of the discharge mixed with normal saline shows a virtual pure culture of tiny bacteria many of which are found clinging to vaginal epithelial cells forming the so-called \"clue cells\".", "offsetInBeginSection": 590, "offsetInEndSection": 840, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6d1db1b750ff4455000033", "body": "What is the purpose of the FaceBase consortium?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27287806", "http://www.ncbi.nlm.nih.gov/pubmed/21458441", "http://www.ncbi.nlm.nih.gov/pubmed/35912790", "http://www.ncbi.nlm.nih.gov/pubmed/32958507", "http://www.ncbi.nlm.nih.gov/pubmed/26168040", "http://www.ncbi.nlm.nih.gov/pubmed/24303230", "http://www.ncbi.nlm.nih.gov/pubmed/24124010", "http://www.ncbi.nlm.nih.gov/pubmed/24175235", "http://www.ncbi.nlm.nih.gov/pubmed/24303452", "http://www.ncbi.nlm.nih.gov/pubmed/21607136"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441", "text": "The FaceBase Consortium consists of ten interlinked research and technology projects whose goal is to generate craniofacial research data and technology for use by the research community through a central data management and integrated bioinformatics hub.", "offsetInBeginSection": 0, "offsetInEndSection": 255, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806", "text": "The FaceBase Consortium, funded by the National Institute of Dental and Craniofacial Research, National Institutes of Health, is designed to accelerate understanding of craniofacial developmental biology by generating comprehensive data resources to empower the research community, exploring high-throughput technology, fostering new scientific collaborations among researchers and human/computer interactions, facilitating hypothesis-driven research and translating science into improved health care to benefit patients.", "offsetInBeginSection": 0, "offsetInEndSection": 521, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806", "text": "The resources generated by the FaceBase projects include a number of dynamic imaging modalities, genome-wide association studies, software tools for analyzing human facial abnormalities, detailed phenotyping, anatomical and molecular atlases, global and specific gene expression patterns, and transcriptional profiling over the course of embryonic and postnatal development in animal models and humans.", "offsetInBeginSection": 522, "offsetInEndSection": 924, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040", "text": "The NIH FACEBASE consortium was established in part to create a central resource for craniofacial researchers.", "offsetInBeginSection": 0, "offsetInEndSection": 110, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040", "text": "This FACEBASE resource is designed to promote discovery by the craniofacial research community.", "offsetInBeginSection": 1241, "offsetInEndSection": 1336, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24124010", "text": "The OCDM is a project of the NIDCR-sponsored FaceBase Consortium, whose goal is to promote and enable research into the genetic and epigenetic causes of specific craniofacial abnormalities through the provision of publicly accessible, integrated craniofacial data.", "offsetInBeginSection": 333, "offsetInEndSection": 597, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24303230", "text": "We introduce the Ontology of Craniofacial Development and Malformation (OCDM), a project of the NIH-funded FaceBase consortium, whose goal is to gather data from multiple species, at levels ranging from genes to gross anatomy, in order to understand the causes of craniofacial abnormalities.", "offsetInBeginSection": 0, "offsetInEndSection": 291, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28261023", "text": "Our aim here is to create the Craniofacial Human Development Ontology (CHDO) to support the Ontology of Craniofacial Development and Malformation (OCDM), which provides the infrastructure for integrating multiple and disparate craniofacial data generated by FaceBase researchers.", "offsetInBeginSection": 1284, "offsetInEndSection": 1563, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9682580", "text": "The purpose of this article is to describe the evolution and implementation of the Northern New Jersey Nursing Education consortium--a consortium of seven member institutions established in 1992.", "offsetInBeginSection": 0, "offsetInEndSection": 195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25804967", "text": "PURPOSE The purpose of this study is to judge the quality of clinical skills assessment in Busan-Gyeongnam Consortium.", "offsetInBeginSection": 0, "offsetInEndSection": 118, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a79d25dfaa1ab7d2e00000f", "body": "Does wheat belongs to the genus Avena, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24226111", "http://www.ncbi.nlm.nih.gov/pubmed/18464810", "http://www.ncbi.nlm.nih.gov/pubmed/25120168", "http://www.ncbi.nlm.nih.gov/pubmed/8984007", "http://www.ncbi.nlm.nih.gov/pubmed/35585233", "http://www.ncbi.nlm.nih.gov/pubmed/10464792", "http://www.ncbi.nlm.nih.gov/pubmed/33980176", "http://www.ncbi.nlm.nih.gov/pubmed/18470162", "http://www.ncbi.nlm.nih.gov/pubmed/12617313", "http://www.ncbi.nlm.nih.gov/pubmed/24202677"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007", "text": "A cloned repetitive sequence, pAvKB30, obtained from an Avena vaviloviana (AB genome) genomic library, along with two polymerase chain reaction products derived from the conserved region of the reverse transcriptase (RT) gene of retrotransposons, were characterized molecularly and cytologically.", "offsetInBeginSection": 0, "offsetInEndSection": 296, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12669804", "text": "The DNA sequence of an extracellular (EXC) domain of an oat (Avena sativa L.) receptor-like kinase (ALrk10) gene was amplified from 23 accessions of 15 Avena species (6 diploid, 6 tetraploid, and 3 hexaploid).", "offsetInBeginSection": 0, "offsetInEndSection": 209, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25120168", "text": "The present results identify a novel protein family affecting cereal kernel texture and would further elucidate the phylogenetic evolution of Avena genus.", "offsetInBeginSection": 1334, "offsetInEndSection": 1488, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10464792", "text": "Further, the chromosomes involved in three C-A and three C-D intergenomic translocations in Avena murphyi (AC genomes) and Avena sativa cv.", "offsetInBeginSection": 1101, "offsetInEndSection": 1240, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29083384", "text": "The water-insoluble storage proteins of cereals (prolamins) are called \"gluten\" in wheat, barley, and rye, and \"avenins\" in oat.", "offsetInBeginSection": 0, "offsetInEndSection": 128, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29083384", "text": "The avenins in the genus Avena (cultivated oat as well as various wild species of which gene bank accessions were analyzed) are free of the known CD immunogenic epitopes from wheat, barley, and rye.", "offsetInBeginSection": 405, "offsetInEndSection": 603, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18356948", "text": "These results could explain the roles of A. clauda, A. longiglumis, and A. atlantica in the evolution of the genus Avena.", "offsetInBeginSection": 2178, "offsetInEndSection": 2299, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25188288", "text": "Two uncorrelated nucleotide sequences, chloroplast intergenic spacer psbA-trnH and acetyl CoA carboxylase gene (Acc1), were used to perform phylogenetic analyses in 75 accessions of the genus Avena, representing 13 diploids, seven tetraploid, and four hexaploids by maximum parsimony and Bayesian inference.", "offsetInBeginSection": 0, "offsetInEndSection": 307, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25188288", "text": "The haplotype that seems to represent the D genome clustered with the tetraploid species Avena murphyi and Avena maroccana, which supported the CD genomic designation instead of AC for A. murphyi and A. maroccana.", "offsetInBeginSection": 1022, "offsetInEndSection": 1235, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25188288", "text": "Phylogenic analyses based on the chloroplast intergenic spacer psbA-trnH confirmed that the A genome diploid might be the maternal donor of species of the genus Avena.", "offsetInBeginSection": 308, "offsetInEndSection": 475, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a68fd01b750ff445500001b", "body": "What is included in the fourth generation HIV test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16208030", "http://www.ncbi.nlm.nih.gov/pubmed/21995933", "http://www.ncbi.nlm.nih.gov/pubmed/19320855", "http://www.ncbi.nlm.nih.gov/pubmed/23080491", "http://www.ncbi.nlm.nih.gov/pubmed/24205491", "http://www.ncbi.nlm.nih.gov/pubmed/24966360", "http://www.ncbi.nlm.nih.gov/pubmed/12037046", "http://www.ncbi.nlm.nih.gov/pubmed/24695446", "http://www.ncbi.nlm.nih.gov/pubmed/24557036", "http://www.ncbi.nlm.nih.gov/pubmed/26558545"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592", "text": "To evaluate its performance to diagnose acute HIV infection (AHI), E4G was compared with fourth generation Ag/Ab ELISA test kits, a third generation PA test kit, WB and real-time PCR for the testing of 25 AHI clinical specimens.", "offsetInBeginSection": 721, "offsetInEndSection": 949, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592", "text": "In 2008, the Espline HIV Ag/Ab test kit (E4G, Fujirebio Inc. Japan) was marketed in Japan belonging to the fourth generation of HIV test kits characterized by its ability to detect both viral antigens (Ag) and anti-HIV-1/2 antibodies (Ab).", "offsetInBeginSection": 372, "offsetInEndSection": 611, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29062724", "text": "CONCLUSION The fourth generation DC offered no advantage over current third generation RT in the diagnosis of HIV infection.", "offsetInBeginSection": 1654, "offsetInEndSection": 1778, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29062724", "text": "Determine Combo (DC) is the first fourth generation RT that detects both p24 antigen (p24Ag) and HIV antibodies (Ab), theoretically reducing the window period and increasing detection rates.", "offsetInBeginSection": 215, "offsetInEndSection": 405, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16908076", "text": "The LG HIV Ag-Ab Plus, a new fourth generation diagnostic assay for HIV infection, was evaluated in comparison to the Enzygnost HIV Integral, an established fourth generation HIV assay.", "offsetInBeginSection": 0, "offsetInEndSection": 185, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19320855", "text": "All HIV-1-positive samples were reactive by the three fourth-generation systems.", "offsetInBeginSection": 1098, "offsetInEndSection": 1178, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28710996", "text": "STUDY DESIGN 5029 VOICE participants were evaluated with third-generation Alere Determine\u2122 HIV-1/2, OraQuick ADVANCE\u00ae Rapid HIV-1/2, Uni-Gold\u2122 Recombigen\u00ae HIV-1/2 and Bio-Rad GS HIV-1/2+O EIA; and fourth-generation Alere Determine\u2122 HIV-1/2 Ag/Ab Combo, Conformit\u00e9 Europ\u00e9ene (CE)-Marked Alere\u2122 HIV Combo and Bio-Rad HIV Combo Ag/Ab EIA.", "offsetInBeginSection": 464, "offsetInEndSection": 811, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25464967", "text": "RESULTS Fourth generation immunoassays identified 34 out of 39 HIV early infections using dried serum spot, whereas the Determine\u2122 HIV-1/2 rapid test detected 24 out of 39 HIV positive serum (87.2% vs 61.5% respectively, p = 0.009).", "offsetInBeginSection": 686, "offsetInEndSection": 920, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25464967", "text": "CONCLUSION Fourth generation Ag/Ab immunoassays performed on dried serum spot had good performance for HIV testing during the early phases of HIV infection.", "offsetInBeginSection": 1304, "offsetInEndSection": 1460, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11595590", "text": "This second diagnostic window was caused by the absence of HIV specific antibodies and the decline of HIV p24 antigen concentrations below the detection limits of the fourth generation assays.", "offsetInBeginSection": 1068, "offsetInEndSection": 1260, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6d2558b750ff4455000036", "body": "Does Uc.160 promote cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30323869", "http://www.ncbi.nlm.nih.gov/pubmed/28382457", "http://www.ncbi.nlm.nih.gov/pubmed/29901203", "http://www.ncbi.nlm.nih.gov/pubmed/34665919", "http://www.ncbi.nlm.nih.gov/pubmed/35624179", "http://www.ncbi.nlm.nih.gov/pubmed/8243836", "http://www.ncbi.nlm.nih.gov/pubmed/32014474", "http://www.ncbi.nlm.nih.gov/pubmed/30907169", "http://www.ncbi.nlm.nih.gov/pubmed/29936451", "http://www.ncbi.nlm.nih.gov/pubmed/34024769"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457", "text": "CONCLUSIONS These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.", "offsetInBeginSection": 1498, "offsetInEndSection": 1597, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457", "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.", "offsetInBeginSection": 399, "offsetInEndSection": 490, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20802525", "text": "Among the T-UCRs that were reactivated upon drug treatment, Uc.160+, Uc283+A and Uc.346+ were found to undergo specific CpG island hypermethylation-associated silencing in cancer cells compared with normal tissues.", "offsetInBeginSection": 1280, "offsetInEndSection": 1494, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28857253", "text": "Taken together, we demonstrated a TP73-AS1/miR-200a/ZEB1 regulating loop in breast cancer cells, which promote cancer cell invasion and migration through regulating E-cadherin and Twist expression.", "offsetInBeginSection": 801, "offsetInEndSection": 998, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24756180", "text": "hPMFs promote the peritoneal dissemination of pancreatic cancer.", "offsetInBeginSection": 1399, "offsetInEndSection": 1463, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23863579", "text": "In Japan, chief pillars of cancer control are improvement of cancer prevention, early detection of cancer and promotion of cancer research for treatment of advanced cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 172, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26540342", "text": "Previous studies have shown that hTERT can promote tumor invasion and metastasis of gastric cancer, liver cancer and esophageal cancer.", "offsetInBeginSection": 271, "offsetInEndSection": 406, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26540342", "text": "Taken together, our findings suggest that hTERT can promote cancer metastasis by stimulating EMT through the ZEB1 pathway and therefore inhibiting them may prevent cancer progression.", "offsetInBeginSection": 1065, "offsetInEndSection": 1248, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28039457", "text": "Previous studies have found that tumor-associated macrophages (TAMs) promote cancer progression.", "offsetInBeginSection": 0, "offsetInEndSection": 96, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28039457", "text": "We previously reported that TAMs promote prostate cancer metastasis via activation of the CCL2-CCR2 axis.", "offsetInBeginSection": 97, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8712af61bb38fb24000002", "body": "What is the link between psoriatic arthritis and depression", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32323218", "http://www.ncbi.nlm.nih.gov/pubmed/30794469", "http://www.ncbi.nlm.nih.gov/pubmed/24474190", "http://www.ncbi.nlm.nih.gov/pubmed/34367160", "http://www.ncbi.nlm.nih.gov/pubmed/23934051", "http://www.ncbi.nlm.nih.gov/pubmed/33977741", "http://www.ncbi.nlm.nih.gov/pubmed/31852324", "http://www.ncbi.nlm.nih.gov/pubmed/28507445", "http://www.ncbi.nlm.nih.gov/pubmed/27455241", "http://www.ncbi.nlm.nih.gov/pubmed/35861930"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775", "text": "CONCLUSION The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population.", "offsetInBeginSection": 1439, "offsetInEndSection": 1607, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27258525", "text": "Further stratified analyses revealed a more rapid and significant reduction in depression/insomnia in those undergoing continuous biologics therapy, younger than 45 years, without psoriatic arthritis and not taking concomitant methotrexate, when compared with their counterparts.The results suggest that biologics therapy may be associated with reduced rates of depression and insomnia, and a reduced rate of regular antidepressants use in psoriasis patients.", "offsetInBeginSection": 1174, "offsetInEndSection": 1633, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27221798", "text": "Many epidemiological studies have shown that psoriasis is associated with psoriatic arthritis as well as cardiovascular and metabolic diseases.", "offsetInBeginSection": 83, "offsetInEndSection": 226, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28507445", "text": "CONCLUSION Prevalence of fatigue was moderate to intense in <25% of patients with psoriatic arthritis.", "offsetInBeginSection": 1722, "offsetInEndSection": 1824, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24407907", "text": "The use of pressure algometry in the evaluation of chronic pain in patients affected by rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis that display comorbid depression could represent an additional and integrative method to improve pain/depression overlap management or research.", "offsetInBeginSection": 1367, "offsetInEndSection": 1669, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23908539", "text": "However, the other manifestations of psoriatic disease including metabolic syndrome, atherosclerotic cardiovascular disease, depression, poor self-esteem, and self-destructive habits including obesity, smoking and excess alcohol consumption are underappreciated.", "offsetInBeginSection": 128, "offsetInEndSection": 390, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28733473", "text": "OBJECTIVE To investigate the predictive value of baseline depression/anxiety on the likelihood of achieving joint remission in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) as well as the associations between baseline depression/anxiety and the components of the remission criteria at follow-up.", "offsetInBeginSection": 0, "offsetInEndSection": 305, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454", "text": "Peripheral arthritis is the most common symptom of psoriatic arthritis and patients also frequently experience involvement of the entheses, spine, skin, and nails.", "offsetInBeginSection": 202, "offsetInEndSection": 365, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454", "text": "Risks also arise from comorbidities that are associated with psoriatic arthritis such as cardiovascular disease, obesity, diabetes mellitus, and gastrointestinal inflammation.", "offsetInBeginSection": 876, "offsetInEndSection": 1051, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454", "text": "Psoriatic arthritis is a part of the family of diseases referred to as spondyloarthropathies, a diverse group of chronic inflammatory disorders with common clinical, radiographic, and genetic features.", "offsetInBeginSection": 0, "offsetInEndSection": 201, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6900ebb750ff445500001d", "body": "Which disease is diagnosed using the Finkelstein's test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15680568", "http://www.ncbi.nlm.nih.gov/pubmed/30154628", "http://www.ncbi.nlm.nih.gov/pubmed/23340762", "http://www.ncbi.nlm.nih.gov/pubmed/17059194", "http://www.ncbi.nlm.nih.gov/pubmed/31463625", "http://www.ncbi.nlm.nih.gov/pubmed/32431971", "http://www.ncbi.nlm.nih.gov/pubmed/34969308", "http://www.ncbi.nlm.nih.gov/pubmed/12723309", "http://www.ncbi.nlm.nih.gov/pubmed/11717090", "http://www.ncbi.nlm.nih.gov/pubmed/18956185"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568", "text": "PURPOSE Finkelstein's test is the classic diagnostic test for de Quervain's disease.", "offsetInBeginSection": 0, "offsetInEndSection": 84, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762", "text": "The purpose of the study was to compare the accuracy of the Eichhoff's test and wrist hyperflexion and abduction of the thumb test to diagnose correctly de Quervain's disease by comparing clinical findings using those tests with the results on ultrasound.", "offsetInBeginSection": 633, "offsetInEndSection": 888, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762", "text": "To compare the Eichhoff's test with a new test, the wrist hyperflexion and abduction of the thumb test, we set up a prospective study over a period of three years for a cohort of 100 patients (88 women, 12 men) presenting spontaneous pain over the radial side of the styloid of the radius (de Quervain tendinopathy).", "offsetInBeginSection": 316, "offsetInEndSection": 632, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762", "text": "Our results support that the wrist hyperflexion and abduction of the thumb test is a more precise tool for the diagnosis of de Quervain's disease than the Eichhoff's test and thus could be adopted to guide clinical diagnosis in the early stages of de Quervain's tendinopathy.", "offsetInBeginSection": 1337, "offsetInEndSection": 1612, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26538761", "text": "The clinical criteria used were Finkelstein's test, tenderness over radial styloid (Ritchie's tenderness scale), grip strength, pain (visual analog scale [VAS]) and radiological criteria was ultrasonographic assessment of change in thickness of APL and EPB tendon sheath.", "offsetInBeginSection": 828, "offsetInEndSection": 1099, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26538761", "text": "MATERIALS AND METHODS Thirty patients clinically diagnosed de Quervains tenosynovitis were included in the study and randomly assigned to two groups.", "offsetInBeginSection": 535, "offsetInEndSection": 684, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15792200", "text": "Three different descriptions of Finkelstein's test were used as described in current literature.", "offsetInBeginSection": 726, "offsetInEndSection": 822, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15792200", "text": "We also found that Finkelstein's test was inaccurately described in literature since Leao's incorrect description in 1958 (quoting Eichhoff's manoeuvre) and the mistake persisted for over 50 years before it could be accredited.", "offsetInBeginSection": 1099, "offsetInEndSection": 1326, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1402284", "text": "Over the last three decades an error in performing Finkelstein's test has crept into the English literature in both text books and journals.", "offsetInBeginSection": 0, "offsetInEndSection": 140, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10070674", "text": "Although Sun's was derived as a test for discrete data and Finkelstein's and Fay's tests were derived under a grouped continuous model, by writing all tests under one general model we see that as long as the regularity conditions hold, any of these three classes of tests may be applied to either grouped continuous or discrete data.", "offsetInBeginSection": 152, "offsetInEndSection": 485, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e1280b750ff4455000037", "body": "For which type of cancer can uc.189 be used as a potential prognostic biomarker?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28941722", "http://www.ncbi.nlm.nih.gov/pubmed/29484123", "http://www.ncbi.nlm.nih.gov/pubmed/34024769", "http://www.ncbi.nlm.nih.gov/pubmed/28928897", "http://www.ncbi.nlm.nih.gov/pubmed/36052239", "http://www.ncbi.nlm.nih.gov/pubmed/34341416", "http://www.ncbi.nlm.nih.gov/pubmed/33567603", "http://www.ncbi.nlm.nih.gov/pubmed/35247258", "http://www.ncbi.nlm.nih.gov/pubmed/19783793", "http://www.ncbi.nlm.nih.gov/pubmed/29843223"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722", "text": "Uc.189 might be considered as a novel molecule involved in ESCC progression, which provides a potential prognostic biomarker and therapeutic target.", "offsetInBeginSection": 1124, "offsetInEndSection": 1272, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722", "text": "High expression of uc.189 might reflect poor prognosis of ESCC and indicate a potential diagnostic target in ESCC patients.", "offsetInBeginSection": 1000, "offsetInEndSection": 1123, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26202601", "text": "Here, we have used a network-based exploration approach to identify a multi-cancer gene expression biomarker highly connected by ESR1, PRKACA, LRP1, JUN and SMAD2 that can be predictive of clinical outcome in 12 types of cancer from The Cancer Genome Atlas (TCGA) repository.", "offsetInBeginSection": 527, "offsetInEndSection": 802, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26202601", "text": "Comparisons with cancer-type specific and other multi-cancer biomarkers in TCGA and other datasets showed that the performance of the proposed multi-cancer biomarker is superior, making the proposed approach and multi-cancer biomarker potentially useful in research and clinical settings.", "offsetInBeginSection": 1062, "offsetInEndSection": 1350, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26709895", "text": "As such, expression of XPO6 may be a potential prognostic biomarker for predicting prostate cancer recurrence.", "offsetInBeginSection": 1084, "offsetInEndSection": 1194, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20661575", "text": "We and others have identified EMMPRIN as a prognostic biomarker in a variety of tumor diseases.", "offsetInBeginSection": 477, "offsetInEndSection": 572, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19424625", "text": "We propose that PRL-3 expression can have a clinical potential as a prognostic biomarker that may facilitate the development of adjuvant chemotherapy for advanced gastric cancer with stage I disease.", "offsetInBeginSection": 1475, "offsetInEndSection": 1674, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27629143", "text": "In conclusion, our results suggest that CA12 may be associated with BCSCs, especially HER2-positive BCSCs, and is a potential novel therapeutic target and biomarker.", "offsetInBeginSection": 1215, "offsetInEndSection": 1380, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27629143", "text": "Finally, by querying a public database, we found that CA12 was a novel prognostic biomarker in HER2-positive breast cancer, which also had prognostic value in all breast cancer types.", "offsetInBeginSection": 1031, "offsetInEndSection": 1214, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26847605", "text": "CONCLUSIONS MALAT1 could serve as a potential prognostic biomarker in various cancers and may be a potential therapeutic target for the treatment and early detection of recurrence.", "offsetInBeginSection": 1450, "offsetInEndSection": 1630, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a87140a61bb38fb24000003", "body": "What is Chronic Wasting Disease (CWD) in deer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20518283", "http://www.ncbi.nlm.nih.gov/pubmed/23764839", "http://www.ncbi.nlm.nih.gov/pubmed/31337719", "http://www.ncbi.nlm.nih.gov/pubmed/23708962", "http://www.ncbi.nlm.nih.gov/pubmed/23467626", "http://www.ncbi.nlm.nih.gov/pubmed/29719000", "http://www.ncbi.nlm.nih.gov/pubmed/17092889", "http://www.ncbi.nlm.nih.gov/pubmed/35634740", "http://www.ncbi.nlm.nih.gov/pubmed/30014840", "http://www.ncbi.nlm.nih.gov/pubmed/31835654"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545", "text": "Chronic wasting disease (CWD) is an invariably fatal transmissible spongiform encephalopathy of white-tailed deer, mule deer, elk, and moose.", "offsetInBeginSection": 0, "offsetInEndSection": 141, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17553219", "text": "Chronic wasting disease (CWD) of deer and elk is a widespread health concern because its potential for crossspecies transmission is undetermined.", "offsetInBeginSection": 0, "offsetInEndSection": 145, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16439622", "text": "The emergence of chronic wasting disease (CWD) in deer and elk in an increasingly wide geographic area, as well as the interspecies transmission of bovine spongiform encephalopathy to humans in the form of variant Creutzfeldt Jakob disease, have raised concerns about the zoonotic potential of CWD.", "offsetInBeginSection": 0, "offsetInEndSection": 298, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27711208", "text": "The recent discovery of chronic wasting disease (CWD) in captive deer facilities in Texas has increased concern about the potential emergence of CWD in free-ranging deer.", "offsetInBeginSection": 120, "offsetInEndSection": 290, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17020952", "text": "Chronic wasting disease (CWD), a prion disease of deer and elk, is highly prevalent in some regions of North America.", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18387626", "text": "Chronic wasting disease (CWD), a prion disease of North American deer, elk and moose, affects both free-ranging and captive cervids.", "offsetInBeginSection": 0, "offsetInEndSection": 132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18387626", "text": "In western blots, the PrP(CWD) glycoform profile resembled that of CWD in deer, typified by a dominant diglycosylated glycoform.", "offsetInBeginSection": 924, "offsetInEndSection": 1052, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28193766", "text": "The etiology of chronic wasting disease (CWD), a relatively new and burgeoning prion epidemic in deer, elk, and moose (members of the cervid family), is more enigmatic.", "offsetInBeginSection": 497, "offsetInEndSection": 665, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17092889", "text": "Chronic wasting disease (CWD) is a fatal, emerging disease of cervids associated with transmissible protease-resistant prion proteins.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15542685", "text": "We generated mice expressing cervid prion protein to produce a transgenic system simulating chronic wasting disease (CWD) in deer and elk.", "offsetInBeginSection": 0, "offsetInEndSection": 138, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a69031bb750ff445500001e", "body": "Can doxycycline cause photosensitivity?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9214073", "http://www.ncbi.nlm.nih.gov/pubmed/33365215", "http://www.ncbi.nlm.nih.gov/pubmed/26189561", "http://www.ncbi.nlm.nih.gov/pubmed/30075748", "http://www.ncbi.nlm.nih.gov/pubmed/25733769", "http://www.ncbi.nlm.nih.gov/pubmed/28291967", "http://www.ncbi.nlm.nih.gov/pubmed/36258981", "http://www.ncbi.nlm.nih.gov/pubmed/35190066", "http://www.ncbi.nlm.nih.gov/pubmed/29619438", "http://www.ncbi.nlm.nih.gov/pubmed/8222522"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17160610", "text": "Treatment with doxycycline is cheap and relatively safe, but gastrointestinal symptoms and photosensitivity reactions can be expected more often than with ceftriaxone.", "offsetInBeginSection": 1913, "offsetInEndSection": 2080, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10233667", "text": "Chronic actinic dermatitis (CAD) is an uncommon, eczematous photosensitive eruption affecting predominantly elderly men and to which drug-induced photosensitivity may sometimes appear clinically identical.", "offsetInBeginSection": 0, "offsetInEndSection": 205, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21879777", "text": "Tetracycline, doxycycline, nalidixic acid, voriconazole, amiodarone, hydrochlorothiazide, naproxen, piroxicam, chlorpromazine and thioridazine are among the most commonly implicated medications.", "offsetInBeginSection": 1107, "offsetInEndSection": 1301, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067", "text": "CONCLUSION Topical or oral corticosteroids followed by prophylactic doxycycline can be effective in rapidly resolving acute flareups and preventing recurrences of NSAGU.", "offsetInBeginSection": 1580, "offsetInEndSection": 1749, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067", "text": "Eight (47%) commenced doxycycline prophylaxis.", "offsetInBeginSection": 966, "offsetInEndSection": 1012, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17315050", "text": "Anti-inflammatory-dose doxycycline should not be used by individuals with known hypersensitivity to tetracyclines or increased photosensitivity, or by pregnant or nursing women (anti-inflammatory-dose doxycycline is a pregnancy category-D medication).", "offsetInBeginSection": 1381, "offsetInEndSection": 1632, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3684731", "text": "Doxycycline is considered by authoritative sources to be generally comparable in side effects to other tetracyclines and penicillins, with the exception that it increases photosensitivity.", "offsetInBeginSection": 433, "offsetInEndSection": 621, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3684731", "text": "As part of a study investigating new methods of detecting adverse drug reactions, adult outpatients receiving new prescriptions for 1 of 4 antibiotics (doxycycline, penicillin VK, ampicillin, or tetracycline) were assigned to 1 of 2 methods of monitoring adverse drug reactions.", "offsetInBeginSection": 0, "offsetInEndSection": 278, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15262663", "text": "BACKGROUND It has been hypothesized that certain Mycoplasma species may cause Gulf War veterans' illnesses (GWVIs), chronic diseases characterized by pain, fatigue, and cognitive symptoms, and that affected patients may benefit from doxycycline treatment.", "offsetInBeginSection": 0, "offsetInEndSection": 255, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26189561", "text": "Doxycycline is a commonly used tetracycline antibiotic showing the broad spectrum of antibacterial action.", "offsetInBeginSection": 0, "offsetInEndSection": 106, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e21b4b750ff445500003a", "body": "Are paralog genes co-regulated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27634932", "http://www.ncbi.nlm.nih.gov/pubmed/34208174", "http://www.ncbi.nlm.nih.gov/pubmed/35273078", "http://www.ncbi.nlm.nih.gov/pubmed/18493055", "http://www.ncbi.nlm.nih.gov/pubmed/36069976", "http://www.ncbi.nlm.nih.gov/pubmed/29166914", "http://www.ncbi.nlm.nih.gov/pubmed/34842711", "http://www.ncbi.nlm.nih.gov/pubmed/27416760", "http://www.ncbi.nlm.nih.gov/pubmed/25217831", "http://www.ncbi.nlm.nih.gov/pubmed/28667373"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055", "text": "By analyzing paralogs of testis-biased genes, we identified \"co-regulated\" paralogous pairs in which both genes are testis biased, \"anti-regulated\" pairs in which one paralog is testis biased and the other downregulated in testes, and \"neutral\" pairs in which one paralog is testis biased and the other constitutively expressed.", "offsetInBeginSection": 511, "offsetInEndSection": 839, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932", "text": "In eukaryotes, genes are regulated in part by distal enhancer elements through looping interactions with gene promoters.", "offsetInBeginSection": 279, "offsetInEndSection": 399, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932", "text": "Paralog genes arise from gene duplication events during evolution, which often lead to similar proteins that cooperate in common pathways and in protein complexes.", "offsetInBeginSection": 0, "offsetInEndSection": 163, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20660482", "text": "CPEB2, CPEB3 and CPEB4 are paralog proteins very similar among themselves referred as the CPEB2 subfamily.", "offsetInBeginSection": 133, "offsetInEndSection": 239, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28716037", "text": "RESULTS Five paralog genes of dnmt3, namely dnmt3aa, dnmt3ab, dnmt3ba, dnmt3bb.1 and dnmt3bb.2 and one gene for dnmt1 were identified.", "offsetInBeginSection": 533, "offsetInEndSection": 667, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187", "text": "Other examined G. max homologs of membrane fusion genes include an endosomal bromo domain-containing protein1 (Bro1), syntaxin6 (SYP6), SYP131, SYP71, SYP8, Bet1, coatomer epsilon (\u03f5-COP), a coatomer zeta (\u03b6-COP) paralog and an ER to Golgi component (ERGIC) protein.", "offsetInBeginSection": 1171, "offsetInEndSection": 1439, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187", "text": "PEN1 has homology to a Saccharomyces cerevisae gene that regulates a Secretion (Sec) protein, Suppressor of Sec 1 (Sso1p).", "offsetInBeginSection": 363, "offsetInEndSection": 485, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187", "text": "Experiments made using the model agricultural Glycine max (soybean) have identified co-regulated gene expression of regulon components.", "offsetInBeginSection": 753, "offsetInEndSection": 888, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22174413", "text": "We cloned a novel zebrafish nrf2 paralog, nrf2b.", "offsetInBeginSection": 403, "offsetInEndSection": 451, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22174413", "text": "Zebrafish-human comparisons demonstrate conserved synteny involving nrf2 and hox genes, indicating that nrf2a and nrf2b are co-orthologs of human NRF2.", "offsetInBeginSection": 590, "offsetInEndSection": 741, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a87145861bb38fb24000004", "body": "What causes Black Lung?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2933965", "http://www.ncbi.nlm.nih.gov/pubmed/8619246", "http://www.ncbi.nlm.nih.gov/pubmed/35657680", "http://www.ncbi.nlm.nih.gov/pubmed/26437452", "http://www.ncbi.nlm.nih.gov/pubmed/29095661", "http://www.ncbi.nlm.nih.gov/pubmed/36007825", "http://www.ncbi.nlm.nih.gov/pubmed/33486252", "http://www.ncbi.nlm.nih.gov/pubmed/27632152", "http://www.ncbi.nlm.nih.gov/pubmed/31143211", "http://www.ncbi.nlm.nih.gov/pubmed/17300721"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721", "text": "CONCLUSION Cigarette smoke exposure to a guinea pig model causes oxidative damage, inflammation, apoptosis and lung injury that are prevented by supplementation of black tea.", "offsetInBeginSection": 1426, "offsetInEndSection": 1600, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721", "text": "Since black tea has antioxidant property, we examined the preventive effect of black tea on cigarette smoke-induced oxidative damage, apoptosis and lung injury in a guinea pig model.", "offsetInBeginSection": 191, "offsetInEndSection": 373, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16304297", "text": "CONCLUSIONS Our analysis suggests that the lower surgical rate among black patients with early stage lung cancer is mainly due to low rates of acceptance of surgical treatment.", "offsetInBeginSection": 1448, "offsetInEndSection": 1624, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28450031", "text": "METHODS We collected survival time data for 105,121 Hispanic, non-Hispanic Asian, non-Hispanic black, and non-Hispanic white patients with early-stage (IA, IB, IIA, and IIB) lung cancer diagnosed between 2004 and 2013 from the Surveillance, Epidemiology, and End-Results registries.", "offsetInBeginSection": 411, "offsetInEndSection": 693, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28450031", "text": "BACKGROUND Black patients with lung cancer diagnosed at early stages-for which surgical resection offers a potential cure-experience worse overall survival than do their white counterparts.", "offsetInBeginSection": 0, "offsetInEndSection": 189, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28450031", "text": "Worse survival from competing causes of death, such as cardiovascular disease and other cancers-rather than from lung cancer itself-led to the disparity in overall survival among non-Hispanic blacks (adjusted relative risk, 1.07; 95%\u00a0CI, 1.02-1.12).", "offsetInBeginSection": 1290, "offsetInEndSection": 1540, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2806196", "text": "The results of these studies support a preeminent role for elastase in neutrophil-induced lung lesions.", "offsetInBeginSection": 1483, "offsetInEndSection": 1586, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17516558", "text": "CONCLUSIONS The findings suggest that carbon black, or chemicals associated with the production of carbon black, had an effect on later stages of lung cancer carcinogenesis at two of the plants but that no such effect was found at the other plants.", "offsetInBeginSection": 1330, "offsetInEndSection": 1578, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7810543", "text": "The case-control analysis found employment in preparation and carding operations (where most of the black males worked) to be associated with a slightly reduced lung cancer risk, although not statistically significant, whereas spinning and twisting employment was associated with a statistically significant increased lung cancer risk compared to other plant operations.", "offsetInBeginSection": 2305, "offsetInEndSection": 2675, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26437452", "text": "In this study, we show that insoluble nanoparticulate carbon black (nCB) accumulates in human myeloid dendritic cells (mDCs) from emphysematous lung and in CD11c(+) lung antigen presenting cells (APC) of mice exposed to smoke.", "offsetInBeginSection": 274, "offsetInEndSection": 500, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f7e6ab750ff4455000052", "body": "List four principles of medical ethics.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26793677", "http://www.ncbi.nlm.nih.gov/pubmed/21625670", "http://www.ncbi.nlm.nih.gov/pubmed/24720355", "http://www.ncbi.nlm.nih.gov/pubmed/18552646", "http://www.ncbi.nlm.nih.gov/pubmed/19534082", "http://www.ncbi.nlm.nih.gov/pubmed/7597402", "http://www.ncbi.nlm.nih.gov/pubmed/25516950", "http://www.ncbi.nlm.nih.gov/pubmed/10461594", "http://www.ncbi.nlm.nih.gov/pubmed/14519842", "http://www.ncbi.nlm.nih.gov/pubmed/26195897"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075", "text": "Only 6% of both graduates and students were able to list the four principles of medical ethics as described by Raanan.", "offsetInBeginSection": 810, "offsetInEndSection": 928, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428", "text": "Through a critique of six positions regarding the aims of medical ethics, four principles are established which are the basis of a philosophy of education for medical ethics.", "offsetInBeginSection": 264, "offsetInEndSection": 438, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428", "text": "The paper concludes with practical examples of a clinically-based medical ethics programme following from the four principles.", "offsetInBeginSection": 594, "offsetInEndSection": 720, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14519842", "text": "It is hypothesised and argued that \"the four principles of medical ethics\" can explain and justify, alone or in combination, all the substantive and universalisable claims of medical ethics and probably of ethics more generally.", "offsetInBeginSection": 0, "offsetInEndSection": 228, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26793677", "text": "There are four principles of medical ethics; Beneficence, Respect for autonomy, Non-maleficence, and Justice.", "offsetInBeginSection": 0, "offsetInEndSection": 109, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26793677", "text": "It is not easy to apply to principles of medical ethics in the special circumstances of obstetrics and gynecology.", "offsetInBeginSection": 110, "offsetInEndSection": 224, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15183570", "text": "The unique role of the chief ethics officer in a sports medicine office is described and guided by the four principles of ethics, as well as the principles and codes of ethics of the American Medical Association, the International Sports Medicine Federation, and the American Academy of Orthopaedic Surgeons.", "offsetInBeginSection": 0, "offsetInEndSection": 308, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25516952", "text": "With the development of medical technology and health services, it became necessary to expand the four basic principles of medical ethics and link them to human rights.", "offsetInBeginSection": 114, "offsetInEndSection": 282, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25516952", "text": "This paper highlights the methodology and principles employed by Muslim jurists in deriving rulings in the field of medical ethics, and it explains how ethical principles are interpreted through the lens of Islamic theory.", "offsetInBeginSection": 515, "offsetInEndSection": 737, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10461594", "text": "This paper first specifies the principles and characteristics of ancient Chinese medical ethics (ACME), then makes a comparison between ACME and the 4PBE with a view to testing out the 4PBE's cross-cultural plausibility when applied to one particular but very extensive and prominent cultural context.", "offsetInBeginSection": 258, "offsetInEndSection": 559, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e22b9b750ff445500003b", "body": "What is CellMaps?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27296979", "http://www.ncbi.nlm.nih.gov/pubmed/30656893", "http://www.ncbi.nlm.nih.gov/pubmed/11326518", "http://www.ncbi.nlm.nih.gov/pubmed/25141310", "http://www.ncbi.nlm.nih.gov/pubmed/6683883", "http://www.ncbi.nlm.nih.gov/pubmed/19702537", "http://www.ncbi.nlm.nih.gov/pubmed/6359612", "http://www.ncbi.nlm.nih.gov/pubmed/15734663", "http://www.ncbi.nlm.nih.gov/pubmed/31798210", "http://www.ncbi.nlm.nih.gov/pubmed/24119119"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979", "text": "AVAILABILITY AND IMPLEMENTATION The application is available at: http://cellmaps.babelomics.org/ and the code can be found in: https://github.com/opencb/cell-maps The client is implemented in JavaScript and the server in C and Java.", "offsetInBeginSection": 406, "offsetInEndSection": 638, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979", "text": "UNLABELLED : CellMaps is an HTML5 open-source web tool that allows displaying, editing, exploring and analyzing biological networks as well as integrating metadata into them.", "offsetInBeginSection": 0, "offsetInEndSection": 174, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27775692", "text": "Pancreatic ductal adenocarcinoma (PDAC) develops in a highly complex and heterogeneous tissue environment and, generally, has a very poor prognosis.", "offsetInBeginSection": 146, "offsetInEndSection": 294, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27775692", "text": "We sought to develop a tIA approach to assess the most common PDAC precursor lesions, pancreatic intraepithelial neoplasia (PanIN), in tissues from KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-Cre (KPC) mice, a validated model of PDAC development.", "offsetInBeginSection": 459, "offsetInEndSection": 699, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27775692", "text": "tIA profiling of training regions of PanIN and tumor microenvironment (TME) cells was utilized to guide identification of PanIN/TME tissue compartment stratification criteria.", "offsetInBeginSection": 700, "offsetInEndSection": 875, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20008397", "text": "In addition, one cannot easily escape into high-level holistic approaches, since the essence of all biological systems is that they are encoded as molecular descriptions in their genes and since genes are molecules and exert their functions through other molecules, the molecular explanation must constitute the core of understanding biological systems.", "offsetInBeginSection": 343, "offsetInEndSection": 696, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28682833", "text": "To address this systematically, an ISH for peptidylprolyl isomerase B (PPIB) (cyclophilin B) mRNA was optimized and applied to a tissue microarray of archival non-small cell lung carcinoma cases, and then automated image analysis for PPIB was refined across 4 commercially available software platforms.", "offsetInBeginSection": 239, "offsetInEndSection": 541, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22548703", "text": "Using a set of growth factor signalling networks as examples (epidermal growth factor, transforming growth factor-beta, tumor necrosis factor, and wingless), we find a multiplicity of network topologies in which receptors couple to downstream components through myriad alternate paths.", "offsetInBeginSection": 1720, "offsetInEndSection": 2005, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22548703", "text": "This ensemble network has many features expected of complex signalling networks assembled from high-throughput data: a power law distribution of both node degree and edge annotations, and topological features of a \"bow tie\" architecture in which diverse pathways converge on a highly conserved set of enzymatic cascades focused around PI3K/AKT, MAPK/ERK, JAK/STAT, NF\u03baB, and apoptotic signaling.", "offsetInBeginSection": 1022, "offsetInEndSection": 1418, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22548703", "text": "As a result of discrepant annotations, it is very difficult to identify biologically meaningful pathways from interactome networks a priori.", "offsetInBeginSection": 2721, "offsetInEndSection": 2861, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8714e261bb38fb24000005", "body": "Is polyadenylation a process that stabilizes a protein by adding a string of Adenosine residues to the end of the molecule?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16467265", "http://www.ncbi.nlm.nih.gov/pubmed/28537233", "http://www.ncbi.nlm.nih.gov/pubmed/8440247", "http://www.ncbi.nlm.nih.gov/pubmed/32560344", "http://www.ncbi.nlm.nih.gov/pubmed/9933592", "http://www.ncbi.nlm.nih.gov/pubmed/23948079", "http://www.ncbi.nlm.nih.gov/pubmed/25941172", "http://www.ncbi.nlm.nih.gov/pubmed/32614436", "http://www.ncbi.nlm.nih.gov/pubmed/9223284", "http://www.ncbi.nlm.nih.gov/pubmed/32989052"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592", "text": "The data show that the degradosome requires a single-stranded \"toehold\" 3' to a secondary structure to recognize and degrade the RNA molecule efficiently; polyadenylation can provide this single-stranded 3'-end.", "offsetInBeginSection": 940, "offsetInEndSection": 1151, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16467265", "text": "Polyadenylation is a process of endonucleolytic cleavage of the mRNA, followed by addition of up to 250 adenosine residues to the 3' end of the mRNA.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16467265", "text": "Polyadenylation is essential for eukaryotic mRNA expression, and CstF-64 is a subunit of the CstF polyadenylation factor that is required for accurate polyadenylation.", "offsetInBeginSection": 150, "offsetInEndSection": 317, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3019671", "text": "Processing at the L3 polyadenylation site of human adenovirus-2 involves endonucleolytic cleavage generating the 3' terminal sequence -UAOH to which adenosine residues are added.", "offsetInBeginSection": 0, "offsetInEndSection": 178, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2160581", "text": "These included CYC1 (iso-1-cytochrome c), HIS4 (histidine biosynthesis), GAL7 (galactose-1-phosphate uridyltransferase), H2B2 (histone H2B2), PRT2 (a protein of unknown function), and CBP1 (cytochrome b mRNA processing).", "offsetInBeginSection": 265, "offsetInEndSection": 485, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2160581", "text": "Ammonium sulfate fractionation of a Saccharomyces cerevisiae whole-cell extract yielded a preparation which carried out correct and efficient endonucleolytic cleavage and polyadenylation of yeast precursor mRNA substrates corresponding to a variety of yeast genes.", "offsetInBeginSection": 0, "offsetInEndSection": 264, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9242905", "text": "The diversity of polyadenylation sites suggests that mRNA polyadenylation in prokaryotes is a relatively indiscriminate process that can occur at all mRNA's 3'-ends and does not require specific consensus sequences as in eukaryotes.", "offsetInBeginSection": 516, "offsetInEndSection": 748, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11557765", "text": "We show that a 3'- to 5'-exoribonuclease activity is responsible for the preferential degradation of polyadenylated mRNAs as compared with non-polyadenylated mRNAs, and that 20-30 adenosine residues constitute the optimal poly(A) tail size for inducing degradation of RNA substrates in vitro.", "offsetInBeginSection": 478, "offsetInEndSection": 770, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12270133", "text": "It is demonstrated that XCCA adds cytosine and adenosine residues to the ends of prepared tRNA and is therefore a functional CCA-adding enzyme.", "offsetInBeginSection": 275, "offsetInEndSection": 418, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9223284", "text": "Polyadenylation of premessenger RNAs occurs posttranscriptionally in the nucleus of eukaryotic cells by cleavage of the precursor and polymerization of adenosine residues.", "offsetInBeginSection": 0, "offsetInEndSection": 171, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f829eb750ff4455000054", "body": "Can multiple myeloma patients develop hyperviscosity syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32778524", "http://www.ncbi.nlm.nih.gov/pubmed/7699907", "http://www.ncbi.nlm.nih.gov/pubmed/34401731", "http://www.ncbi.nlm.nih.gov/pubmed/27079282", "http://www.ncbi.nlm.nih.gov/pubmed/2385441", "http://www.ncbi.nlm.nih.gov/pubmed/32572827", "http://www.ncbi.nlm.nih.gov/pubmed/1201229", "http://www.ncbi.nlm.nih.gov/pubmed/10861819", "http://www.ncbi.nlm.nih.gov/pubmed/22827791", "http://www.ncbi.nlm.nih.gov/pubmed/11954894"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907", "text": "Plasmapheresis is known as an efficient method for rapid improvement of the hyperviscosity syndrome, and double filtration plasmapheresis is most commonly used for plasma exchange of multiple myeloma patients in our country.", "offsetInBeginSection": 520, "offsetInEndSection": 744, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907", "text": "Five to 10 percent of patients with multiple myeloma are suffered from the hyperviscosity syndrome because of increased serum viscosity due to the presence of myeloma protein.", "offsetInBeginSection": 246, "offsetInEndSection": 421, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441", "text": "The present report describes a patient with IgA myeloma complicated by hyperviscosity syndrome and multiple bone fractures.", "offsetInBeginSection": 1290, "offsetInEndSection": 1413, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441", "text": "And this syndrome has been associated frequently with macroglobulinemia of Waldenstr\u00f6m, occasionally with immunoglobulin (Ig) G myeloma, rarely with IgA myeloma, and with other dysproteinemia.", "offsetInBeginSection": 864, "offsetInEndSection": 1057, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22827791", "text": "Hyperglobulinemia of multiple myeloma (MM) plays a role in hyperviscosity syndrome (HVS).", "offsetInBeginSection": 205, "offsetInEndSection": 294, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9046114", "text": "PE is the most effective method in the treatment of hyperviscosity syndrome often seen with multiple myeloma and Waldenstr\u00f6m's macroglobulinemia, and it is therapy of choice for this complication.", "offsetInBeginSection": 961, "offsetInEndSection": 1158, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26623375", "text": "The present study reported for the first time the use of double filtration plasmapheresis to reduce clinical signs of hyperviscosity syndrome in a dog with multiple myeloma.", "offsetInBeginSection": 527, "offsetInEndSection": 700, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14631546", "text": "Monoclonal hypergammaglobulinemia resulting in hyperviscosity syndrome is seen in multiple myeloma and Waldenstr\u00f6m's macroglobulinemia.", "offsetInBeginSection": 106, "offsetInEndSection": 242, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1201229", "text": "Two cases of multiple myeloma with IgA gammopathy and the syndrome of serum hyperviscosity are reported.", "offsetInBeginSection": 0, "offsetInEndSection": 104, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1201229", "text": "The hyperviscosity syndrome is being diagnosed with increasing frequency in association with IgA multiple myeloma, and should be investigated in all cases with monoclonal proteins exceeding a concentration of 3-0 g/dl.", "offsetInBeginSection": 754, "offsetInEndSection": 972, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e2578b750ff445500003d", "body": "Which package in Bioconductor has been developed with the aim to analyze differential DNA loops from sequencing data?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22847932", "http://www.ncbi.nlm.nih.gov/pubmed/27441086", "http://www.ncbi.nlm.nih.gov/pubmed/30346483", "http://www.ncbi.nlm.nih.gov/pubmed/22174279", "http://www.ncbi.nlm.nih.gov/pubmed/21349869", "http://www.ncbi.nlm.nih.gov/pubmed/27008016", "http://www.ncbi.nlm.nih.gov/pubmed/20861030", "http://www.ncbi.nlm.nih.gov/pubmed/23379655", "http://www.ncbi.nlm.nih.gov/pubmed/24618468", "http://www.ncbi.nlm.nih.gov/pubmed/25605792"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932", "text": "MOTIVATION RNA sequencing is becoming a standard for expression profiling experiments and many tools have been developed in the past few years to analyze RNA-Seq data.", "offsetInBeginSection": 0, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932", "text": "RESULTS We developed 'easyRNASeq', an R package that simplifies the processing of RNA sequencing data, hiding the complex interplay of the required packages behind a single functionality.", "offsetInBeginSection": 558, "offsetInEndSection": 745, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29028898", "text": "To systematically assess changes in DNA looping architecture between samples, we introduce diffloop, an R/Bioconductor package that provides a suite of functions for the quality control, statistical testing, annotation, and visualization of DNA loops.", "offsetInBeginSection": 288, "offsetInEndSection": 539, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27008016", "text": "The protocol provides a detailed description for the comparative analysis of DNA-IP sequencing data including basic data processing, quality controls, and identification of differential enrichment using the Bioconductor package \"MEDIPS\".", "offsetInBeginSection": 638, "offsetInEndSection": 875, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27008016", "text": "We present a protocol for genome-wide comparative analysis of DNA-IP sequencing data to identify statistically significant differential sequencing coverage between two conditions by considering variation across replicates.", "offsetInBeginSection": 415, "offsetInEndSection": 637, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24227674", "text": "RESULTS Here, we present a major update of the R/Bioconductor package MEDIPS, which allows for an arbitrary number of replicates per group and integrates sophisticated statistical methods for the detection of differential coverage between experimental conditions.", "offsetInBeginSection": 625, "offsetInEndSection": 888, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058", "text": "We have previously developed an R/Bioconductor package 'exomePeak' for detecting RNA methylation sites under a specific experimental condition or the identifying the differential RNA methylation sites in a case control study from MeRIP-Seq data.", "offsetInBeginSection": 488, "offsetInEndSection": 733, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058", "text": "We therein provide here a detailed and easy-to-use protocol of using exomePeak R/Bioconductor package along with other software programs for analysis of MeRIP-Seq data, which covers raw reads alignment, RNA methylation site detection, motif discovery, differential RNA methylation analysis, and functional analysis.", "offsetInBeginSection": 983, "offsetInEndSection": 1298, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27347386", "text": "In the context of the ever-growing need for tools analyzing\u00a0Ribo-seq reads, we have developed 'RiboProfiling', a new Bioconductor open-source\u00a0package.", "offsetInBeginSection": 403, "offsetInEndSection": 555, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29052185", "text": "The methylPipe Bioconductor package is adopted for the identification of the differentially methylated regions, and all the steps from the raw data to the required input are described in detail.", "offsetInBeginSection": 642, "offsetInEndSection": 836, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8715a961bb38fb24000006", "body": "Silent Allosteric Modulation of mGluR5 is a form of treatment for what disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27496211", "http://www.ncbi.nlm.nih.gov/pubmed/28683325", "http://www.ncbi.nlm.nih.gov/pubmed/35648810", "http://www.ncbi.nlm.nih.gov/pubmed/17987523", "http://www.ncbi.nlm.nih.gov/pubmed/21067920", "http://www.ncbi.nlm.nih.gov/pubmed/24793143", "http://www.ncbi.nlm.nih.gov/pubmed/25323624", "http://www.ncbi.nlm.nih.gov/pubmed/16368268", "http://www.ncbi.nlm.nih.gov/pubmed/20583985", "http://www.ncbi.nlm.nih.gov/pubmed/21368721"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325", "text": "Our data show that mGluR5's role in A\u03b2o-dependent AD phenotypes is separate from its role in glutamate signaling and silent allosteric modulation of mGluR5 has promise as a disease-modifying AD intervention with a broad therapeutic window.", "offsetInBeginSection": 821, "offsetInEndSection": 1061, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325", "text": "We used a potent mGluR5 silent allosteric modulator (SAM, BMS-984923) to separate its well-known physiological role in glutamate signaling from a pathological role in mediating amyloid-\u03b2 oligomer (A\u03b2o) action.", "offsetInBeginSection": 184, "offsetInEndSection": 395, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25323624", "text": "The central activity of mGluR5 negative allosteric modulators (2-methyl-6-(phenylethynyl)pyridine (MPEP) and [(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) and positive allosteric modulators (S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone (ADX47273) and (7S)-3-tert-butyl-7-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine (LSN2814617) was examined on sleep-wake architecture.", "offsetInBeginSection": 803, "offsetInEndSection": 1273, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15608073", "text": "We found that 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5).", "offsetInBeginSection": 0, "offsetInEndSection": 186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24793143", "text": "Metabotropic glutamate receptors (mGluRs) are high-profile G-protein coupled receptors drug targets because of their involvement in several neurological disease states, and mGluR5 in particular is a subtype whose controlled allosteric modulation, both positive and negative, can potentially be useful for the treatment of schizophrenia and relief of chronic pain, respectively.", "offsetInBeginSection": 0, "offsetInEndSection": 377, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27496211", "text": "Herein we describe the structure activity relationships uncovered in the pursuit of an mGluR5 positive allosteric modulator (PAM) for the treatment of schizophrenia.", "offsetInBeginSection": 0, "offsetInEndSection": 165, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21067920", "text": "Positive allosteric modulation of metabotropic glutamate receptor 5 (mGluR5) is regarded as a potential novel treatment for schizophrenic patients.", "offsetInBeginSection": 0, "offsetInEndSection": 147, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21067920", "text": "Herein we report the synthesis and SAR of 4-aryl piperazine and piperidine amides as potent mGluR5 positive allosteric modulators (PAMs).", "offsetInBeginSection": 148, "offsetInEndSection": 285, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23189054", "text": "Positive allosteric modulation of the type-5 metabotropic glutamate receptor (mGluR5) in particular has emerged as a treatment strategy for the enhancement of extinction of drug-motivated behaviors.", "offsetInBeginSection": 175, "offsetInEndSection": 373, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19100966", "text": "Following the establishment of a cocaine CPP, rats were treated with the mGluR5 positive allosteric modulator 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB; 0.3, 3 and 30 mg/kg) before extinction test sessions.", "offsetInBeginSection": 559, "offsetInEndSection": 780, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f853ab750ff4455000055", "body": "Which disease can be diagnosed with the \"probe to bone\" test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23001730", "http://www.ncbi.nlm.nih.gov/pubmed/21219428", "http://www.ncbi.nlm.nih.gov/pubmed/29558213", "http://www.ncbi.nlm.nih.gov/pubmed/19141236", "http://www.ncbi.nlm.nih.gov/pubmed/18601422", "http://www.ncbi.nlm.nih.gov/pubmed/3552663", "http://www.ncbi.nlm.nih.gov/pubmed/3328893", "http://www.ncbi.nlm.nih.gov/pubmed/12409399", "http://www.ncbi.nlm.nih.gov/pubmed/32418417", "http://www.ncbi.nlm.nih.gov/pubmed/30031030"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27369321", "text": "The probe-to-bone (PTB) test is a commonly used clinical test for osteomyelitis (OM), but its utility has been questioned in clinical settings where the prevalence of OM is low.", "offsetInBeginSection": 0, "offsetInEndSection": 177, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428", "text": "CONCLUSIONS Clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain X-ray, or especially both, are positive.", "offsetInBeginSection": 1470, "offsetInEndSection": 1750, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428", "text": "AIMS To investigate the accuracy of the sequential combination of the probe-to-bone test and plain X-rays for diagnosing osteomyelitis in the foot of patients with diabetes.", "offsetInBeginSection": 0, "offsetInEndSection": 173, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428", "text": "All patients with positive results on either the probe-to-bone test or plain X-ray underwent an appropriate surgical procedure, which included obtaining a bone specimen that was processed for histology and culture.", "offsetInBeginSection": 537, "offsetInEndSection": 751, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17259493", "text": "OBJECTIVE We sought to assess the accuracy of the probe-to-bone (PTB) test in diagnosing foot osteomyelitis in a cohort of diabetic patients with bone culture proven disease.", "offsetInBeginSection": 0, "offsetInEndSection": 174, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7770390", "text": "CONCLUSIONS The minisatellite probes MS31 and MS43 were found to be sensitive, effective tests for bone marrow transplants which can be used in routine follow-up.", "offsetInBeginSection": 835, "offsetInEndSection": 997, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24356116", "text": "However, scintigraphy is a nuclear scanning test to trace bone healing during stress fracture and osteomyelitis and thus can be used to probe the osseointegration process in vivo in the context of the dental implant.", "offsetInBeginSection": 82, "offsetInEndSection": 298, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18601422", "text": "In the Osteoprobe IItrade mark, the probe assembly, which is designed to penetrate soft tissue, consists of a reference probe (a 22 gauge hypodermic needle) and a test probe (a small diameter, sharpened rod) which slides through the inside of the reference probe.", "offsetInBeginSection": 347, "offsetInEndSection": 610, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18601422", "text": "The distance that the test probe is indented into the bone can be measured relative to the position of the reference probe.", "offsetInBeginSection": 680, "offsetInEndSection": 803, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1922909", "text": "Bone biopsy in an invasive method of diagnosing aluminium related bone disease (ABD).", "offsetInBeginSection": 0, "offsetInEndSection": 85, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e33e4b750ff4455000041", "body": "Describe annotatr", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28369316", "http://www.ncbi.nlm.nih.gov/pubmed/22189359", "http://www.ncbi.nlm.nih.gov/pubmed/28433298", "http://www.ncbi.nlm.nih.gov/pubmed/35944273", "http://www.ncbi.nlm.nih.gov/pubmed/15651245", "http://www.ncbi.nlm.nih.gov/pubmed/19520143", "http://www.ncbi.nlm.nih.gov/pubmed/25346200", "http://www.ncbi.nlm.nih.gov/pubmed/12595822", "http://www.ncbi.nlm.nih.gov/pubmed/23858254", "http://www.ncbi.nlm.nih.gov/pubmed/27269376"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18428249", "text": "Several support protocols describe methods for adenovirus growth and purification, biotinylation, inactivation with psoralen, and quantitation of the adenovirus particles.", "offsetInBeginSection": 279, "offsetInEndSection": 450, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11800821", "text": "We introduce two simple stochastic growth models which describe the motion of the interfaces driven through random media in two and three dimensions.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12725838", "text": "The resulting model equations are used to describe experimental surface pressure data published in the literature.", "offsetInBeginSection": 177, "offsetInEndSection": 291, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26579876", "text": "As anatomists we owe it to the medical and research community to correct the nomenclature to minimize confusion, and to describe the heart properly in respect to its surrounding structures.", "offsetInBeginSection": 692, "offsetInEndSection": 881, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18301504", "text": "The Babinet principle is used to separate components that describe the data signal, servo signals, and three types of cross talk.", "offsetInBeginSection": 166, "offsetInEndSection": 295, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23495128", "text": "OBJECTIVE The aim of the present study was to explore patients' views on the acceptability and feasibility of using colour to describe osteoarthritis (OA) pain, and whether colour could be used to communicate pain to healthcare professionals.", "offsetInBeginSection": 0, "offsetInEndSection": 242, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23495128", "text": "CONCLUSIONS For some patients, using colour to describe their pain experience may be a useful tool to improve doctor-patient communication.", "offsetInBeginSection": 1605, "offsetInEndSection": 1744, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23495128", "text": "Discussion topics included first impressions about using colour to describe pain, whether participants could associate their pain with colour, how colours related to changes to intensity and different pain qualities, and whether they could envisage using colour to describe pain to healthcare professionals.", "offsetInBeginSection": 320, "offsetInEndSection": 627, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498", "text": "We propose describing a manipulative technique using 6 characteristics: Rate of force application: Describe the rate at which the force was applied.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498", "text": "Relative structural movement: Describe which structure or region was intended to remain stable and which structure or region was intended to move, with the moving structure or region being named first and the stable segment named second, separated by the word \"on.\"", "offsetInBeginSection": 581, "offsetInEndSection": 846, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8718c861bb38fb24000008", "body": "What are check point inhibitors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33142728", "http://www.ncbi.nlm.nih.gov/pubmed/24485523", "http://www.ncbi.nlm.nih.gov/pubmed/28878676", "http://www.ncbi.nlm.nih.gov/pubmed/29340281", "http://www.ncbi.nlm.nih.gov/pubmed/36274472", "http://www.ncbi.nlm.nih.gov/pubmed/28351171", "http://www.ncbi.nlm.nih.gov/pubmed/36428923", "http://www.ncbi.nlm.nih.gov/pubmed/31692018", "http://www.ncbi.nlm.nih.gov/pubmed/33429744", "http://www.ncbi.nlm.nih.gov/pubmed/33177863"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363", "text": "OBJECTIVE To clarify the role of immune check point inhibitors in GBM management.", "offsetInBeginSection": 490, "offsetInEndSection": 571, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676", "text": "Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction.", "offsetInBeginSection": 236, "offsetInEndSection": 423, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676", "text": "In recent times, more than four check point antibody inhibitors have been commercialized for targeting PD-1, PDL-1, and CTLA-4.", "offsetInBeginSection": 588, "offsetInEndSection": 715, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706", "text": "check point inhibitors.", "offsetInBeginSection": 296, "offsetInEndSection": 319, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706", "text": "Patients with BRAFv600 mutations can be treated with a combination of a BRAF-inhibitor and an MEK-inhibitor.", "offsetInBeginSection": 84, "offsetInEndSection": 192, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706", "text": "AREAS COVERED We conducted a comprehensive review of the literature on the efficacy and predictive markers, safety, and pharmacoeconomics of ipilimumab in melanoma Expert commentary: Ipilimumab was the first check point inhibitor reaching the clinic, gaining FDA and EMA approval for metastatic melanoma in 2011.", "offsetInBeginSection": 322, "offsetInEndSection": 634, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25956379", "text": "Check point kinase 1 (Chk1) is an important protein in G2 phase checkpoint arrest required by cancer cells to maintain cell cycle and to prevent cell death.", "offsetInBeginSection": 0, "offsetInEndSection": 156, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26942589", "text": "Ongoing clinical trials are evaluating the role of check point inhibitors in combination with chemotherapy.", "offsetInBeginSection": 1487, "offsetInEndSection": 1594, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27722817", "text": "We implemented this new methodology to develop valid pharmacophore models for check point kinase 1 (Chk1) and beta-secretase 1 (BACE1) inhibitors as case studies.", "offsetInBeginSection": 784, "offsetInEndSection": 946, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18069260", "text": "Accumulating evidences suggest that many molecules are working as inhibitors of proliferation in myeloma cells e.g., PTEN, mTOR(PI3-kinase signal molecules), p53, RB1, INK4 family and KIP/CIP family (cell cycle check point molecules), PF4 (inhibitor of angiogenesis).", "offsetInBeginSection": 0, "offsetInEndSection": 267, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f87c5b750ff4455000056", "body": "Are patients with Sjogren syndrome at increased risk for lymphoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34277270", "http://www.ncbi.nlm.nih.gov/pubmed/23982978", "http://www.ncbi.nlm.nih.gov/pubmed/9806368", "http://www.ncbi.nlm.nih.gov/pubmed/12886135", "http://www.ncbi.nlm.nih.gov/pubmed/1591382", "http://www.ncbi.nlm.nih.gov/pubmed/27336863", "http://www.ncbi.nlm.nih.gov/pubmed/7646335", "http://www.ncbi.nlm.nih.gov/pubmed/30371536", "http://www.ncbi.nlm.nih.gov/pubmed/33991884", "http://www.ncbi.nlm.nih.gov/pubmed/30476667"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863", "text": "The heightened risk of non-Hodgkin lymphoma (NHL) development in primary Sjogren syndrome (SS) is well established.", "offsetInBeginSection": 0, "offsetInEndSection": 115, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517", "text": "RECENT FINDINGS Despite a lack of a strong association between rheumatoid arthritis and cancer overall, studies show an increased risk for the development of lymphoma in rheumatoid arthritis.", "offsetInBeginSection": 447, "offsetInEndSection": 638, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517", "text": "Data substantiate an increased risk of certain cancers in systemic lupus erythematosus; the risk appears to be most heightened for lymphoma.", "offsetInBeginSection": 911, "offsetInEndSection": 1051, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25368273", "text": "The average risk of lymphoma in RA may be composed of a markedly increased risk in patients with most severe disease.", "offsetInBeginSection": 937, "offsetInEndSection": 1054, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2110929", "text": "Clinical features such as age, duration of disease, extent of lymphadenopathy, splenomegaly, or parotid swelling failed to identify those subsets of patients with lymphadenopathy at increased risk for lymphoma.", "offsetInBeginSection": 1026, "offsetInEndSection": 1236, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24159176", "text": "Several autoimmune diseases, including primary Sj\u00f6gren's syndrome (pSS), are associated with an increased risk for lymphoma.", "offsetInBeginSection": 0, "offsetInEndSection": 125, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24159176", "text": "The rs2230926 exonic variant was associated with an increased risk for pSS complicated by lymphoma (odds ratio, 3.36 [95% confidence interval, 1.34-8.42], and odds ratio, 3.26 [95% confidence interval, 1.31-8.12], vs controls and pSS patients without lymphoma, respectively; P = .011).", "offsetInBeginSection": 720, "offsetInEndSection": 1005, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20084442", "text": "These findings suggest that patients with pSS who have ACA may be a subgroup of patients at increased risk of extraglandular systemic manifestations and lymphoma.", "offsetInBeginSection": 668, "offsetInEndSection": 830, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12064854", "text": "In contrast to secondary SS, the risk for developing non-Hodgkin's lymphoma is highly increased in patients with primary SS.", "offsetInBeginSection": 293, "offsetInEndSection": 417, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24153350", "text": "Sjogren's syndrome (SS) is a chronic autoimmune disorder with the highest risk for lymphoma development among all autoimmune diseases.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e3d21b750ff4455000043", "body": "What is BBCAnalyzer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28241736", "http://www.ncbi.nlm.nih.gov/pubmed/19702537", "http://www.ncbi.nlm.nih.gov/pubmed/6683883", "http://www.ncbi.nlm.nih.gov/pubmed/31798210", "http://www.ncbi.nlm.nih.gov/pubmed/11326518", "http://www.ncbi.nlm.nih.gov/pubmed/30656893", "http://www.ncbi.nlm.nih.gov/pubmed/6359612", "http://www.ncbi.nlm.nih.gov/pubmed/31342198", "http://www.ncbi.nlm.nih.gov/pubmed/15734663", "http://www.ncbi.nlm.nih.gov/pubmed/24119119"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736", "text": "RESULTS BBCAnalyzer (Bases By CIGAR Analyzer) provides a novel visual approach to facilitate this step of time-consuming, manual inspection of common mutation sites.", "offsetInBeginSection": 501, "offsetInEndSection": 666, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736", "text": "CONCLUSIONS BBCAnalyzer provides a unique, novel approach to facilitate variant calling where classical tools frequently fail to call.", "offsetInBeginSection": 1412, "offsetInEndSection": 1546, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736", "text": "BBCAnalyzer is able to visualize base counts at predefined positions or regions in any sequence alignment data that are available as BAM files.", "offsetInBeginSection": 667, "offsetInEndSection": 810, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736", "text": "Video demonstrating the exemplary usage of the web application \"BBCAnalyzer\".", "offsetInBeginSection": 2026, "offsetInEndSection": 2103, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736", "text": "Any expected mutations (e.g.", "offsetInBeginSection": 373, "offsetInEndSection": 401, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736", "text": "Information on the counted number of bases, the reference bases, known mutations or polymorphisms, called mutations and base qualities is summarized in a single plot.", "offsetInBeginSection": 1060, "offsetInEndSection": 1226, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736", "text": "Thereby, the tool provides a straightforward solution for evaluating any list of expected mutations like hotspot mutations, or even whole regions of interest.", "offsetInBeginSection": 811, "offsetInEndSection": 969, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736", "text": "hotspot mutations), that have not been called by the software, need to be investigated manually.", "offsetInBeginSection": 402, "offsetInEndSection": 498, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736", "text": "BACKGROUND Deriving valid variant calling results from raw next-generation sequencing data is a particularly challenging task, especially with respect to clinical diagnostics and personalized medicine.", "offsetInBeginSection": 0, "offsetInEndSection": 201, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736", "text": "A documentation of the R package (Additional file 1) as well as the web application (Additional file 2) with detailed descriptions, examples of all input- and output elements, exemplary code as well as exemplary data are included.", "offsetInBeginSection": 1671, "offsetInEndSection": 1901, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a871a6861bb38fb24000009", "body": "What disease is the ALK tyrosine kinase associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21829174", "http://www.ncbi.nlm.nih.gov/pubmed/30813562", "http://www.ncbi.nlm.nih.gov/pubmed/22998583", "http://www.ncbi.nlm.nih.gov/pubmed/29488330", "http://www.ncbi.nlm.nih.gov/pubmed/17611412", "http://www.ncbi.nlm.nih.gov/pubmed/25979929", "http://www.ncbi.nlm.nih.gov/pubmed/21288922", "http://www.ncbi.nlm.nih.gov/pubmed/20223922", "http://www.ncbi.nlm.nih.gov/pubmed/31366041", "http://www.ncbi.nlm.nih.gov/pubmed/26503946"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755", "text": "Two ALK tyrosine kinase inhibitors (TKIs), crizotinib and ceritinib, are currently approved in Europe for use in ALK-positive NSCLC and several others are in development.", "offsetInBeginSection": 1103, "offsetInEndSection": 1273, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20223922", "text": "NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) and TPM3-ALK (nonmuscular tropomyosin 3-anaplastic lymphoma kinase) are oncogenic tyrosine kinases implicated in the pathogenesis of human ALK-positive lymphoma.", "offsetInBeginSection": 0, "offsetInEndSection": 212, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901", "text": "In contrast, ALK tyrosine kinase inhibitor (ALK TKI) crizotinib has shown superior effects in combating NSCLCs with EML4-ALK.", "offsetInBeginSection": 450, "offsetInEndSection": 575, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901", "text": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib.", "offsetInBeginSection": 254, "offsetInEndSection": 449, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901", "text": "BACKGROUND The translocations of the anaplastic lymphoma kinase (ALK) gene with the echinoderm microtubule-associated protein-like 4 (EML4) gene on chromosome 2p have been identified in non-small-cell lung cancers (NSCLCs) as oncogenic driver mutations.", "offsetInBeginSection": 0, "offsetInEndSection": 253, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25351247", "text": "Although tyrosine kinase inhibitors abrogating ALK activity are currently in clinical use for the treatment of ALK-positive (ALK(+)) disease, monotherapy with ALK tyrosine kinase inhibitors may not be an adequate solution for ALK(+) neuroblastoma patients.", "offsetInBeginSection": 84, "offsetInEndSection": 340, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27217763", "text": "Crizotinib was the first ALK tyrosine kinase inhibitor licensed for the treatment of metastatic ALK-positive NSCLC based on a randomized Phase III trial.", "offsetInBeginSection": 167, "offsetInEndSection": 320, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23714228", "text": "CASE PRESENTATION We report that a case of EML4-ALK-positive NSCLC with EGFR mutation had a response of stable disease to both an EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK inhibitor.", "offsetInBeginSection": 355, "offsetInEndSection": 545, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23714228", "text": "BACKGROUND The EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) fusion oncogene represents a novel molecular target in a small subset of non-small-cell lung cancers (NSCLCs).", "offsetInBeginSection": 0, "offsetInEndSection": 230, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26811689", "text": "Anaplastic lymphoma kinase (ALK) rearrangement lung cancer responds to ALK tyrosine kinase inhibitors.", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f8dc6b750ff4455000058", "body": "Is trastuzumab associated cardiotoxicity reversible?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21310845", "http://www.ncbi.nlm.nih.gov/pubmed/28694974", "http://www.ncbi.nlm.nih.gov/pubmed/30859381", "http://www.ncbi.nlm.nih.gov/pubmed/18514938", "http://www.ncbi.nlm.nih.gov/pubmed/14613026", "http://www.ncbi.nlm.nih.gov/pubmed/19669637", "http://www.ncbi.nlm.nih.gov/pubmed/19147689", "http://www.ncbi.nlm.nih.gov/pubmed/29225726", "http://www.ncbi.nlm.nih.gov/pubmed/23282614", "http://www.ncbi.nlm.nih.gov/pubmed/29189161"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985", "text": "The cardiotoxicity of antibodies has been associated to trastuzumab, a humanized anti-ErbB2 monoclonal antibody currently in clinical use for the therapy of breast carcinomas, which induces cardiac dysfunction when used in monotherapy, or in combination with anthracyclines.", "offsetInBeginSection": 563, "offsetInEndSection": 837, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985", "text": "Two categories of cardiotoxic side effects of antineoplastic drugs have been previously proposed: Type I cardiotoxicity, defined as permanent cardiotoxicity, is usually caused by anthracyclines; Type II cardiotoxicity, considered as reversible cardiotoxicity, has been mainly related to monoclonal antibodies.", "offsetInBeginSection": 253, "offsetInEndSection": 562, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637", "text": "INTRODUCTION Although having high clinical efficacy in the treatment of human epidermal growth factor receptor-2 (HER2+) metastatic breast cancer, trastuzumab has been associated with cardiotoxicity, and the etiology and pathogenesis of this condition is currently under investigation.", "offsetInBeginSection": 0, "offsetInEndSection": 285, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637", "text": "RESULTS The increased risk of cardiotoxicity is lower when trastuzumab is given as monotherapy (3%-7%) compared with anthracyclines + trastuzumab therapy (27%).", "offsetInBeginSection": 442, "offsetInEndSection": 602, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18514938", "text": "Although reversible in most cases, cardiotoxicity frequently results in the discontinuation of trastuzumab.", "offsetInBeginSection": 356, "offsetInEndSection": 463, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21310845", "text": "The long-term significance of these events, isolating known cardiotoxic effects of anthracyclines from those of trastuzumab, and the appropriateness of referring to trastuzumab-related cardiotoxicity as reversible rather than responsive to trastuzumab withdrawal and heart failure medical therapy, are issues that continue to be debated.", "offsetInBeginSection": 150, "offsetInEndSection": 487, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21310845", "text": "The use of trastuzumab in the adjuvant and metastatic treatment of breast cancer is associated with both symptomatic and asymptomatic cardiotoxicity.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18484781", "text": "Cardiotoxicity has been shown to be potentiated when the agent is used concurrently or sequentially with an anthracycline, and this has limited the use of trastuzumab in some patients.", "offsetInBeginSection": 533, "offsetInEndSection": 717, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18484781", "text": "Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor tyrosine kinase HER2/ErbB2.", "offsetInBeginSection": 0, "offsetInEndSection": 120, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19147689", "text": "Concomitant anthracycline therapy significantly increases the risk for cardiotoxicity during trastuzumab treatment, and such regimens are therefore not recommended.", "offsetInBeginSection": 415, "offsetInEndSection": 579, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e3fe3b750ff4455000044", "body": "Does the human lncRNA LINC-PINT promote tumorigenesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33531456", "http://www.ncbi.nlm.nih.gov/pubmed/32828314", "http://www.ncbi.nlm.nih.gov/pubmed/28680141", "http://www.ncbi.nlm.nih.gov/pubmed/33037850", "http://www.ncbi.nlm.nih.gov/pubmed/31070482", "http://www.ncbi.nlm.nih.gov/pubmed/31921860", "http://www.ncbi.nlm.nih.gov/pubmed/30569513", "http://www.ncbi.nlm.nih.gov/pubmed/29050257", "http://www.ncbi.nlm.nih.gov/pubmed/33688258", "http://www.ncbi.nlm.nih.gov/pubmed/31711064"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818", "text": "RESULTS Here we characterize the function of the p53-regulated human lncRNA LINC-PINT in cancer.", "offsetInBeginSection": 405, "offsetInEndSection": 501, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818", "text": "We find that LINC-PINT is downregulated in multiple types of cancer and acts as a tumor suppressor lncRNA by reducing the invasive phenotype of cancer cells.", "offsetInBeginSection": 502, "offsetInEndSection": 659, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818", "text": "CONCLUSIONS Our findings support a conserved functional co-dependence between LINC-PINT and PRC2 and lead us to propose a new mechanism where the lncRNA regulates the availability of free PRC2 at the proximity of co-regulated genomic loci.", "offsetInBeginSection": 970, "offsetInEndSection": 1209, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818", "text": "This sequence mediates a specific interaction with PRC2, necessary for the LINC-PINT-dependent repression of a pro-invasion signature of genes regulated by the transcription factor EGR1.", "offsetInBeginSection": 781, "offsetInEndSection": 967, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27708234", "text": "Long intergenic non-protein coding RNA, p53 induced transcript (Linc-pint) is a long noncoding RNA (lncRNA) that regulates tumor cell viability and proliferation.", "offsetInBeginSection": 0, "offsetInEndSection": 162, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24922071", "text": "The lncRNA linc-ROR has been shown to contribute to the maintenance of induced pluripotent stem cells and embryonic stem cells.", "offsetInBeginSection": 207, "offsetInEndSection": 334, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24922071", "text": "Thus our results indicate that linc-ROR functions as an important regulator of EMT and can promote breast cancer progression and metastasis through regulation of miRNAs.", "offsetInBeginSection": 1046, "offsetInEndSection": 1215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24381249", "text": "We also report growth defects for two additional mutant strains (linc-Brn1b and linc-Pint).", "offsetInBeginSection": 582, "offsetInEndSection": 673, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29050257", "text": "Long intergenic non-protein coding RNA, regulator of reprogramming (linc-ROR) is an intergenic long non-coding RNA (lncRNA) previously shown to contribute to tumorigenesis in several malignancies.", "offsetInBeginSection": 0, "offsetInEndSection": 196, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24463816", "text": "These studies show that linc-RoR is a hypoxia-responsive lncRNA that is functionally linked to hypoxia signaling in HCC through a miR-145-HIF-1\u03b1 signaling module.", "offsetInBeginSection": 1193, "offsetInEndSection": 1356, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a871b8d61bb38fb2400000a", "body": "What body process does the Dentate Gyrus Mossy Cell control?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35526721", "http://www.ncbi.nlm.nih.gov/pubmed/9187278", "http://www.ncbi.nlm.nih.gov/pubmed/27466143", "http://www.ncbi.nlm.nih.gov/pubmed/35181595", "http://www.ncbi.nlm.nih.gov/pubmed/28132828", "http://www.ncbi.nlm.nih.gov/pubmed/23407806", "http://www.ncbi.nlm.nih.gov/pubmed/28132825", "http://www.ncbi.nlm.nih.gov/pubmed/18189312", "http://www.ncbi.nlm.nih.gov/pubmed/1308178", "http://www.ncbi.nlm.nih.gov/pubmed/25031412"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312", "text": "In the examined four monkey species, mossy cells were found to be calretinin-positive at the uncal pole and at variable length within the main body of the dentate gyrus but not in the tail part.", "offsetInBeginSection": 580, "offsetInEndSection": 774, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9187278", "text": "Mossy cells in the hilus of the rat dentate gyrus are the main cells of origin of the dentate commissural and associational projections.", "offsetInBeginSection": 0, "offsetInEndSection": 136, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17765742", "text": "The influence on granule cells is indirect, through hilar mossy cells and GABAergic neurons of the dentate gyrus, and appears to include direct projections in the case of CA3c pyramidal cells of ventral hippocampus.", "offsetInBeginSection": 1638, "offsetInEndSection": 1853, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14999076", "text": "However, whether it is the disappearance of hilar mossy cells from the dentate gyrus circuitry after various insults or the subsequent synaptic-cellular alterations (e.g., reactive axonal sprouting) that lead to dentate hyperexcitability has not been rigorously tested, because of the lack of available techniques to rapidly remove specific classes of nonprincipal cells from neuronal networks.", "offsetInBeginSection": 372, "offsetInEndSection": 766, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10531454", "text": "These findings support hypotheses of temporal lobe epileptogenesis that involve mossy cell and somatostatinergic neuron loss and suggest that lateral inhibition in the dentate gyrus does not require mossy cells but, instead, may be generated directly by GABAergic interneurons.", "offsetInBeginSection": 1462, "offsetInEndSection": 1739, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10531454", "text": "Kainate-treated rats lose an average of 52% of their GAD-negative hilar neurons (putative mossy cells) and 13% of their GAD-positive cells (GABAergic interneurons) in the dentate gyrus.", "offsetInBeginSection": 323, "offsetInEndSection": 508, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1308178", "text": "The present results indicate that connections between granule cells and hilar mossy cells of the human dentate gyrus develop through an extended postnatal period of time that may last until the fifth year.", "offsetInBeginSection": 1584, "offsetInEndSection": 1789, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18077687", "text": "Semilunar granule cells appear to represent a distinct excitatory neuron population in the dentate gyrus that may be an important target for mossy fiber sprouting in patients and rodent models of temporal lobe epilepsy.", "offsetInBeginSection": 1050, "offsetInEndSection": 1269, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24811867", "text": "This complex arrangement of cells and processes allowed us to study the combined effect of mossy fiber sprouting, altered apical dendritic tree and dendritic spine loss in newborn granule cells on the excitability of the dentate gyrus model.", "offsetInBeginSection": 1305, "offsetInEndSection": 1546, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7721998", "text": "These results establish the validity of Timm staining as a marker for mossy fiber sprouting and support the view that status epilepticus provokes the formation of a novel recurrent excitatory circuit in the dentate gyrus.", "offsetInBeginSection": 1829, "offsetInEndSection": 2050, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f922fb750ff4455000059", "body": "Can canagliflozin cause euglycemic diabetic ketoacidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30234515", "http://www.ncbi.nlm.nih.gov/pubmed/27375734", "http://www.ncbi.nlm.nih.gov/pubmed/35698468", "http://www.ncbi.nlm.nih.gov/pubmed/35495849", "http://www.ncbi.nlm.nih.gov/pubmed/27928503", "http://www.ncbi.nlm.nih.gov/pubmed/27088018", "http://www.ncbi.nlm.nih.gov/pubmed/29099159", "http://www.ncbi.nlm.nih.gov/pubmed/29634546", "http://www.ncbi.nlm.nih.gov/pubmed/28090050", "http://www.ncbi.nlm.nih.gov/pubmed/34925578"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734", "text": "We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin.", "offsetInBeginSection": 0, "offsetInEndSection": 182, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050", "text": "We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persistent diuresis in the absence of hyperglycemia.", "offsetInBeginSection": 175, "offsetInEndSection": 442, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592", "text": "SGLT2 inhibitors such as canagliflozin may predispose patients not only to diabetic ketoacidosis but also to prolonged glucosuria.", "offsetInBeginSection": 1103, "offsetInEndSection": 1233, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503", "text": "We present a case of euglycemic diabetic ketoacidosis secondary to canagliflozin in a type 2 diabetic patient.", "offsetInBeginSection": 558, "offsetInEndSection": 668, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503", "text": "Ketoacidosis is a significant and often a life-threatening complication of diabetes mellitus seen mostly in type 1 diabetes mellitus as well as occasionally in type 2 diabetes mellitus.", "offsetInBeginSection": 0, "offsetInEndSection": 185, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503", "text": "Diabetic ketoacidosis usually manifests with high blood glucose more than 250\u2009mg/dL, but euglycemic diabetic ketoacidosis is defined as ketoacidosis associated with blood glucose level less than 250\u2009mg/dL.", "offsetInBeginSection": 186, "offsetInEndSection": 395, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27088018", "text": "However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported.", "offsetInBeginSection": 333, "offsetInEndSection": 478, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29099159", "text": "OBJECTIVE Canagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, one of a class of novel antiglycemic agents that are gaining in popularity in the treatment of diabetes.", "offsetInBeginSection": 0, "offsetInEndSection": 185, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18975036", "text": "True euglycemic diabetic ketoacidosis [blood glucose <200 mg/dl (11.1 mmol/l)] is relatively uncommon and in type 1 diabetes can be caused by starvation of any cause in conjunction with an intercurrent illness.", "offsetInBeginSection": 0, "offsetInEndSection": 210, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18975036", "text": "This case involves the complex interplay among type 1 diabetes, depression, ketoacidosis, and starvation physiology resulting in glucose concentrations in keeping with euglycemic diabetic ketoacidosis.", "offsetInBeginSection": 531, "offsetInEndSection": 732, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e4136b750ff4455000045", "body": "Describe the Match BAM to VCF (MBV) method.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28186259", "http://www.ncbi.nlm.nih.gov/pubmed/27153667", "http://www.ncbi.nlm.nih.gov/pubmed/25346813", "http://www.ncbi.nlm.nih.gov/pubmed/9626439", "http://www.ncbi.nlm.nih.gov/pubmed/26895526", "http://www.ncbi.nlm.nih.gov/pubmed/24451629", "http://www.ncbi.nlm.nih.gov/pubmed/18276517", "http://www.ncbi.nlm.nih.gov/pubmed/29590101", "http://www.ncbi.nlm.nih.gov/pubmed/29678686", "http://www.ncbi.nlm.nih.gov/pubmed/10912870"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259", "text": "Results We described here MBV (Match BAM to VCF); a method to quickly solve sample mislabeling and detect cross-sample contamination and PCR amplification bias.", "offsetInBeginSection": 189, "offsetInEndSection": 349, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19749478", "text": "CONCLUSIONS Valsartan, an angiotensin II receptor blocker, corrected the decreased MBV in association with regression of LVH in patients with HT.", "offsetInBeginSection": 1286, "offsetInEndSection": 1431, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23765705", "text": "BACKGROUND Transthoracic (TTE) and intracardiac echocardiography (ICE) have both been established as modalities for imaging guidance in mitral balloon valvuloplasty (MBV).", "offsetInBeginSection": 0, "offsetInEndSection": 171, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17891616", "text": "A perfusion quantification method was applied to obtain MBV maps.", "offsetInBeginSection": 718, "offsetInEndSection": 783, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23997439", "text": "Besides MBV, two strains of SNPV are reported-plebejus baculovirus and bennettae baculovirus.", "offsetInBeginSection": 337, "offsetInEndSection": 430, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23997439", "text": "Although complete genome sequence of MBV is not available, nucleic acid of MBV is circular, double-stranded DNA with a genome size ranging from 80 to 160\u00a0kbp.", "offsetInBeginSection": 1725, "offsetInEndSection": 1884, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23997439", "text": "Among the viruses infecting penaeid shrimp, monodon-type baculovirus (MBV) otherwise known as Penaeus monodon singly enveloped nuclear polyhedrosis virus (PmSNPV), is one of the widely reported and well described viruses.", "offsetInBeginSection": 0, "offsetInEndSection": 221, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28369524", "text": "Here, we describe NGSCheckMate, a user-friendly software package for verifying sample identities from FASTQ, BAM or VCF files.", "offsetInBeginSection": 438, "offsetInEndSection": 564, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19622362", "text": "A real-time PCR method was developed to detect monodon baculovirus (MBV) in penaeid shrimp.", "offsetInBeginSection": 0, "offsetInEndSection": 91, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19622362", "text": "A pair of MBV primers to amplify a 135bp DNA fragment and a TaqMan probe were developed.", "offsetInBeginSection": 92, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a897601fcd1d6a10c000008", "body": "A SLEDAI score is associated with Systemic Lupus Erythematosus. What is a SLEDAI score?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32292454", "http://www.ncbi.nlm.nih.gov/pubmed/19762400", "http://www.ncbi.nlm.nih.gov/pubmed/8235662", "http://www.ncbi.nlm.nih.gov/pubmed/10685800", "http://www.ncbi.nlm.nih.gov/pubmed/26657735", "http://www.ncbi.nlm.nih.gov/pubmed/12007552", "http://www.ncbi.nlm.nih.gov/pubmed/11838846", "http://www.ncbi.nlm.nih.gov/pubmed/34063379", "http://www.ncbi.nlm.nih.gov/pubmed/10955329", "http://www.ncbi.nlm.nih.gov/pubmed/16761499"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800", "text": "OBJECTIVE To determine whether Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores correlate with the clinician's impression of level of disease activity.", "offsetInBeginSection": 0, "offsetInEndSection": 170, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19762400", "text": "The objective of this study is to determine if digital vasculitis (DV), a clinical manifestation with a high systemic lupus erythematosus disease activity index (SLEDAI) score, is associated with lupus severity.", "offsetInBeginSection": 0, "offsetInEndSection": 211, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22516994", "text": "The antepartum SLEDAI score was 6.2\u00b11.6, the postpartum SLEDAI score  was 6.4\u00b12.9.", "offsetInBeginSection": 673, "offsetInEndSection": 757, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22516994", "text": "The impact of the disease duration, the use of cyclophosphamide, the highest systematic lupus erythematosus disease activity index  (SLEDAI) score during the disease and the antepartum SLEDAI score to the outcome of delivery were analyzed.", "offsetInBeginSection": 313, "offsetInEndSection": 552, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27365721", "text": "Systemic lupus erythematosus disease activity index (SLEDAI), C3, C4 and anti-double stranded DNA levels were estimated and repeated monthly till remission.", "offsetInBeginSection": 297, "offsetInEndSection": 453, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23172751", "text": "METHODS Patients who met \u22654 of the American College of Rheumatology criteria, had a score of \u22656 on the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and did not have an A score on the British Isles Lupus Assessment Group (BILAG)-2004 scale were eligible.", "offsetInBeginSection": 177, "offsetInEndSection": 458, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17477466", "text": "OBJECTIVE To determine the flare rate and the change in Safety of Estrogens in Lupus Erythematosus: National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) score with disease flare in pediatric systemic lupus erythematosus (pSLE).", "offsetInBeginSection": 0, "offsetInEndSection": 262, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16354890", "text": "Secondary outcomes included the maximum SLEDAI score, change in SLEDAI score, incidence of lupus flares, median time to first flare, systemic lupus erythematosus treatment, and adverse events.", "offsetInBeginSection": 637, "offsetInEndSection": 829, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16354890", "text": "Disease activity was assessed at 0, 1, 2, 3, 6, 9, and 12 months according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).", "offsetInBeginSection": 379, "offsetInEndSection": 522, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11480850", "text": "Sociodemographic, disease activity using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), therapy and laboratory variables were evaluated.", "offsetInBeginSection": 384, "offsetInEndSection": 539, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f941eb750ff445500005b", "body": "What is the association between kidney donation risk of gestational complications?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35016135", "http://www.ncbi.nlm.nih.gov/pubmed/35404873", "http://www.ncbi.nlm.nih.gov/pubmed/35237556", "http://www.ncbi.nlm.nih.gov/pubmed/30619691", "http://www.ncbi.nlm.nih.gov/pubmed/26090646", "http://www.ncbi.nlm.nih.gov/pubmed/35716049", "http://www.ncbi.nlm.nih.gov/pubmed/27591246", "http://www.ncbi.nlm.nih.gov/pubmed/30472740", "http://www.ncbi.nlm.nih.gov/pubmed/29884919", "http://www.ncbi.nlm.nih.gov/pubmed/27769207"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246", "text": "A modest rise in uric acid levels beginning early after donation, and a small (1.4%) increase in the 8-year incidence of gout, have also been reported in comparisons to healthy nondonors.", "offsetInBeginSection": 965, "offsetInEndSection": 1152, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646", "text": "Kidney donation seems to elevate the risks of gestational hypertension and pre-eclampsia.", "offsetInBeginSection": 462, "offsetInEndSection": 551, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646", "text": "Living kidney donation is associated with an increased risk of end-stage renal disease, although this outcome is uncommon (<0\u00b75% increase in incidence at 15 years).", "offsetInBeginSection": 296, "offsetInEndSection": 461, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22252087", "text": "BACKGROUND Although older maternal age is a risk factor for pregnancy complications, an increasing number of women delay conception until the age of 40, and some must resort to IVF with oocyte donation.", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12351541", "text": "CONCLUSIONS There is a high risk of obstetric complications in singleton oocyte donation pregnancies, but the perinatal outcomes are favourable.", "offsetInBeginSection": 1189, "offsetInEndSection": 1333, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12351541", "text": "LBW deliveries were significantly associated with PIH, STB, nulliparity and maternal smoking.", "offsetInBeginSection": 950, "offsetInEndSection": 1043, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26895841", "text": "We conclude that medical complications experienced by either the donor or recipient is a risk factor for deterioration in donors' mental health after living kidney donation.", "offsetInBeginSection": 1165, "offsetInEndSection": 1338, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26895841", "text": "A minority of living kidney donors (between 5-25%) have poor psychological outcomes after donation.", "offsetInBeginSection": 0, "offsetInEndSection": 99, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27271097", "text": "WIDER IMPLICATIONS Oocyte donation pregnancies are associated with a higher rate of placental disorders of pregnancy, such as gestational hypertension and pre-eclampsia.", "offsetInBeginSection": 1320, "offsetInEndSection": 1489, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15240849", "text": "Major complications after kidney donation are rare.", "offsetInBeginSection": 154, "offsetInEndSection": 205, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e4592b750ff4455000047", "body": "What is the 959 Nematode Genomes initiative?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22058131", "http://www.ncbi.nlm.nih.gov/pubmed/24058822", "http://www.ncbi.nlm.nih.gov/pubmed/22044053", "http://www.ncbi.nlm.nih.gov/pubmed/18952001", "http://www.ncbi.nlm.nih.gov/pubmed/2698851", "http://www.ncbi.nlm.nih.gov/pubmed/14681448", "http://www.ncbi.nlm.nih.gov/pubmed/18983679", "http://www.ncbi.nlm.nih.gov/pubmed/20507524", "http://www.ncbi.nlm.nih.gov/pubmed/1367926", "http://www.ncbi.nlm.nih.gov/pubmed/28356679"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822", "text": "To inspire, promote and coordinate genomic sequencing across the diversity of the phylum, we have launched a community wiki and the 959 Nematode Genomes initiative (www.nematodegenomes.org/).", "offsetInBeginSection": 1003, "offsetInEndSection": 1194, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822", "text": "Just as the deciphering of the developmental lineage of the 959 cells of the adult hermaphrodite C. elegans was the gateway to broad advances in biomedical science, we hope that a nematode phylogeny with (at least) 959 sequenced species will underpin further advances in understanding the origins of parasitism, the dynamics of genomic change and the adaptations that have made Nematoda one of the most successful animal phyla.", "offsetInBeginSection": 1195, "offsetInEndSection": 1622, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053", "text": "These efforts are being coordinated through the 959 Nematode Genomes initiative.", "offsetInBeginSection": 1379, "offsetInEndSection": 1459, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22058131", "text": "In this article, we describe '959 Nematode Genomes'--a community-curated semantic wiki to coordinate the sequencing efforts of individual labs to collectively sequence 959 genomes spanning the phylum Nematoda.", "offsetInBeginSection": 130, "offsetInEndSection": 339, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28706308", "text": "The Journal of Nematology now offers publication of Nematode Genome Announcements (NGA) and Nematode Transcriptome Announcements (NTA).", "offsetInBeginSection": 0, "offsetInEndSection": 135, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27415016", "text": "Characterization of four gene copies from a model parasitic nematode, Haemonchus contortus, demonstrated that each copy has acquired unique functional characteristics based on phenotype rescue of transgenic C. elegans and electrophysiology of receptors reconstituted in Xenopus oocytes.", "offsetInBeginSection": 1343, "offsetInEndSection": 1629, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21707658", "text": "The Wellcome Trust Sanger Institute (WTSI) is producing de novo reference quality genomes for parasitic helminth species from platyhelminth tapeworms (cestodes), flukes (trematodes) and roundworms (nematodes) primarily using second-generation (Illumina and 454) sequencing technologies.", "offsetInBeginSection": 0, "offsetInEndSection": 286, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18983679", "text": "BACKGROUND Nematode.net http://www.nematode.net is a web-accessible resource for investigating gene sequences from parasitic and free-living nematode genomes.", "offsetInBeginSection": 0, "offsetInEndSection": 158, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18983679", "text": "The NemaPath approach consists of two parts: 1) a backend tool to align and evaluate nematode genomic sequences (curated EST contigs) against the annotated Kyoto Encyclopedia of Genes and Genomes (KEGG) protein database; 2) a web viewing application that displays annotated KEGG pathway maps based on desired confidence levels of primary sequence similarity as defined by a user.", "offsetInBeginSection": 940, "offsetInEndSection": 1319, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18983679", "text": "The nematode source sequences used for the metabolic pathway mappings are available via FTP http://www.nematode.net/FTP/index.php, as provided by the Genome Center at Washington University School of Medicine.", "offsetInBeginSection": 1913, "offsetInEndSection": 2121, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a897927fcd1d6a10c00000a", "body": "What does A1C measure?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26630892", "http://www.ncbi.nlm.nih.gov/pubmed/20923490", "http://www.ncbi.nlm.nih.gov/pubmed/30447705", "http://www.ncbi.nlm.nih.gov/pubmed/22226280", "http://www.ncbi.nlm.nih.gov/pubmed/18030866", "http://www.ncbi.nlm.nih.gov/pubmed/16336550", "http://www.ncbi.nlm.nih.gov/pubmed/20067972", "http://www.ncbi.nlm.nih.gov/pubmed/19875553", "http://www.ncbi.nlm.nih.gov/pubmed/30364018", "http://www.ncbi.nlm.nih.gov/pubmed/21470266"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866", "text": "A CONCEPTUAL MODEL FOR ASSESSING THE QUALITY OF GLYCEMIC CONTROL A continuous measure of A1C, as the cornerstone in quality assessment for diabetes, can incorporate each of the Institute of Medicine's (IOM)'s quality domains: effectiveness and equity, patient safety, patient-centered care, timeliness, and efficiency.", "offsetInBeginSection": 933, "offsetInEndSection": 1251, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866", "text": "CONCLUSIONS A continuous measure of A1C can better capture than a dichotomous measure the complexity of glycemic control at a population level.", "offsetInBeginSection": 1254, "offsetInEndSection": 1397, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550", "text": "OBJECTIVE To study within-patient longitudinal changes in A1c levels at Veterans Health Administration (VHA) facilities as an alternative to cross-sectional measures of quality of diabetes care.", "offsetInBeginSection": 181, "offsetInEndSection": 375, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550", "text": "PATIENTS Diabetic veteran users with A1c measurement performed using National Glycosylated Hemoglobin Standardization Project certified A1c lab assay methods.", "offsetInBeginSection": 655, "offsetInEndSection": 813, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18509211", "text": "We assessed differences in A1C performance measure threshold attainment by case mix factors for A1C >9% and examined how lowering the threshold to A1C >8% or >7% changed these differences.", "offsetInBeginSection": 249, "offsetInEndSection": 437, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28843470", "text": "RESULTS Among 253 dyads, the frequencies of patients compared to caregivers who could accurately describe what the A1C level assesses, identify the ideal A1C target, and identify the ideal BG range were 20 vs. 66, 31 vs. 56, and 72 vs. 76%, respectively.", "offsetInBeginSection": 733, "offsetInEndSection": 987, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28843470", "text": "METHODS Patients (8 to 18 years) with T1D and caregivers completed questionnaires that queried their perceptions of (1) what the A1C level assesses, (2) the ideal A1C target, and (3) the ideal BG range.", "offsetInBeginSection": 358, "offsetInEndSection": 560, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28843470", "text": "OBJECTIVES (1) to describe pediatric patients with T1D and their caregivers' perceptions of measures of glycemic control (hemoglobin [A1C] and blood glucose [BG] levels) and (2) to determine the relationship between patients' and caregivers' perceptions of measures of glycemic control with actual A1C levels and adherence to diabetes self-care behaviors.", "offsetInBeginSection": 0, "offsetInEndSection": 355, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28964455", "text": "OBJECTIVES To estimate the impact of increased glycated hemoglobin (A1C) monitoring and treatment intensification for patients with type 2 diabetes (T2D) on quality measures and reimbursement within the Medicare Advantage Star (MA Star) program.", "offsetInBeginSection": 0, "offsetInEndSection": 245, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28964455", "text": "Using the estimated changes in measured A1C levels, we calculated corresponding changes in the plan-level A1C quality measure, overall star rating, and reimbursement.", "offsetInBeginSection": 554, "offsetInEndSection": 720, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f98e6b750ff445500005d", "body": "Which ligament is most commonly injured in dashboard injury?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10623985", "http://www.ncbi.nlm.nih.gov/pubmed/7377448", "http://www.ncbi.nlm.nih.gov/pubmed/31584902", "http://www.ncbi.nlm.nih.gov/pubmed/33440798", "http://www.ncbi.nlm.nih.gov/pubmed/31510833", "http://www.ncbi.nlm.nih.gov/pubmed/31895325", "http://www.ncbi.nlm.nih.gov/pubmed/17135950", "http://www.ncbi.nlm.nih.gov/pubmed/3425783", "http://www.ncbi.nlm.nih.gov/pubmed/22890899", "http://www.ncbi.nlm.nih.gov/pubmed/33852441"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783", "text": "Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury.", "offsetInBeginSection": 438, "offsetInEndSection": 574, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7377448", "text": "The anterior cruciate ligament (50%) is most often injured followed by the medial collateral ligament (31%), lateral collateral ligament (13%), and posterior cruciate ligament (6%).", "offsetInBeginSection": 765, "offsetInEndSection": 946, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22890899", "text": "The medial collateral ligament (MCL) is the most commonly injured ligament of the knee.", "offsetInBeginSection": 0, "offsetInEndSection": 87, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27623865", "text": "CONCLUSIONS The anterior inferior tibiofibular ligament is the most commonly injured ligament in the syndesmosis in sports injury and results in subtle variations in the syndesmotic anatomy, which plain radiographs cannot assess.", "offsetInBeginSection": 1181, "offsetInEndSection": 1410, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15474227", "text": "The ulnar collateral ligament (UCL) is more commonly injured than previously suggested.", "offsetInBeginSection": 0, "offsetInEndSection": 87, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15474227", "text": "Injury to this ligament can result in secondary symptoms and problems in other parts of the elbow, including the ulnar nerve, the flexor-pronator musculotendinous unit, the radiocapitellar joint, and the posterior compartment of the elbow, in addition to being a cause of loose bodies within the elbow.", "offsetInBeginSection": 88, "offsetInEndSection": 390, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21257845", "text": "BACKGROUND Humeral avulsion of the inferior glenohumeral ligament is a rare injury resulting from hyperabduction and external rotation, and it is most commonly seen with sports-related injuries, including those from volleyball.", "offsetInBeginSection": 0, "offsetInEndSection": 227, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21257845", "text": "The anterior band of the inferior glenohumeral ligament is most commonly injured (93%), whereas the posterior band is infrequently injured.", "offsetInBeginSection": 228, "offsetInEndSection": 367, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18980604", "text": "The thigh, especially the hamstrings, was the overall most commonly injured region in both sexes, while the hip/groin was more commonly injured in male players and the knee in female players.", "offsetInBeginSection": 568, "offsetInEndSection": 759, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19468882", "text": "The medial collateral ligament is one of the most commonly injured ligaments of the knee.", "offsetInBeginSection": 0, "offsetInEndSection": 89, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e49a4b750ff445500004b", "body": "Is LDB1-mediated enhancer looping dependent on cohesin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25605944", "http://www.ncbi.nlm.nih.gov/pubmed/28520978", "http://www.ncbi.nlm.nih.gov/pubmed/31127120", "http://www.ncbi.nlm.nih.gov/pubmed/34260936", "http://www.ncbi.nlm.nih.gov/pubmed/35353576", "http://www.ncbi.nlm.nih.gov/pubmed/35440598", "http://www.ncbi.nlm.nih.gov/pubmed/28636938", "http://www.ncbi.nlm.nih.gov/pubmed/36018801", "http://www.ncbi.nlm.nih.gov/pubmed/22682246", "http://www.ncbi.nlm.nih.gov/pubmed/36097291"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978", "text": "Moreover, ENCODE data and our chromatin immunoprecipitation results indicate that cohesin is almost completely absent from validated and predicted LDB1-regulated erythroid enhancer-gene pairs.", "offsetInBeginSection": 1172, "offsetInEndSection": 1364, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978", "text": "Further, Cas9-directed tethering of mutant LDB1 to the \u03b2-globin promoter forced LCR loop formation in the absence of mediator or cohesin occupancy.", "offsetInBeginSection": 1023, "offsetInEndSection": 1171, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25605944", "text": "LDB1-mediated enhancer:promoter looping appears to be required for both activation and repression of these target genes.", "offsetInBeginSection": 658, "offsetInEndSection": 778, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25605944", "text": "Here we report the required actions of LIM domain-binding protein 1 (LDB1)/cofactor of LIM homeodomain protein 2/nuclear LIM interactor, interacting with the enhancer-binding protein achaete-scute complex homolog 1, to mediate looping to target gene promoters and target gene regulation in corticotrope cells.", "offsetInBeginSection": 348, "offsetInEndSection": 657, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28636938", "text": "Both LDB1 and CTCF are required for enhancer-Car2 looping, and the domain of LDB1 contacted by CTCF is necessary to rescue Car2 transcription in LDB1-deficient cells.", "offsetInBeginSection": 494, "offsetInEndSection": 660, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28636938", "text": "Genome-wide studies and CRISPR/Cas9 genome editing indicate that LDB1-CTCF enhancer looping underlies activation of a substantial fraction of erythroid genes.", "offsetInBeginSection": 661, "offsetInEndSection": 819, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28636938", "text": "The LDB1 complex mediates enhancer-gene interactions at the \u03b2-globin locus through LDB1 self-interaction.", "offsetInBeginSection": 230, "offsetInEndSection": 336, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20720539", "text": "DNA looping is observed between the enhancers and promoters occupied by mediator and cohesin.", "offsetInBeginSection": 745, "offsetInEndSection": 838, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23610375", "text": "Ldb1 proteins are capable of coassociation, and long-range Ldb1-mediated oligomerization of enhancer- and promoter-bound Ldb1 complexes has been shown to be required for \u03b2-globin gene expression.", "offsetInBeginSection": 433, "offsetInEndSection": 629, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25081205", "text": "CTCF mediates the interactions between CTCF/cohesin binding sites, some of which have enhancer-blocking insulator activity.", "offsetInBeginSection": 726, "offsetInEndSection": 849, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a897a06fcd1d6a10c00000b", "body": "What is the normal body temperature in dogs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3976908", "http://www.ncbi.nlm.nih.gov/pubmed/25854787", "http://www.ncbi.nlm.nih.gov/pubmed/873588", "http://www.ncbi.nlm.nih.gov/pubmed/6302799", "http://www.ncbi.nlm.nih.gov/pubmed/28549943", "http://www.ncbi.nlm.nih.gov/pubmed/34515588", "http://www.ncbi.nlm.nih.gov/pubmed/495147", "http://www.ncbi.nlm.nih.gov/pubmed/35066483", "http://www.ncbi.nlm.nih.gov/pubmed/25320380", "http://www.ncbi.nlm.nih.gov/pubmed/1910939"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/495147", "text": "The effect of intraventricular injection of thyroxine 1 microgram/animal on body temperature was studied in dogs under resting conditions: at normal ambient temperature, at high ambient temperature (35 degrees C) and during administration of pyrogen.", "offsetInBeginSection": 0, "offsetInEndSection": 250, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/495147", "text": "Thyroxine exerted its central action on body temperature only in dogs performing physical exercise.", "offsetInBeginSection": 387, "offsetInEndSection": 486, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/495147", "text": "Besides, changes in body temperature were elucidated in dogs performing physical exercise following I.V.", "offsetInBeginSection": 251, "offsetInEndSection": 355, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21102554", "text": "CONCLUSION These findings document an association between obesity and reduced body temperature in dogs and support the hypothesis that obesity in this and other species of homeotherms may result from an increase in metabolic efficiency achieved by a regulated lowering of body temperature.", "offsetInBeginSection": 1097, "offsetInEndSection": 1386, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21102554", "text": "METHODS We compared the rectal temperature of lean dogs and obese dogs by (a) conducting cross-sectional measurements in 287 dogs of many breeds varying greatly in body size, (b) conducting longitudinal measurements in individual dogs over 7-10 years and (c) tracking rectal temperature of lean and obese dogs at 3-h intervals for 48 consecutive hours in the laboratory.", "offsetInBeginSection": 447, "offsetInEndSection": 817, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22058348", "text": "All dogs with TB had a normal body temperature, and three had systemic disease and one had clinical signs limited to testicular disease.", "offsetInBeginSection": 629, "offsetInEndSection": 765, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22058348", "text": "Three dogs with PB had an elevated body temperature and all had systemic disease.", "offsetInBeginSection": 547, "offsetInEndSection": 628, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416", "text": "Compared with normal gravity controls, exposed dogs showed a slower growth rate and a reduced amount of body fat.", "offsetInBeginSection": 557, "offsetInEndSection": 670, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416", "text": "Initially, centrifuged dogs showed transient decreases in heart rate and body temperature along with changes in their diurnal rhythm patterns.", "offsetInBeginSection": 414, "offsetInEndSection": 556, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416", "text": "In spite of the various changes noted, results from this and other studies affirm the view that dogs can tolerate and adapt to sustained loads as high as 2.5 g without serious impairment of their body structure and function.", "offsetInBeginSection": 1038, "offsetInEndSection": 1262, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70d12899e2c3af26000001", "body": "List symptoms of Heerfordt syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2307892", "http://www.ncbi.nlm.nih.gov/pubmed/18454397", "http://www.ncbi.nlm.nih.gov/pubmed/22565854", "http://www.ncbi.nlm.nih.gov/pubmed/33247650", "http://www.ncbi.nlm.nih.gov/pubmed/12233082", "http://www.ncbi.nlm.nih.gov/pubmed/8046854", "http://www.ncbi.nlm.nih.gov/pubmed/25087562", "http://www.ncbi.nlm.nih.gov/pubmed/36187020", "http://www.ncbi.nlm.nih.gov/pubmed/28954117", "http://www.ncbi.nlm.nih.gov/pubmed/24082416"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529", "text": "This case demonstrates the importance of being aware of the leading clinical signs and symptoms in case of Heerfordt syndrome.", "offsetInBeginSection": 774, "offsetInEndSection": 900, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241", "text": "Various clinical symptoms indicated Heerfordt syndrome.", "offsetInBeginSection": 638, "offsetInEndSection": 693, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241", "text": "We found no cases of familial sarcoidosis with Heerfordt syndrome in the literature.", "offsetInBeginSection": 0, "offsetInEndSection": 84, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397", "text": "BACKGROUND Heerfordt syndrome is rare and is characterized by fever, uveitis, parotid gland enlargement, and facial nerve palsy.", "offsetInBeginSection": 0, "offsetInEndSection": 128, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397", "text": "Chest computed tomography and transbronchial lymph node biopsy set the diagnosis of sarcoidosis.", "offsetInBeginSection": 668, "offsetInEndSection": 764, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397", "text": "We hereby present a case of Heerfordt syndrome with unilateral facial nerve palsy as a presentation of sarcoidosis.", "offsetInBeginSection": 129, "offsetInEndSection": 244, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22565854", "text": "Angiography revealed a dense pattern of hyperfluorescent lesions and these observations resulted in the diagnosis of Heerfordt syndrome.", "offsetInBeginSection": 401, "offsetInEndSection": 537, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25087562", "text": "Other examinations revealed bilateral hilar lymphadenopathy, high serum titer of angiotensin coenzyme, and no response in a tuberculin-tested, non-caseating epithelioid granuloma from lip biopsy, leading to the diagnosis of complete Heerfordt syndrome.", "offsetInBeginSection": 479, "offsetInEndSection": 731, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25685372", "text": "Heerfordt's syndrome as a cause of facial palsy is very rare.", "offsetInBeginSection": 124, "offsetInEndSection": 185, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2307892", "text": "Heerfordt syndrome is an unusual manifestation of systemic sarcoidosis and is characterized by parotitis, uveitis, and facial nerve paralysis.", "offsetInBeginSection": 0, "offsetInEndSection": 142, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e4b72b750ff445500004c", "body": "Is there any link between ERCC1-XPF and cohesin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/14512883", "http://www.ncbi.nlm.nih.gov/pubmed/11160918", "http://www.ncbi.nlm.nih.gov/pubmed/15932882", "http://www.ncbi.nlm.nih.gov/pubmed/20518486", "http://www.ncbi.nlm.nih.gov/pubmed/28368372", "http://www.ncbi.nlm.nih.gov/pubmed/22323595", "http://www.ncbi.nlm.nih.gov/pubmed/32099408", "http://www.ncbi.nlm.nih.gov/pubmed/24158589", "http://www.ncbi.nlm.nih.gov/pubmed/11790111", "http://www.ncbi.nlm.nih.gov/pubmed/22941649"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372", "text": "We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.", "offsetInBeginSection": 806, "offsetInEndSection": 1051, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372", "text": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development.", "offsetInBeginSection": 128, "offsetInEndSection": 521, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372", "text": "Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and\u00a0the aberrant developmental expression of imprinted genes without altering DNA methylation.", "offsetInBeginSection": 522, "offsetInEndSection": 805, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20518486", "text": "This binding between FANCG and the ERCC1-XPF endonuclease, combined with our previous studies which show that FANCG is involved in the incision step mediated by ERCC1-XPF, establishes a link between an FA protein and the critical unhooking step of the ICL repair process.", "offsetInBeginSection": 1428, "offsetInEndSection": 1699, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24158589", "text": "Occurrence of theses variations adversely affected the regular interaction between ERCC1 and XPF protein.", "offsetInBeginSection": 875, "offsetInEndSection": 980, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10882712", "text": "However, in mammalian cells there is evidence that the ERCC1-XPF nuclease has a specialized additional function during interstrand DNA cross-link repair, beyond its role in nucleotide excision repair.", "offsetInBeginSection": 192, "offsetInEndSection": 392, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14706347", "text": "Bulky DNA lesions are mainly repaired by nucleotide excision repair (NER), in which the interaction of ERCC1 with XPA protein recruits the ERCC1-XPF complex, which acts as a structure-specific endonuclease in the repair process.", "offsetInBeginSection": 0, "offsetInEndSection": 228, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12509251", "text": "ERCC1-XPF is also involved in recombinational repair processes distinct from NER.", "offsetInBeginSection": 127, "offsetInEndSection": 208, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11707424", "text": "The Ercc1-Xpf heterodimer, a highly conserved structure-specific endonuclease, functions in multiple DNA repair pathways that are pivotal for maintaining genome stability, including nucleotide excision repair, interstrand crosslink repair and homologous recombination.", "offsetInBeginSection": 0, "offsetInEndSection": 268, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11160918", "text": "ERCC1-XPF is a structure-specific nuclease with two subunits, ERCC1 and XPF.", "offsetInBeginSection": 0, "offsetInEndSection": 76, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8afbf2fcd1d6a10c00001c", "body": "In quadruped mammals, what bones make up the stifle?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2297078", "http://www.ncbi.nlm.nih.gov/pubmed/28975655", "http://www.ncbi.nlm.nih.gov/pubmed/19378269", "http://www.ncbi.nlm.nih.gov/pubmed/27718092", "http://www.ncbi.nlm.nih.gov/pubmed/15930721", "http://www.ncbi.nlm.nih.gov/pubmed/11956920", "http://www.ncbi.nlm.nih.gov/pubmed/15705848", "http://www.ncbi.nlm.nih.gov/pubmed/16032317", "http://www.ncbi.nlm.nih.gov/pubmed/7573376", "http://www.ncbi.nlm.nih.gov/pubmed/34993698"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668", "text": "In the stifle joints of quadrupeds, the MFL is a substantial structure and appears to be related to the caudal tibial slope.", "offsetInBeginSection": 1234, "offsetInEndSection": 1358, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21113010", "text": "Monophasic lateral bending and long-axis rotation, biphasic sagittal bending and maximal amplitude of sagittal bending at the lumbo-sacral joint were also found in other quadruped mammals and may represent general aspects of mammalian symmetric gaits.", "offsetInBeginSection": 1270, "offsetInEndSection": 1521, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21113010", "text": "Given the importance of thoraco-lumbar spine movements in the locomotion of mammals, it is surprising that in vivo three-dimensional (3-D) data on the intervertebral movement of the mammalian thoraco-lumbar vertebral column during symmetrical gaits is limited to horses and dogs.", "offsetInBeginSection": 0, "offsetInEndSection": 279, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290", "text": "Based on this survey, I suggest that olecranon orientation can be used for inferring the elbow joint angles of quadruped mammals with prominent olecranons, regardless of taxon, body size, and locomotor guild.", "offsetInBeginSection": 919, "offsetInEndSection": 1127, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19378269", "text": "Determining scapular position is a major issue in reconstructing the skeletal systems of extinct quadruped archosaurs and mammals, because the proximal portion of the scapulae has no direct skeletal joint with the vertebrae or ribs.", "offsetInBeginSection": 0, "offsetInEndSection": 232, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19378269", "text": "This implies that the location of robust ribs is associated with the arrangement of the serratus muscle, and provides a probable candidate for determination of the scapular position for extinct quadruped archosaurs and mammals.", "offsetInBeginSection": 1209, "offsetInEndSection": 1436, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24323904", "text": "High-resolution microtomographic scans were collected of the lunate, scaphoid, and capitate in 41 individuals and eight genera (Homo, Gorilla, Pan, Papio, Pongo, Symphalangus, Hylobates, and Ateles).", "offsetInBeginSection": 632, "offsetInEndSection": 831, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23977887", "text": "CONCLUSIONS AND CLINICAL RELEVANCE Compared with results for quadruped dogs, the vertebral column, carpus, and ipsilateral hip and stifle joints had significant biomechanical changes after amputation of a thoracic limb.", "offsetInBeginSection": 1323, "offsetInEndSection": 1542, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3218668", "text": "MACN-SC 101 may represent the incipient divergence of a generalized platyrrhine arboreal quadruped toward a more suspensory form.", "offsetInBeginSection": 951, "offsetInEndSection": 1080, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3218668", "text": "Primate scapula and ulna fragments of uncertain taxonomic affinity (MACN-SC 101) have been recovered from the Pinturas deposits at Arroyo Feo, Santa Cruz, Argentina in association with Santacrucian (Early Miocene) land mammals.", "offsetInBeginSection": 0, "offsetInEndSection": 227, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70d42899e2c3af26000002", "body": "Mutation of which gene causes arterial tortuosity syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18818946", "http://www.ncbi.nlm.nih.gov/pubmed/20735855", "http://www.ncbi.nlm.nih.gov/pubmed/18774132", "http://www.ncbi.nlm.nih.gov/pubmed/22488877", "http://www.ncbi.nlm.nih.gov/pubmed/30425910", "http://www.ncbi.nlm.nih.gov/pubmed/19622975", "http://www.ncbi.nlm.nih.gov/pubmed/19028722", "http://www.ncbi.nlm.nih.gov/pubmed/31203799", "http://www.ncbi.nlm.nih.gov/pubmed/19781076", "http://www.ncbi.nlm.nih.gov/pubmed/35302653"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946", "text": "This syndrome is caused by mutations in the SLC2A10 gene.", "offsetInBeginSection": 212, "offsetInEndSection": 269, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946", "text": "This mutation in the SLC2A10 gene replaces a cysteine encoding codon with a stop signal.", "offsetInBeginSection": 655, "offsetInEndSection": 743, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132", "text": "This syndrome is caused by mutation in SLC2A10 gene which encodes for the facilitative glucose transporter, GLUT10.", "offsetInBeginSection": 310, "offsetInEndSection": 425, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132", "text": "In the single patient of Family 1, sequencing of the candidate gene, SLC2A10, identified a novel missense c.313C>T mutation encoding a p.Arg105Cys substitution in the second extracellular domain of GLUT10.", "offsetInBeginSection": 718, "offsetInEndSection": 923, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16550171", "text": "GLUT10 deficiency is associated with upregulation of the TGFbeta pathway in the arterial wall, a finding also observed in Loeys-Dietz syndrome, in which aortic aneurysms associate with arterial tortuosity.", "offsetInBeginSection": 568, "offsetInEndSection": 773, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19622975", "text": "BACKGROUND Arterial tortuosity syndrome is a rare, autosomal recessive, severe, connective tissue disorder caused by a mutation in the SLC2A10 gene.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19028722", "text": "Mutations in the SLC2A10 gene cause arterial tortuosity syndrome (ATS) in humans.", "offsetInBeginSection": 137, "offsetInEndSection": 218, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19781076", "text": "ATS is caused by mutations in SLC2A10 gene, encoding for the facilitative glucose transporter 10 (GLUT10).", "offsetInBeginSection": 290, "offsetInEndSection": 396, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20735855", "text": "BACKGROUND Recent data indicate that loss-of-function mutation in the gene encoding the facilitative glucose transporter GLUT10 (SLC2A10) causes arterial tortuosity syndrome via upregulation of the TGF-\u03b2 pathway in the arterial wall, a mechanism possibly causing vascular changes in diabetes.", "offsetInBeginSection": 0, "offsetInEndSection": 293, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20735855", "text": "CONCLUSION Our data demonstrate that genetic polymorphism of the SLC2A10 gene is an independent risk factor for PAD in type 2 diabetes.", "offsetInBeginSection": 1186, "offsetInEndSection": 1321, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f940bb750ff445500005a", "body": "What is the aim of the 4D nucleome project?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28905911", "http://www.ncbi.nlm.nih.gov/pubmed/35501320", "http://www.ncbi.nlm.nih.gov/pubmed/29626919", "http://www.ncbi.nlm.nih.gov/pubmed/26338265", "http://www.ncbi.nlm.nih.gov/pubmed/26080430", "http://www.ncbi.nlm.nih.gov/pubmed/28961756", "http://www.ncbi.nlm.nih.gov/pubmed/28745542", "http://www.ncbi.nlm.nih.gov/pubmed/33794739", "http://www.ncbi.nlm.nih.gov/pubmed/31001557", "http://www.ncbi.nlm.nih.gov/pubmed/30262815"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911", "text": "The 4D Nucleome Network aims to develop and apply approaches to map the structure and dynamics of the human and mouse genomes in space and time with the goal of gaining deeper mechanistic insights into how the nucleus is organized and functions.", "offsetInBeginSection": 0, "offsetInEndSection": 245, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911", "text": "The project will develop and benchmark experimental and computational approaches for measuring genome conformation and nuclear organization, and investigate how these contribute to gene regulation and other genome functions.", "offsetInBeginSection": 246, "offsetInEndSection": 470, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28745542", "text": "The recent conference 4D Nucleome: The Cell Nucleus in Space and Time, which was held in Krak\u00f3w in May 2017, was an opportunity to appreciate the growing number of conceptual approaches and newly emerging analytical techniques that are revolutionizing our understanding of the structure of chromatin and the nucleus.", "offsetInBeginSection": 272, "offsetInEndSection": 589, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26338265", "text": "The 4D nucleome has the potential to render challenges in neuropsychiatric pharmacogenomics more tractable.", "offsetInBeginSection": 0, "offsetInEndSection": 107, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26338265", "text": "This perspective assesses recent advances likely to reveal novel pharmacodynamic regulatory pathways in human brain, charting a future new avenue of pharmacogenomics research, using the spatial and temporal architecture of the human epigenome as its foundation.", "offsetInBeginSection": 611, "offsetInEndSection": 872, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28961756", "text": "Results The 4D Nucleome Analysis Toolbox (NAT) is a user-friendly and powerful MATLAB toolbox for time series analysis of genome-wide chromosome conformation capture (Hi-C) data and gene expression (RNA-seq).", "offsetInBeginSection": 165, "offsetInEndSection": 373, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26080430", "text": "The 4D organization of the interphase nucleus, or the 4D Nucleome (4DN), reflects a dynamical interaction between 3D genome structure and function and its relationship to phenotype.", "offsetInBeginSection": 0, "offsetInEndSection": 181, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28385536", "text": "These examples in regulatory pharmacoepigenomics illustrate how ongoing research using the 4D nucleome provides a foundation to further insight into previously unrecognized psychotropic drug pharmacodynamic pathways in the human CNS.", "offsetInBeginSection": 1335, "offsetInEndSection": 1568, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25738524", "text": "We propose the establishment of an International Nucleome Consortium to coordinate this effort worldwide.", "offsetInBeginSection": 508, "offsetInEndSection": 613, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25738524", "text": "Understanding genome function will therefore require the elucidation of the structure-function relationship of the cell nucleus as a complex, dynamic biological system, referred to as the nucleome.", "offsetInBeginSection": 208, "offsetInEndSection": 405, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8b1264fcd1d6a10c00001d", "body": "Fusarium oxysporum f. sp lycopersici. is a plant pathogen in plants producing what common food?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30533622", "http://www.ncbi.nlm.nih.gov/pubmed/24909710", "http://www.ncbi.nlm.nih.gov/pubmed/34338933", "http://www.ncbi.nlm.nih.gov/pubmed/24024636", "http://www.ncbi.nlm.nih.gov/pubmed/24313955", "http://www.ncbi.nlm.nih.gov/pubmed/11319099", "http://www.ncbi.nlm.nih.gov/pubmed/18312397", "http://www.ncbi.nlm.nih.gov/pubmed/35154061", "http://www.ncbi.nlm.nih.gov/pubmed/18606236", "http://www.ncbi.nlm.nih.gov/pubmed/18943372"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025", "text": "lycopersici.", "offsetInBeginSection": 518, "offsetInEndSection": 530, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025", "text": "lycopersici.", "offsetInBeginSection": 518, "offsetInEndSection": 530, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025", "text": "Fusarium oxysporum f. sp.", "offsetInBeginSection": 198, "offsetInEndSection": 223, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899", "text": "lycopersici.", "offsetInBeginSection": 456, "offsetInEndSection": 468, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899", "text": "lycopersici.", "offsetInBeginSection": 456, "offsetInEndSection": 468, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18945093", "text": "lycopersici.", "offsetInBeginSection": 706, "offsetInEndSection": 718, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18945093", "text": "lycopersici.", "offsetInBeginSection": 706, "offsetInEndSection": 718, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24909710", "text": "lycopersici (FOL).", "offsetInBeginSection": 387, "offsetInEndSection": 405, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18943589", "text": "F. oxysporum f. sp.", "offsetInBeginSection": 636, "offsetInEndSection": 655, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9237400", "text": "Fusarium oxysporum f. sp.", "offsetInBeginSection": 154, "offsetInEndSection": 179, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70d43b99e2c3af26000003", "body": "Does prolactinoma increase osteoporosis risk?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17578827", "http://www.ncbi.nlm.nih.gov/pubmed/22553947", "http://www.ncbi.nlm.nih.gov/pubmed/9550540", "http://www.ncbi.nlm.nih.gov/pubmed/31545521", "http://www.ncbi.nlm.nih.gov/pubmed/33664388", "http://www.ncbi.nlm.nih.gov/pubmed/30090794", "http://www.ncbi.nlm.nih.gov/pubmed/30293506", "http://www.ncbi.nlm.nih.gov/pubmed/26319389", "http://www.ncbi.nlm.nih.gov/pubmed/11293923", "http://www.ncbi.nlm.nih.gov/pubmed/35190851"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/11293923", "text": "The relative risk for developing osteoporosis in women with prolactinoma was found to be 4.5, indicating that hyperprolactinemia in women is a major risk factor for osteoporosis.", "offsetInBeginSection": 1145, "offsetInEndSection": 1323, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855", "text": "Prolactinoma in old people may present insidiously with chronic anaemia and osteoporosis with or without sexual dysfunction.", "offsetInBeginSection": 249, "offsetInEndSection": 373, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947", "text": "CONCLUSION In the premenopausal women, patients with prolactinoma or craniopharyngioma are often accompanied with osteopenia or osteoporosis, and disease duration and hypogonadism are the risk factors of bone loss in prolactinoma.", "offsetInBeginSection": 1085, "offsetInEndSection": 1315, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947", "text": "OBJECTIVE Patients with prolactinoma seem to be at high risk for osteopenia.", "offsetInBeginSection": 0, "offsetInEndSection": 76, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17578827", "text": "INTRODUCTION Osteopenia and osteoporosis because of hyperprolactinaemia caused by prolactinoma may be followed by an increased risk of fracture.", "offsetInBeginSection": 0, "offsetInEndSection": 144, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389", "text": "Hyperprolactinaemia related to prolactinoma significantly (more than functional hyperprolactiaemia) increases the risk of osteopenia, osteoporosis and bone fractures.", "offsetInBeginSection": 1014, "offsetInEndSection": 1180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389", "text": "High serum prolactin levels lead to increase of the risk of osteopenia or/and osteoporosis.", "offsetInBeginSection": 782, "offsetInEndSection": 873, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389", "text": "Important group of patients threatened by osteoporosis and bone fracture is constituted by women which use antipsychotic drugs (which induce hyperprolactinaemia).", "offsetInBeginSection": 1181, "offsetInEndSection": 1343, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15816365", "text": "In conclusion, men with prolactinoma have high prevalence of osteopenia and osteoporosis.", "offsetInBeginSection": 1442, "offsetInEndSection": 1531, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9550540", "text": "Humans with prolactinoma are at risk for osteoporosis.", "offsetInBeginSection": 0, "offsetInEndSection": 54, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6fa31ab750ff445500005e", "body": "Which method has been developed for assignment of enhancers to target genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29070071", "http://www.ncbi.nlm.nih.gov/pubmed/30758829", "http://www.ncbi.nlm.nih.gov/pubmed/26780995", "http://www.ncbi.nlm.nih.gov/pubmed/28869592", "http://www.ncbi.nlm.nih.gov/pubmed/31969180", "http://www.ncbi.nlm.nih.gov/pubmed/27941893", "http://www.ncbi.nlm.nih.gov/pubmed/31316726", "http://www.ncbi.nlm.nih.gov/pubmed/27515742", "http://www.ncbi.nlm.nih.gov/pubmed/34879086", "http://www.ncbi.nlm.nih.gov/pubmed/26446758"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071", "text": "We devised a machine learning approach, McEnhancer, which links target genes to putative enhancers via a semi-supervised learning algorithm that predicts gene expression patterns based on enriched sequence features.", "offsetInBeginSection": 178, "offsetInEndSection": 393, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071", "text": "Transcriptional enhancers regulate spatio-temporal gene expression.", "offsetInBeginSection": 0, "offsetInEndSection": 67, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22084256", "text": "This is especially true in mammalian systems, where regulation often occurs through long-range enhancers in gene-rich neighborhoods, rather than proximal promoters, preventing straightforward assignment of a binding site to a target gene.", "offsetInBeginSection": 354, "offsetInEndSection": 592, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26446758", "text": "After reviewing models of enhancer function, we discuss recent methods for identifying target genes of enhancers.", "offsetInBeginSection": 736, "offsetInEndSection": 849, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26390058", "text": "We carried out an integrative analysis of enhancer landscape and gene expression dynamics during hematopoietic differentiation using DNase-seq, histone mark ChIP-seq and RNA sequencing to model how the early establishment of enhancers and regulatory locus complexity govern gene expression changes at cell state transitions.", "offsetInBeginSection": 0, "offsetInEndSection": 324, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26390058", "text": "Our method suggests a new mechanistic role for PU.1 at transition peaks during B cell specification and can be used to correct assignments of enhancers to genes.", "offsetInBeginSection": 898, "offsetInEndSection": 1059, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26780995", "text": "Various experimental and computational approaches including chromatin signature profiling have been developed to predict enhancers on a genome-wide scale, although each method has its advantages and disadvantages.", "offsetInBeginSection": 95, "offsetInEndSection": 308, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26780995", "text": "Enhancers are distal cis-regulatory DNA elements that increase the expression of target genes.", "offsetInBeginSection": 0, "offsetInEndSection": 94, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26780995", "text": "Here we overview an emerging method to identify transcribed enhancers at exceedingly high nucleotide resolution based on enhancer RNA transcripts captured by Cap Analysis of Gene Expression (CAGE) technology.", "offsetInBeginSection": 309, "offsetInEndSection": 517, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22678587", "text": "Phenotypes associated with suppression of target sequence enable the assignment of functions to specific genes.", "offsetInBeginSection": 833, "offsetInEndSection": 944, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8dc6b4fcd1d6a10c000026", "body": "List 2 approved drug treatments for Inflammatory Bowel Disease (IBD).", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25110258", "http://www.ncbi.nlm.nih.gov/pubmed/17461487", "http://www.ncbi.nlm.nih.gov/pubmed/23051720", "http://www.ncbi.nlm.nih.gov/pubmed/30374806", "http://www.ncbi.nlm.nih.gov/pubmed/25110260", "http://www.ncbi.nlm.nih.gov/pubmed/25572840", "http://www.ncbi.nlm.nih.gov/pubmed/33667791", "http://www.ncbi.nlm.nih.gov/pubmed/35166398", "http://www.ncbi.nlm.nih.gov/pubmed/25685145", "http://www.ncbi.nlm.nih.gov/pubmed/32598943"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694", "text": "BACKGROUND Currently, 200 genetic risk loci have been identified for inflammatory bowel disease (IBD).", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694", "text": "CONCLUSIONS We confirm that proteins encoded by IBD candidate genes are targeted by approved IBD therapies.", "offsetInBeginSection": 1283, "offsetInEndSection": 1390, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23051720", "text": "First-line treatments were defined as the following drug categories: 5-aminosalicylates, budesonide, systemic steroids, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab and certolizumab pegol.", "offsetInBeginSection": 452, "offsetInEndSection": 664, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23051720", "text": "The following drug categories were not included: cyclosporine and tacrolimus (not yet approved by Swissmedic for IBD treatment).", "offsetInBeginSection": 665, "offsetInEndSection": 793, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21936033", "text": "Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor-\u03b1 (TNF\u03b1), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients.", "offsetInBeginSection": 0, "offsetInEndSection": 234, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21936033", "text": "Currently, infliximab is the only anti-TNF drug that has been approved for use in refractory pediatric Crohn's disease (CD).", "offsetInBeginSection": 235, "offsetInEndSection": 359, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27570643", "text": "Inflammatory Bowel Disease (IBD) is a chronic and relapsing disorder, which affects millions people worldwide.", "offsetInBeginSection": 0, "offsetInEndSection": 110, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25685145", "text": "Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD.", "offsetInBeginSection": 307, "offsetInEndSection": 425, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17461487", "text": "Mainstays of drug treatments for IBD include aminosalicylates, corticosteroids and immunosuppressants such as azathioprine, methotrexate and cyclosporin.", "offsetInBeginSection": 190, "offsetInEndSection": 343, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26631943", "text": "More recently, vedolizumab, an anti-\u03b14\u03b27 integrin monoclonal antibody, has been approved for the treatment of Crohn's disease and ulcerative colitis.", "offsetInBeginSection": 893, "offsetInEndSection": 1044, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70e4b399e2c3af26000008", "body": "Glecaprevir and Pibrentasvir are used for tratment of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31167814", "http://www.ncbi.nlm.nih.gov/pubmed/28688001", "http://www.ncbi.nlm.nih.gov/pubmed/29465262", "http://www.ncbi.nlm.nih.gov/pubmed/34125405", "http://www.ncbi.nlm.nih.gov/pubmed/33592123", "http://www.ncbi.nlm.nih.gov/pubmed/31254392", "http://www.ncbi.nlm.nih.gov/pubmed/30874328", "http://www.ncbi.nlm.nih.gov/pubmed/28800195", "http://www.ncbi.nlm.nih.gov/pubmed/30861340", "http://www.ncbi.nlm.nih.gov/pubmed/31129632"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195", "text": "Glecaprevir and pibrentasvir are direct-acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection.", "offsetInBeginSection": 0, "offsetInEndSection": 160, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195", "text": "The results of these studies demonstrate that race/ethnicity has no clinically meaningful impact on direct-acting antiviral agent exposures, safety, or tolerability of the glecaprevir and pibrentasvir combination.", "offsetInBeginSection": 1388, "offsetInEndSection": 1601, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28807904", "text": "The combination of glecaprevir (formerly ABT-493), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (formerly ABT-530), an NS5A protein inhibitor, is being developed as treatment for HCV genotype 1 to 6 infection.", "offsetInBeginSection": 0, "offsetInEndSection": 239, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28807904", "text": "The pharmacokinetics, pharmacodynamics, safety, and tolerability of methadone or buprenorphine-naloxone when coadministered with the glecaprevir-pibrentasvir combination in HCV-negative subjects on stable opioid maintenance therapy were investigated in a phase 1, single-center, two-arm, multiple-dose, open-label sequential study.", "offsetInBeginSection": 240, "offsetInEndSection": 571, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28412293", "text": "LAY SUMMARY The combination of direct-acting antivirals glecaprevir and pibrentasvir comprise a once-daily, all-oral, pangenotypic treatment for HCV genotype 1-6 infection.", "offsetInBeginSection": 1749, "offsetInEndSection": 1921, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29020583", "text": "METHODS We conducted a multicenter, open-label, phase 3 trial to evaluate the efficacy and safety of treatment with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults who had HCV genotype 1, 2, 3, 4, 5, or 6 infection and also had compensated liver disease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both.", "offsetInBeginSection": 460, "offsetInEndSection": 876, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28128852", "text": "This phase 2, open-label study (MAGELLAN-1) evaluated the efficacy and safety of glecaprevir (GLE) + pibrentasvir (PIB) \u00b1 ribavirin (RBV) in HCV genotype 1-infected patients with prior virologic failure to HCV DAA-containing therapy.", "offsetInBeginSection": 503, "offsetInEndSection": 737, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28128852", "text": "CONCLUSION The combination of GLE and PIB was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA-containing therapy; RBV coadministration did not improve efficacy.", "offsetInBeginSection": 1588, "offsetInEndSection": 1805, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28925068", "text": "A recently approved, pan-genotypic, direct-acting antiviral regimen, glecaprevir and pibrentasvir, may simplify prescribing.", "offsetInBeginSection": 550, "offsetInEndSection": 674, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28929412", "text": "A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET\u2122 (EU); MAVYRET\u2122 (USA)] has been developed by AbbVie.", "offsetInBeginSection": 0, "offsetInEndSection": 237, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6fa417b750ff445500005f", "body": "Describe the RNA Centric Annotation System (RCAS)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28334930", "http://www.ncbi.nlm.nih.gov/pubmed/12950142", "http://www.ncbi.nlm.nih.gov/pubmed/25555582", "http://www.ncbi.nlm.nih.gov/pubmed/19253393", "http://www.ncbi.nlm.nih.gov/pubmed/23514627", "http://www.ncbi.nlm.nih.gov/pubmed/22688707", "http://www.ncbi.nlm.nih.gov/pubmed/29337371", "http://www.ncbi.nlm.nih.gov/pubmed/32015437", "http://www.ncbi.nlm.nih.gov/pubmed/27337980", "http://www.ncbi.nlm.nih.gov/pubmed/31792138"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930", "text": "Here, we present the RNA Centric Annotation System (RCAS), an R package, which is designed to ease the process of creating gene-centric annotations and analysis for the genomic regions of interest obtained from various RNA-based omics technologies.", "offsetInBeginSection": 288, "offsetInEndSection": 536, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930", "text": "The meta-gene profiles, gene-centric annotation, motif analysis and gene-set analysis provided by RCAS provide contextual knowledge which is necessary for understanding the functional aspects of different biological events that involve RNAs.", "offsetInBeginSection": 966, "offsetInEndSection": 1207, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20689021", "text": "Such set-centric features address a host of applications, including microarray data analysis, cross-database annotation mapping and gene-disorder associations for drug targeting.", "offsetInBeginSection": 1011, "offsetInEndSection": 1189, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20689021", "text": "Its gene-centric content is automatically mined and integrated from over 80 digital sources, resulting in a web-based deep-linked card for each of >73,000 human gene entries, encompassing the following categories: protein coding, pseudogene, RNA gene, genetic locus, cluster and uncategorized.", "offsetInBeginSection": 153, "offsetInEndSection": 446, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15099404", "text": "CONCLUSIONS As the proteomic data for several organisms begins to accumulate, BioBuilder will prove to be an invaluable platform for functional annotation and development of customizable protein centric databases.", "offsetInBeginSection": 1025, "offsetInEndSection": 1238, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17145711", "text": "The database is now built around a sophisticated genome browser (Ensembl), our own microarray information management and annotation system (MIMAS) used to extensively describe experimental data obtained with high-density oligonucleotide microarrays (GeneChips) and a comprehensive system for online editing of database entries (MediaWiki).", "offsetInBeginSection": 410, "offsetInEndSection": 749, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27337980", "text": "The Ensembl gene annotation system has been used to annotate over 70 different vertebrate species across a wide range of genome projects.", "offsetInBeginSection": 0, "offsetInEndSection": 137, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27337980", "text": "The system is based on the alignment of biological sequences, including cDNAs, proteins and RNA-seq reads, to the target genome in order to construct candidate transcript models.", "offsetInBeginSection": 248, "offsetInEndSection": 426, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29038749", "text": "While the pipeline provides a list of environmental terms on the basis of sample datasets and, therefore, the annotations obtained are at the dataset level, it lacks a taxa centric approach to environmental annotation.", "offsetInBeginSection": 702, "offsetInEndSection": 920, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20592237", "text": "Integration of proteomics, transcriptomics, RNA polymerase, and sigma factor-binding information with deep-sequencing-based analysis of primary 5'-end transcripts allowed for a most precise annotation.", "offsetInBeginSection": 405, "offsetInEndSection": 606, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a76018c83b0d9ea6600000e", "body": "List the ten types of conjoined twins.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7112433", "http://www.ncbi.nlm.nih.gov/pubmed/32721891", "http://www.ncbi.nlm.nih.gov/pubmed/19429398", "http://www.ncbi.nlm.nih.gov/pubmed/21660094", "http://www.ncbi.nlm.nih.gov/pubmed/23733407", "http://www.ncbi.nlm.nih.gov/pubmed/29064095", "http://www.ncbi.nlm.nih.gov/pubmed/35248881", "http://www.ncbi.nlm.nih.gov/pubmed/3421755", "http://www.ncbi.nlm.nih.gov/pubmed/31188131", "http://www.ncbi.nlm.nih.gov/pubmed/25599848"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193", "text": "OBJECTIVES Conjoined twins are rare.", "offsetInBeginSection": 0, "offsetInEndSection": 36, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193", "text": "In evaluating conjoined twins, 2-dimensional ultrasound is the criterion standard.", "offsetInBeginSection": 796, "offsetInEndSection": 878, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12483645", "text": "RESULTS Three sets of female conjoined twins underwent successful separation 2 pygopagus, one ischiopagus tripus) with 5 surviving infants.", "offsetInBeginSection": 577, "offsetInEndSection": 716, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12483645", "text": "This study reviews the authors' experience with the perineal reconstruction of these types of conjoined twins.", "offsetInBeginSection": 209, "offsetInEndSection": 319, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8787375", "text": "A case study describes the perioperative management of conjoined twins at Texas Children's Hospital's, Houston.", "offsetInBeginSection": 309, "offsetInEndSection": 420, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29064095", "text": "Eight different types of conjoined twins have been described in the literature.", "offsetInBeginSection": 154, "offsetInEndSection": 233, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19060714", "text": "Conjoined twins are a rare complication of monochorionic twinning.", "offsetInBeginSection": 0, "offsetInEndSection": 66, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16677900", "text": "RESULTS Ten sets of complete conjoined twins and two sets of parasitic conjoined twins were successfully separated.", "offsetInBeginSection": 392, "offsetInEndSection": 507, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16677900", "text": "BACKGROUND/PURPOSE Conjoined twins are rare and complex anomalies of the newborn.", "offsetInBeginSection": 0, "offsetInEndSection": 81, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27369817", "text": "We describe the urologic presentation, evaluation, and treatment of thoracoomphalopagus conjoined twins.", "offsetInBeginSection": 485, "offsetInEndSection": 589, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70e6e899e2c3af26000009", "body": "What is the mechanism of action of Fremanezumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28972120", "http://www.ncbi.nlm.nih.gov/pubmed/31043094", "http://www.ncbi.nlm.nih.gov/pubmed/32116061", "http://www.ncbi.nlm.nih.gov/pubmed/32508742", "http://www.ncbi.nlm.nih.gov/pubmed/30109438", "http://www.ncbi.nlm.nih.gov/pubmed/28642283", "http://www.ncbi.nlm.nih.gov/pubmed/33626922", "http://www.ncbi.nlm.nih.gov/pubmed/31127003", "http://www.ncbi.nlm.nih.gov/pubmed/32832978", "http://www.ncbi.nlm.nih.gov/pubmed/31752521"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120", "text": "To investigate the basis for this selective inhibitory effect, and further explore the mechanism of action of CGRP-mAbs, we tested the effect of fremanezumab on the cortical spreading depression-evoked activation of mechanosensitive primary afferent meningeal nociceptors that innervate the cranial dura, using single-unit recording in the trigeminal ganglion of anesthetized male rats.", "offsetInBeginSection": 742, "offsetInEndSection": 1128, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120", "text": "The selectivity in its peripheral inhibitory action may partly account for fremanezumab's selective inhibition of high-threshold, as a result of a predominant A-\u03b4 input to high-threshold neurons, but not wide dynamic-range dorsal horn neurons, and why it may not be effective in all migraine patients.SIGNIFICANCE STATEMENT Recently, we reported that humanized CGRP monoclonal antibodies (CGRP-mAbs) prevent activation and sensitization of high-threshold (HT) but not wide-dynamic range trigeminovascular neurons by cortical spreading depression (CSD).", "offsetInBeginSection": 1474, "offsetInEndSection": 2027, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120", "text": "We recently tested the effect of fremanezumab (TEV-48125), a CGRP-mAb, on the activity of second-order trigeminovascular dorsal horn neurons that receive peripheral input from the cranial dura, and found a selective inhibition of high-threshold but not wide-dynamic range class of neurons.", "offsetInBeginSection": 452, "offsetInEndSection": 741, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283", "text": "However, their mechanism of action is unknown.", "offsetInBeginSection": 1875, "offsetInEndSection": 1921, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "WHAT IS NEW AND CONCLUSION Further research is needed to uncover the mechanism of analgesic action of paracetamol.", "offsetInBeginSection": 1072, "offsetInEndSection": 1186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "METHODS A literature search was conducted of clinical and preclinical literature and the information obtained was organized and reviewed from the perspective of its contribution to an understanding of the mechanism of analgesic action of paracetamol.", "offsetInBeginSection": 576, "offsetInEndSection": 826, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "WHAT IS KNOWN AND BACKGROUND Although paracetamol (acetaminophen), N-(4-Hydroxyphenyl)acetamide, is one of the world's most widely used analgesics, the mechanism by which it produces its analgesic effect is largely unknown.", "offsetInBeginSection": 0, "offsetInEndSection": 223, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "OBJECTIVE To review the clinical profile and preclinical studies of paracetamol as means of gaining insight into its mechanism of analgesic action.", "offsetInBeginSection": 426, "offsetInEndSection": 573, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "RESULTS Paracetamol's broad spectrum of analgesic and other pharmacological actions is presented, along with its multiple postulated mechanism(s) of action.", "offsetInBeginSection": 829, "offsetInEndSection": 985, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20350658", "text": "Such studies need to be accompanied by rigorous correlative analysis if we are to understand the importance of various mechanisms of action of rituximab and use that information to improve on what is already an indispensable component of therapy.", "offsetInBeginSection": 922, "offsetInEndSection": 1168, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6fa61ab750ff4455000060", "body": "Which tool exists for microsatellite (SSR) loci detection and primer design?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27366148", "http://www.ncbi.nlm.nih.gov/pubmed/29983488", "http://www.ncbi.nlm.nih.gov/pubmed/18670612", "http://www.ncbi.nlm.nih.gov/pubmed/24312419", "http://www.ncbi.nlm.nih.gov/pubmed/14962913", "http://www.ncbi.nlm.nih.gov/pubmed/18510760", "http://www.ncbi.nlm.nih.gov/pubmed/31872654", "http://www.ncbi.nlm.nih.gov/pubmed/15640126", "http://www.ncbi.nlm.nih.gov/pubmed/22734866", "http://www.ncbi.nlm.nih.gov/pubmed/21708569"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148", "text": "FullSSR is a new bioinformatic tool for microsatellite (SSR) loci detection and primer design using genomic data from NGS assay.", "offsetInBeginSection": 150, "offsetInEndSection": 278, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23324172", "text": "We selected a set of 500 microsatellite loci identified in contigs with minimum 100X coverage for primer design and synthesis, and tested a subset of 269 primer pairs, 198 of which were polymorphic on 11 representative B. ruziziensis accessions.", "offsetInBeginSection": 889, "offsetInEndSection": 1134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23324172", "text": "Recently, next-generation sequencing technologies have been applied to generate sequence data for the identification of microsatellite regions and primer design.", "offsetInBeginSection": 448, "offsetInEndSection": 609, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11292858", "text": "A modified selectively amplified microsatellite polymorphic loci assay is used to generate multi-locus SSR fingerprints that provide a source of polymorphic DNA markers (SAMs) for use in genetic studies.", "offsetInBeginSection": 165, "offsetInEndSection": 368, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25223041", "text": "In total, 1890 EST-SSR loci were identified, of which, 1296 SSR sequences could be used for primer design.", "offsetInBeginSection": 199, "offsetInEndSection": 305, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18631390", "text": "CONCLUSION The combined approach of identifying SSR-enriched fragments by FIASCO coupled with the primer design and in silico amplification using phpSSRMiner represents an efficient and low cost pipeline for the large-scale development of microsatellite markers in plants.The approach described here could be readily adapted and utilized in other non-related species with none or limited genomic resources.", "offsetInBeginSection": 1548, "offsetInEndSection": 1954, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12582546", "text": "These 66 mapped microsatellite (SSR) loci add to the existing 384 microsatellite loci earlier mapped in bread wheat.", "offsetInBeginSection": 903, "offsetInEndSection": 1019, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11292857", "text": "Alternatively, sequence tag primers can be used to directly amplify corresponding SSR loci from genomic DNA, thereby reducing the cost of developing a microsatellite marker to the synthesis of just one sequence-specific primer.", "offsetInBeginSection": 1106, "offsetInEndSection": 1333, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24312419", "text": "Both 454 and Illumina reads have been used directly in microsatellite discovery and primer design (the \"Seq-to-SSR\" approach).", "offsetInBeginSection": 143, "offsetInEndSection": 269, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24312419", "text": "However, constraints of this approach include: 1) many microsatellite-containing reads do not have sufficient flanking sequences to allow primer design, and 2) difficulties in removing microsatellite loci residing in longer, repetitive regions.", "offsetInBeginSection": 270, "offsetInEndSection": 514, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70e88699e2c3af2600000a", "body": "Describe mechanism of action of Nusinersen.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32233169", "http://www.ncbi.nlm.nih.gov/pubmed/33762737", "http://www.ncbi.nlm.nih.gov/pubmed/29443664", "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "http://www.ncbi.nlm.nih.gov/pubmed/36291640", "http://www.ncbi.nlm.nih.gov/pubmed/29091570", "http://www.ncbi.nlm.nih.gov/pubmed/36297509", "http://www.ncbi.nlm.nih.gov/pubmed/31388901", "http://www.ncbi.nlm.nih.gov/pubmed/32456992", "http://www.ncbi.nlm.nih.gov/pubmed/33963091"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "text": "INTERPRETATION Administration of multiple intrathecal doses of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended mechanism of action, and encouraging clinical efficacy.", "offsetInBeginSection": 2944, "offsetInEndSection": 3158, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "text": "Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy.", "offsetInBeginSection": 3159, "offsetInEndSection": 3299, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "text": "METHODS This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy.", "offsetInBeginSection": 348, "offsetInEndSection": 626, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28884620", "text": "Clinical use of nusinersen is also reviewed.", "offsetInBeginSection": 750, "offsetInEndSection": 794, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", "text": "OBJECTIVE To examine safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of intrathecal nusinersen (previously ISIS-SMNRx), an antisense oligonucleotide designed to alter splicing of SMN2 mRNA, in patients with childhood spinal muscular atrophy (SMA).", "offsetInBeginSection": 0, "offsetInEndSection": 273, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29091570", "text": "METHODS We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy.", "offsetInBeginSection": 339, "offsetInEndSection": 493, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28485722", "text": "Recent approval of nusinersen provides a much-needed boost for antisense technology that is just beginning to realize its potential.", "offsetInBeginSection": 1124, "offsetInEndSection": 1256, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29105153", "text": "We review the chemistry, pharmacology and mechanisms of action of ASOs, pre-clinical data and clinical trials in neuromuscular diseases and discuss some ethical, regulatory and policy considerations in the clinical development and use of ASOs.", "offsetInBeginSection": 797, "offsetInEndSection": 1040, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29130140", "text": "OBJECTIVE This study describes the early results of technical success, complications and radiation dose of intrathecal delivery of nusinersen using cone-beam CT guidance with two-axis fluoroscopic navigational overlay.", "offsetInBeginSection": 651, "offsetInEndSection": 869, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29130140", "text": "CONCLUSION Cone-beam CT guidance with two-axis navigational overlay is a safe, effective method for gaining transforaminal intrathecal access in children with spinal abnormalities and hardware precluding the use of standard techniques.", "offsetInBeginSection": 1674, "offsetInEndSection": 1909, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6fa9f7b750ff4455000061", "body": "Describe Click-PEGylation", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32326525", "http://www.ncbi.nlm.nih.gov/pubmed/34995558", "http://www.ncbi.nlm.nih.gov/pubmed/31234016", "http://www.ncbi.nlm.nih.gov/pubmed/19236204", "http://www.ncbi.nlm.nih.gov/pubmed/35019548", "http://www.ncbi.nlm.nih.gov/pubmed/25270687", "http://www.ncbi.nlm.nih.gov/pubmed/18590303", "http://www.ncbi.nlm.nih.gov/pubmed/23496167", "http://www.ncbi.nlm.nih.gov/pubmed/30499020", "http://www.ncbi.nlm.nih.gov/pubmed/25407370"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801", "text": "To establish a more robust method for redox-selective PEGylation, we have utilised a Click chemistry approach, where free thiol groups are first labelled with a reagent modified to contain an alkyne moiety, which is subsequently Click-reacted with a PEG molecule containing a complementary azide function.", "offsetInBeginSection": 1551, "offsetInEndSection": 1856, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801", "text": "Here we show how the Click-PEGylation technique can be used to interrogate the redox state of proteins.", "offsetInBeginSection": 2068, "offsetInEndSection": 2171, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22988919", "text": "To this end, we describe the development of copper-catalyzed azide-alkyne cycloaddition (CuAAC, a click chemistry reaction) for site-specific PEGylation of interferon \u03b2-1b (IFNb) containing azidohomoalanine (Aha) at the N-terminus.", "offsetInBeginSection": 381, "offsetInEndSection": 613, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18590303", "text": "In this work, we investigate the PEGylation of porous silicon wafers using click chemistry.", "offsetInBeginSection": 159, "offsetInEndSection": 250, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28205176", "text": "Here, we describe the method of PEGylation, which uses a cysteine-reactive molecule, maleimide polyethylene glycol (mPEG), to determine the cytosolic accessibility of introduced cysteine residues.", "offsetInBeginSection": 188, "offsetInEndSection": 384, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23106398", "text": "Protein PEGylation (attaching PEG chains to proteins) has been widely used in pharmaceuticals and nanotechnology.", "offsetInBeginSection": 0, "offsetInEndSection": 113, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27213717", "text": "In an effort to develop new enabling technologies to integrate bioprocessing and protein modification, we describe the use of disulfide-bridging conjugation to conduct PEGylation during protein refolding.", "offsetInBeginSection": 252, "offsetInEndSection": 456, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27213717", "text": "Our results demonstrate that the simultaneous refolding and disulfide bridging PEGylation of proteins could be a useful strategy in the development of affordable modified protein therapeutics.", "offsetInBeginSection": 1153, "offsetInEndSection": 1345, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23613182", "text": "CONCLUSIONS We describe a novel method for effective monopegylation of apoAI in HDL particles, in which lipid binding seems to protect against pegylation of key functional residues.", "offsetInBeginSection": 1520, "offsetInEndSection": 1701, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21618993", "text": "Here, we describe a novel method for the site-specific C-terminal PEGylation of recombinant proteins.", "offsetInBeginSection": 0, "offsetInEndSection": 101, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70ea8299e2c3af2600000b", "body": "Does Evolocumab improve cognitive function?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36210291", "http://www.ncbi.nlm.nih.gov/pubmed/32381158", "http://www.ncbi.nlm.nih.gov/pubmed/35404972", "http://www.ncbi.nlm.nih.gov/pubmed/28813214", "http://www.ncbi.nlm.nih.gov/pubmed/28207168", "http://www.ncbi.nlm.nih.gov/pubmed/35287972", "http://www.ncbi.nlm.nih.gov/pubmed/29544724", "http://www.ncbi.nlm.nih.gov/pubmed/35581018", "http://www.ncbi.nlm.nih.gov/pubmed/33144414", "http://www.ncbi.nlm.nih.gov/pubmed/30895178"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168", "text": "EBBINGHAUS will evaluate whether the addition of evolocumab to statin therapy affects cognitive function over time in patients with stable cardiovascular disease.", "offsetInBeginSection": 1748, "offsetInEndSection": 1910, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214", "text": "Conclusions In a randomized trial involving patients who received either evolocumab or placebo in addition to statin therapy, no significant between-group difference in cognitive function was observed over a median of 19 months.", "offsetInBeginSection": 2301, "offsetInEndSection": 2529, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214", "text": "Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.", "offsetInBeginSection": 0, "offsetInEndSection": 275, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28744103", "text": "Appropriate candidates for evolocumab primarily are individuals at high cardiovascular risk, including those with familial hypercholesterolemia and/or established cardiovascular disease, who are already on statin therapy.", "offsetInBeginSection": 769, "offsetInEndSection": 990, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26868195", "text": "INTERPRETATION Evolocumab markedly reduces atherogenic lipoproteins in patients with type 2 diabetes, an effect that is consistent across subgroups and similar to that seen in patients without type 2 diabetes.", "offsetInBeginSection": 2339, "offsetInEndSection": 2548, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26414456", "text": "EXPERT OPINION In OSLER and ODYSSEY LONG TERM, there were very few cardiovascular outcomes, but the trials do suggest that evolocumab and alirocumab may reduce these outcomes.", "offsetInBeginSection": 549, "offsetInEndSection": 724, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28988500", "text": "Evolocumab is an injectable, fully human monoclonal antibody and a member of the newest class of low density lipoprotein cholesterol (LDL-C) lowering agents called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.", "offsetInBeginSection": 0, "offsetInEndSection": 229, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28988500", "text": "This review will focus on the overall safety of evolocumab including cognitive impairment, very low LDL-C levels, new onset diabetes and glucose abnormalities, effect on vitamin E and steroid hormones, liver and muscle abnormalities, and immunogenicity and injection site reactions.", "offsetInBeginSection": 624, "offsetInEndSection": 906, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28683788", "text": "This suggests that evolocumab clinically improves the nephrotic condition.", "offsetInBeginSection": 1032, "offsetInEndSection": 1106, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27092712", "text": "Randomized trials have shown marked reductions in low-density lipoprotein cholesterol (LDL-C), a risk factor for cardiovascular disease (CVD), when evolocumab is administered.", "offsetInBeginSection": 0, "offsetInEndSection": 175, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a75dff883b0d9ea66000003", "body": "Name curated data resources for ChIP-seq data", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21097880", "http://www.ncbi.nlm.nih.gov/pubmed/28529706", "http://www.ncbi.nlm.nih.gov/pubmed/31809632", "http://www.ncbi.nlm.nih.gov/pubmed/27789702", "http://www.ncbi.nlm.nih.gov/pubmed/30413482", "http://www.ncbi.nlm.nih.gov/pubmed/22495751", "http://www.ncbi.nlm.nih.gov/pubmed/34718747", "http://www.ncbi.nlm.nih.gov/pubmed/24335146", "http://www.ncbi.nlm.nih.gov/pubmed/21940749", "http://www.ncbi.nlm.nih.gov/pubmed/36318256"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702", "text": "Although rapidly accumulating publicly available ChIP-seq, DNase-seq and ATAC-seq data are a valuable resource for the systematic investigation of gene regulation processes, a lack of standardized curation, quality control and analysis procedures have hindered extensive reuse of these data.", "offsetInBeginSection": 236, "offsetInEndSection": 527, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702", "text": "To overcome this challenge, we built the Cistrome database, a collection of ChIP-seq and chromatin accessibility data (DNase-seq and ATAC-seq) published before January 1, 2016, including 13 366 human and 9953 mouse samples.", "offsetInBeginSection": 528, "offsetInEndSection": 751, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22495751", "text": "We have created CistromeMap as a web server to provide a comprehensive knowledgebase of all of the publicly available ChIP-Seq and DNase-Seq data in mouse and human.", "offsetInBeginSection": 118, "offsetInEndSection": 283, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24253304", "text": "Within this database, we collected all publicly available ChIP-Seq data on CRs in human and mouse and categorized the data into four cohorts: the reader, writer, eraser and remodeler cohorts, together with curated introductions and ChIP-Seq data analysis results.", "offsetInBeginSection": 761, "offsetInEndSection": 1024, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706", "text": "Therefore, a relational database in which available ChIP-Seq datasets are curated is essential.", "offsetInBeginSection": 438, "offsetInEndSection": 533, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706", "text": "Results: We present Expresso (database and webserver) as a tool for the collection and integration of available Arabidopsis ChIP-Seq peak data, which in turn can be linked to a user's gene expression data.", "offsetInBeginSection": 534, "offsetInEndSection": 739, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706", "text": "Known target genes of transcription factors were identified by motif analysis of publicly available GEO ChIP-Seq data sets.", "offsetInBeginSection": 740, "offsetInEndSection": 863, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21097880", "text": "MPromDb (Mammalian Promoter Database) is a curated database that strives to annotate gene promoters identified from ChIP-seq results with the goal of providing an integrated resource for mammalian transcriptional regulation and epigenetics.", "offsetInBeginSection": 0, "offsetInEndSection": 240, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27863463", "text": "CONCLUSIONS The various ChIP-Seq command line tools and web services either complement or compare favorably to related bioinformatics resources in terms of computational efficiency, ease of access to public data and interoperability with other web-based tools.", "offsetInBeginSection": 888, "offsetInEndSection": 1148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27863463", "text": "RESULTS Here we present the ChIP-Seq command line tools and web server, implementing basic algorithms for ChIP-seq data analysis starting with a read alignment file.", "offsetInBeginSection": 295, "offsetInEndSection": 460, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a72284b2dc08e987e000001", "body": "Can radius fracture cause carpal tunnel syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35603016", "http://www.ncbi.nlm.nih.gov/pubmed/23026468", "http://www.ncbi.nlm.nih.gov/pubmed/29169594", "http://www.ncbi.nlm.nih.gov/pubmed/10207976", "http://www.ncbi.nlm.nih.gov/pubmed/26566562", "http://www.ncbi.nlm.nih.gov/pubmed/27454517", "http://www.ncbi.nlm.nih.gov/pubmed/18360927", "http://www.ncbi.nlm.nih.gov/pubmed/3402128", "http://www.ncbi.nlm.nih.gov/pubmed/20470591", "http://www.ncbi.nlm.nih.gov/pubmed/35562282"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594", "text": "Carpal tunnel syndrome (CTS) after distal radius fractures can present in 3 forms: acute, transient, and delayed.", "offsetInBeginSection": 0, "offsetInEndSection": 113, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594", "text": "Prophylactic carpal tunnel release in the absence of signs and symptoms of CTS after a distal radius fracture is not indicated.", "offsetInBeginSection": 314, "offsetInEndSection": 441, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468", "text": "Delayed carpal tunnel syndrome presenting after a distal radius fracture has healed is best managed in standard fashion.", "offsetInBeginSection": 465, "offsetInEndSection": 585, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468", "text": "Carpal tunnel syndrome is a common condition and is a well-recognized phenomenon following a distal radius fracture.", "offsetInBeginSection": 0, "offsetInEndSection": 116, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21786553", "text": "CONCLUSION Simultaneous anterior transverse carpal ligament resection can effectively prevent the delayed carpal tunnel syndrome occurrence for the distal radius fracture with open reduction by palm side.", "offsetInBeginSection": 1211, "offsetInEndSection": 1415, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21505639", "text": "We report the incidence of late onset post-operative carpal tunnel syndrome (late carpal tunnel syndrome) and late median nerve neuropathy after volar plating of distal radius fracture by conducting a retrospective study on volar plating for distal radius fracture performed during 2002 to 2006.", "offsetInBeginSection": 0, "offsetInEndSection": 295, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26566562", "text": "We report a case of acute rupture of the flexor pollicis longus and flexor carpi radialis tendons with acute carpal tunnel syndrome after a Gustilo-Anderson type II open distal radius fracture.", "offsetInBeginSection": 141, "offsetInEndSection": 334, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27454517", "text": "Carpal tunnel syndrome is a common complication associated with distal radius fractures.", "offsetInBeginSection": 0, "offsetInEndSection": 88, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27454517", "text": "Being well known and accepted techniques of carpal tunnel release, we believe that the techniques described in this paper provide a viable alternative for carpal tunnel release in the setting of distal radius fracture fixation; with the added advantages of the original minimally invasive techniques.", "offsetInBeginSection": 628, "offsetInEndSection": 928, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10207976", "text": "Carpal tunnel syndrome after fracture of the distal radius is a well known complication in adults, but in small children carpal tunnel syndrome is extremely rare.", "offsetInBeginSection": 0, "offsetInEndSection": 162, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a75f1f383b0d9ea66000006", "body": "Can Logic Alignment Free (LAF) be used for bacterial genomes classification?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26664519", "http://www.ncbi.nlm.nih.gov/pubmed/29713314", "http://www.ncbi.nlm.nih.gov/pubmed/24372034", "http://www.ncbi.nlm.nih.gov/pubmed/32075081", "http://www.ncbi.nlm.nih.gov/pubmed/25573913", "http://www.ncbi.nlm.nih.gov/pubmed/30505941", "http://www.ncbi.nlm.nih.gov/pubmed/24053649", "http://www.ncbi.nlm.nih.gov/pubmed/30943897", "http://www.ncbi.nlm.nih.gov/pubmed/33304326", "http://www.ncbi.nlm.nih.gov/pubmed/22312592"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519", "text": "In this paper, we present Logic Alignment Free (LAF), a method that combines alignment-free techniques and rule-based classification algorithms in order to assign biological samples to their taxa.", "offsetInBeginSection": 315, "offsetInEndSection": 511, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519", "text": "We apply LAF successfully to the classification of bacterial genomes to their corresponding taxonomy.", "offsetInBeginSection": 690, "offsetInEndSection": 791, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519", "text": "Alignment-free algorithms can be used to estimate the similarity of biological sequences and hence are often applied to the phylogenetic reconstruction of genomes.", "offsetInBeginSection": 0, "offsetInEndSection": 163, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15984937", "text": "The findings can be readily introduced into software for gene prediction, sequence alignment or microbial genomes classification.", "offsetInBeginSection": 795, "offsetInEndSection": 924, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22312592", "text": "We have therefore developed an alignment-free algorithm for rapidly detecting horizontal gene transfer between closely related bacterial genomes.", "offsetInBeginSection": 526, "offsetInEndSection": 671, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22312592", "text": "Our implementation of this algorithm is called alfy for \"ALignment Free local homologY\" and is freely available from http://guanine.evolbio.mpg.de/alfy/.", "offsetInBeginSection": 672, "offsetInEndSection": 825, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25990029", "text": "This approach has been implemented for the development of a tool 'Microtaxi' which can be used for the taxonomic assignment of complete bacterial genomes.", "offsetInBeginSection": 857, "offsetInEndSection": 1011, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25990029", "text": "CONCLUSION The taxon-specific gene based approach provides an alternate valuable methodology to carry out the taxonomic classification of newly sequenced or existing bacterial genomes.", "offsetInBeginSection": 1014, "offsetInEndSection": 1198, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25990029", "text": "The taxon-specific genes identified at each taxonomic rank have been successfully used for the taxonomic classification of 2,342 genomes present in the NCBI genomes, 36 newly sequenced genomes, and 17 genomes for which the complete taxonomy is not yet known.", "offsetInBeginSection": 598, "offsetInEndSection": 856, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16566836", "text": "Additionally, the classification support vector machine method is shown to be sensitive and specific on genomic ncRNA screens of two different Escherichia coli and Salmonella typhi genome alignments, in which many ncRNAs are known.", "offsetInBeginSection": 1343, "offsetInEndSection": 1574, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a722a052dc08e987e000002", "body": "Is Marfan syndrome associated with chordal rupture?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15755703", "http://www.ncbi.nlm.nih.gov/pubmed/15266886", "http://www.ncbi.nlm.nih.gov/pubmed/23700867", "http://www.ncbi.nlm.nih.gov/pubmed/9793850", "http://www.ncbi.nlm.nih.gov/pubmed/7790334", "http://www.ncbi.nlm.nih.gov/pubmed/23273625", "http://www.ncbi.nlm.nih.gov/pubmed/34290752", "http://www.ncbi.nlm.nih.gov/pubmed/1297143", "http://www.ncbi.nlm.nih.gov/pubmed/24378247", "http://www.ncbi.nlm.nih.gov/pubmed/14658812"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700", "text": "The neonatal Marfan syndrome is an autosomal dominantly inherited disease with an extremely poor prognosis.", "offsetInBeginSection": 0, "offsetInEndSection": 107, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700", "text": "This report gives a clinical and echocardiographic description of an infant with a mutation in exon 29 of the fibrillin-1 gene (FBN1), a region in which this severe form of Marfan syndrome seems to cluster.", "offsetInBeginSection": 108, "offsetInEndSection": 314, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812", "text": "Three patients underwent mitral annuloplasty and chordal shortening.", "offsetInBeginSection": 772, "offsetInEndSection": 840, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7790334", "text": "It is worthy to report this case because of rarities such as Marfan's syndrome accompanied by Prinzmetal's variant angina, perioperative coronary artery spasm in modified Bentall's operation, and perioperative chordal rupture of the mitral valve and progression of mitral valve regurgitation.", "offsetInBeginSection": 659, "offsetInEndSection": 951, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7790334", "text": "In a modified Bentall's operation (button technique), perioperative severe coronary artery spasm occurred in spite of the preventive use of nitroglycerin infusion, which resulted in profound ventricular fibrillation and subsequent chordal rupture of the mitral valve with Sellers IV regurgitation.", "offsetInBeginSection": 130, "offsetInEndSection": 427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18172522", "text": "Repair of the mitral valve in children who have Marfan syndrome is especially difficult due to the presence of generalized connective tissue disorder, which may lead to future elongation and rupture of chordae tendineae that were unaffected at the time of mitral valve repair.", "offsetInBeginSection": 205, "offsetInEndSection": 481, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1888465", "text": "Gargoylism promotes abnormal thickening of collagen fibers in the fibrosa via acid-mucopolysaccharide (aMPS) overproduction, but Marfan syndrome weakens the valves in spite of increased aMPS.", "offsetInBeginSection": 345, "offsetInEndSection": 536, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9586150", "text": "The Marfan syndrome is an autosomal dominant disorder of the connective tissue with mutations on the fibrillin-1 gene encoding for fibrillin, a major component of the extracellular microfibrils.", "offsetInBeginSection": 0, "offsetInEndSection": 194, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9586150", "text": "Pathogenesis and the natural cause of each cardiovascular manifestation is thoroughly discussed with the problems resulting from associated cardiac arrhythmias, sudden cardiac death, endocarditis, and less frequent cardiovascular manifestations of the Marfan syndrome.", "offsetInBeginSection": 821, "offsetInEndSection": 1089, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/4012631", "text": "The authors provide the results of the use of two-dimensional echocardiography for diagnosing chordal ruptures of the mitral valve depending on the etiological factor of chordal pathology (mesenchymal abnormalities, rheumatic fever, infective endocarditis, coronary heart disease).", "offsetInBeginSection": 189, "offsetInEndSection": 470, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a75f2fc83b0d9ea66000007", "body": "What is TCGA2BED?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28049410", "http://www.ncbi.nlm.nih.gov/pubmed/19702537", "http://www.ncbi.nlm.nih.gov/pubmed/11326518", "http://www.ncbi.nlm.nih.gov/pubmed/6683883", "http://www.ncbi.nlm.nih.gov/pubmed/30656893", "http://www.ncbi.nlm.nih.gov/pubmed/15734663", "http://www.ncbi.nlm.nih.gov/pubmed/31798210", "http://www.ncbi.nlm.nih.gov/pubmed/6359612", "http://www.ncbi.nlm.nih.gov/pubmed/31342198", "http://www.ncbi.nlm.nih.gov/pubmed/3406186"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410", "text": "We also provide and maintain an automatically updated data repository with publicly available Copy Number Variation, DNA-methylation, DNA-seq, miRNA-seq, and RNA-seq (V1,V2) experimental data of TCGA converted into the BED format, and their associated clinical and biospecimen meta data in attribute-value text format.", "offsetInBeginSection": 814, "offsetInEndSection": 1132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410", "text": "RESULTS We propose TCGA2BED a software tool to search and retrieve TCGA data, and convert them in the structured BED format for their seamless use and integration.", "offsetInBeginSection": 417, "offsetInEndSection": 580, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410", "text": "Furthermore, TCGA2BED extends TCGA data with information extracted from other genomic databases (i.e., NCBI Entrez Gene, HGNC, UCSC, and miRBase).", "offsetInBeginSection": 667, "offsetInEndSection": 813, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410", "text": "CONCLUSIONS The availability of the valuable TCGA data in BED format reduces the time spent in taking advantage of them: it is possible to efficiently and effectively deal with huge amounts of cancer genomic data integratively, and to search, retrieve and extend them with additional information.", "offsetInBeginSection": 1135, "offsetInEndSection": 1431, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410", "text": "In this work, we focus on The Cancer Genome Atlas, a comprehensive archive of tumoral data containing the results of high-throughout experiments, mainly Next Generation Sequencing, for more than 30 cancer types.", "offsetInBeginSection": 203, "offsetInEndSection": 414, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410", "text": "BACKGROUND Data extraction and integration methods are becoming essential to effectively access and take advantage of the huge amounts of heterogeneous genomics and clinical data increasingly available.", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410", "text": "The BED format facilitates the investigators allowing several knowledge discovery analyses on all tumor types in TCGA with the final aim of understanding pathological mechanisms and aiding cancer treatments.", "offsetInBeginSection": 1432, "offsetInEndSection": 1639, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410", "text": "Additionally, it supports the conversion in CSV, GTF, JSON, and XML standard formats.", "offsetInBeginSection": 581, "offsetInEndSection": 666, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a722ccd2dc08e987e000003", "body": "What is the mechanism of action of Tezepelumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34256031", "http://www.ncbi.nlm.nih.gov/pubmed/36470789", "http://www.ncbi.nlm.nih.gov/pubmed/34913186", "http://www.ncbi.nlm.nih.gov/pubmed/35184265", "http://www.ncbi.nlm.nih.gov/pubmed/33568920", "http://www.ncbi.nlm.nih.gov/pubmed/33922072", "http://www.ncbi.nlm.nih.gov/pubmed/33050900", "http://www.ncbi.nlm.nih.gov/pubmed/33469316", "http://www.ncbi.nlm.nih.gov/pubmed/36425526", "http://www.ncbi.nlm.nih.gov/pubmed/33050934"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "WHAT IS NEW AND CONCLUSION Further research is needed to uncover the mechanism of analgesic action of paracetamol.", "offsetInBeginSection": 1072, "offsetInEndSection": 1186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "METHODS A literature search was conducted of clinical and preclinical literature and the information obtained was organized and reviewed from the perspective of its contribution to an understanding of the mechanism of analgesic action of paracetamol.", "offsetInBeginSection": 576, "offsetInEndSection": 826, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "WHAT IS KNOWN AND BACKGROUND Although paracetamol (acetaminophen), N-(4-Hydroxyphenyl)acetamide, is one of the world's most widely used analgesics, the mechanism by which it produces its analgesic effect is largely unknown.", "offsetInBeginSection": 0, "offsetInEndSection": 223, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20350658", "text": "Such studies need to be accompanied by rigorous correlative analysis if we are to understand the importance of various mechanisms of action of rituximab and use that information to improve on what is already an indispensable component of therapy.", "offsetInBeginSection": 922, "offsetInEndSection": 1168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "text": "What kind of action understanding, if any, can be ascribed to the mirror mechanism?", "offsetInBeginSection": 298, "offsetInEndSection": 381, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "text": "Since its discovery in the monkey and human brain, many have claimed that the mirror mechanism is critically involved in understanding action.", "offsetInBeginSection": 119, "offsetInEndSection": 261, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1957124", "text": "The action of sucralfate can now be defined by the '1 x 1 x 1' mechanism of action--that is, one action of sucralfate is important for acute prevention, one is relevant to both acute and chronic protection, and one is important for chronic ulcer healing.", "offsetInBeginSection": 269, "offsetInEndSection": 523, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15649562", "text": "There is considerable evidence that indicates that ribavirin triphosphate (RTP) can interact with the various viral RNA polymerases, and it seems likely that this interaction is important to the mechanism of action of ribavirin.", "offsetInBeginSection": 442, "offsetInEndSection": 670, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15649562", "text": "Thirty years after its synthesis, the mechanism of action of ribavirin is still not completely understood.", "offsetInBeginSection": 0, "offsetInEndSection": 106, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15649562", "text": "Although much is known about the metabolism and biochemical effects of ribavirin in human cells, there is still much to be learned about the precise mechanism of action of ribavirin with the various viruses.", "offsetInBeginSection": 107, "offsetInEndSection": 314, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a75f5aa83b0d9ea66000008", "body": "Describe JACUSA", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28049429", "http://www.ncbi.nlm.nih.gov/pubmed/6957905", "http://www.ncbi.nlm.nih.gov/pubmed/23858254", "http://www.ncbi.nlm.nih.gov/pubmed/28433298", "http://www.ncbi.nlm.nih.gov/pubmed/15651245", "http://www.ncbi.nlm.nih.gov/pubmed/15162768", "http://www.ncbi.nlm.nih.gov/pubmed/19520143", "http://www.ncbi.nlm.nih.gov/pubmed/3293163", "http://www.ncbi.nlm.nih.gov/pubmed/35944273", "http://www.ncbi.nlm.nih.gov/pubmed/25346200"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18428249", "text": "Several support protocols describe methods for adenovirus growth and purification, biotinylation, inactivation with psoralen, and quantitation of the adenovirus particles.", "offsetInBeginSection": 279, "offsetInEndSection": 450, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12725838", "text": "The resulting model equations are used to describe experimental surface pressure data published in the literature.", "offsetInBeginSection": 177, "offsetInEndSection": 291, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18301504", "text": "The Babinet principle is used to separate components that describe the data signal, servo signals, and three types of cross talk.", "offsetInBeginSection": 166, "offsetInEndSection": 295, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11800821", "text": "We introduce two simple stochastic growth models which describe the motion of the interfaces driven through random media in two and three dimensions.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498", "text": "We propose describing a manipulative technique using 6 characteristics: Rate of force application: Describe the rate at which the force was applied.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498", "text": "Relative structural movement: Describe which structure or region was intended to remain stable and which structure or region was intended to move, with the moving structure or region being named first and the stable segment named second, separated by the word \"on.\"", "offsetInBeginSection": 581, "offsetInEndSection": 846, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498", "text": "Target of force: Describe the location to which the therapist intended to apply the force.", "offsetInBeginSection": 490, "offsetInEndSection": 580, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825", "text": "We describe first a field deployable mass spectrometer, based on an ion trap analyzer, and variants of that system.", "offsetInBeginSection": 375, "offsetInEndSection": 490, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825", "text": "We describe four sensing and characterization technologies recently developed at Los Alamos National Laboratory; a select set of mass spectral and optical techniques is emphasized.", "offsetInBeginSection": 0, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825", "text": "We then describe a hand-held, battery-operated optical spectrometer, usable in either absorption, or fluorescence excitation mode.", "offsetInBeginSection": 491, "offsetInEndSection": 621, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a722d9f2dc08e987e000004", "body": "What is mechanism of action of Benralizumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32593131", "http://www.ncbi.nlm.nih.gov/pubmed/31344472", "http://www.ncbi.nlm.nih.gov/pubmed/34289975", "http://www.ncbi.nlm.nih.gov/pubmed/31190733", "http://www.ncbi.nlm.nih.gov/pubmed/30802500", "http://www.ncbi.nlm.nih.gov/pubmed/32133878", "http://www.ncbi.nlm.nih.gov/pubmed/34096329", "http://www.ncbi.nlm.nih.gov/pubmed/33815803", "http://www.ncbi.nlm.nih.gov/pubmed/31033373", "http://www.ncbi.nlm.nih.gov/pubmed/22136436"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165", "text": "Benralizumab is an anti-interleukin-5 receptor \u03b1 monoclonal antibody that depletes blood and airway eosinophils.", "offsetInBeginSection": 215, "offsetInEndSection": 328, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165", "text": "CONCLUSIONS Benralizumab reduced asthma exacerbation and improved lung function and asthma control in adults with uncontrolled eosinophilic asthma.", "offsetInBeginSection": 1393, "offsetInEndSection": 1540, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25306557", "text": "In a phase 2b dose-ranging study, we aimed to assess the efficacy and safety of benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody that depletes blood and airway eosinophils, in adults with uncontrolled eosinophilic asthma.", "offsetInBeginSection": 102, "offsetInEndSection": 342, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28109128", "text": "Benralizumab is a humanized, afucosylated, anti-interleukin-5 receptor \u03b1, immunoglobulin G (IgG) 1 \u03ba monoclonal antibody.", "offsetInBeginSection": 0, "offsetInEndSection": 123, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28109128", "text": "Stochastic simulations supported an every-8-week dosing schedule of benralizumab for a phase IIb study in patients with uncontrolled asthma.", "offsetInBeginSection": 945, "offsetInEndSection": 1085, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29086236", "text": "Benralizumab is a monoclonal antibody that targets interleukin-5 receptor \u03b1 to deplete blood eosinophils and improve the clinical outcomes of allergic asthma.", "offsetInBeginSection": 0, "offsetInEndSection": 159, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28919200", "text": "BACKGROUND Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor \u03b1 monoclonal antibody that has been shown to significantly reduce asthma exacerbations and improve lung function for patients with severe, uncontrolled asthma.", "offsetInBeginSection": 0, "offsetInEndSection": 237, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051", "text": "Anti-IL-5-based therapies (mepolizumab and reslizumab are humanized monoclonal antibodies (hmAbs) that recognize free IL-5, benralizumab is a hmAb directed at the \u03b1 subunit of the IL-5R) target the IL-5-signaling in eosinophilic asthma.", "offsetInBeginSection": 299, "offsetInEndSection": 536, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051", "text": "Other benefits of benralizumab are fast (within 24\u00a0h) depletion of peripheral blood eosinophils, potent suppressive activity of bone marrow eosinophils and eosinophil precursors, tissue eosinophil apoptosis regardless of the presence of eosinophil survival factors and even at low IL-5R densities.", "offsetInBeginSection": 952, "offsetInEndSection": 1250, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25208464", "text": "Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, depletes blood and sputum eosinophils.", "offsetInBeginSection": 131, "offsetInEndSection": 238, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a75f6e083b0d9ea66000009", "body": "Which data simulator is available for CLIP-SEQ experiments?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26776207", "http://www.ncbi.nlm.nih.gov/pubmed/24451213", "http://www.ncbi.nlm.nih.gov/pubmed/30329090", "http://www.ncbi.nlm.nih.gov/pubmed/34874992", "http://www.ncbi.nlm.nih.gov/pubmed/31757204", "http://www.ncbi.nlm.nih.gov/pubmed/24398258", "http://www.ncbi.nlm.nih.gov/pubmed/31598633", "http://www.ncbi.nlm.nih.gov/pubmed/35135477", "http://www.ncbi.nlm.nih.gov/pubmed/31510652", "http://www.ncbi.nlm.nih.gov/pubmed/27812418"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207", "text": "To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data.", "offsetInBeginSection": 325, "offsetInEndSection": 457, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21037263", "text": "In this study, we introduce a novel database, starBase (sRNA target Base), which we have developed to facilitate the comprehensive exploration of miRNA-target interaction maps from CLIP-Seq and Degradome-Seq data.", "offsetInBeginSection": 421, "offsetInEndSection": 634, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24451213", "text": "Here, we present PIPE-CLIP, a Galaxy framework-based comprehensive online pipeline for reliable analysis of data generated by three types of CLIP-seq protocol: HITS-CLIP, PAR-CLIP and iCLIP.", "offsetInBeginSection": 232, "offsetInEndSection": 422, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745", "text": "DESCRIPTION Here, we constructed a database, CLIPdb, to describe RBP-RNA interactions based on 395 publicly available CLIP-seq data sets for 111 RBPs from four organisms: human, mouse, worm and yeast.", "offsetInBeginSection": 426, "offsetInEndSection": 626, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745", "text": "We consistently annotated the CLIP-seq data sets and RBPs, and developed a user-friendly interface for rapid navigation of the CLIP-seq data.", "offsetInBeginSection": 627, "offsetInEndSection": 768, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745", "text": "We applied a unified computational method to identify transcriptome-wide binding sites, making the binding sites directly comparable and the data available for integration across different CLIP-seq studies.", "offsetInBeginSection": 769, "offsetInEndSection": 975, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745", "text": "CONCLUSION Manually curated metadata and uniformly identified binding sites of publicly available CLIP-seq data sets will be a foundation for further integrative and comparative analyses.", "offsetInBeginSection": 1266, "offsetInEndSection": 1453, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745", "text": "Large amounts of crosslinking immunoprecipitation (CLIP)-seq data (including HITS-CLIP, PAR-CLIP, and iCLIP) have been recently produced to reveal transcriptome-wide binding sites of RBPs at the single-nucleotide level.", "offsetInBeginSection": 204, "offsetInEndSection": 423, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26539468", "text": "Our findings can serve as a general guideline for CLIP experiments design and the comprehensive analysis of CLIP-Seq data.", "offsetInBeginSection": 894, "offsetInEndSection": 1016, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21994224", "text": "RESULTS We describe Pyicos, a powerful toolkit for the analysis of mapped reads from diverse HTS experiments: ChIP-Seq, either punctuated or broad signals, CLIP-Seq and RNA-Seq.", "offsetInBeginSection": 355, "offsetInEndSection": 532, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a72302b2dc08e987e000005", "body": "Treatment of which disease was studied in the Gore REDUCE Clinical Study?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29090661", "http://www.ncbi.nlm.nih.gov/pubmed/10847965", "http://www.ncbi.nlm.nih.gov/pubmed/7790748", "http://www.ncbi.nlm.nih.gov/pubmed/30612825", "http://www.ncbi.nlm.nih.gov/pubmed/34144884", "http://www.ncbi.nlm.nih.gov/pubmed/2054076", "http://www.ncbi.nlm.nih.gov/pubmed/26808286", "http://www.ncbi.nlm.nih.gov/pubmed/34773685", "http://www.ncbi.nlm.nih.gov/pubmed/35840046", "http://www.ncbi.nlm.nih.gov/pubmed/28222987"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29090661", "text": "Aims The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "offsetInBeginSection": 194, "offsetInEndSection": 507, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29090661", "text": "The trial should determine whether patent foramen ovale closure with the Gore septal occluders is safe and more effective than medical therapy alone for the prevention of recurrent clinical ischemic stroke or new silent brain infarct; the neuroimaging data will provide an opportunity to further support the proof of concept.", "offsetInBeginSection": 1629, "offsetInEndSection": 1954, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987", "text": "CONCLUSIONS Our multicenter experience with the GORE TIGRIS Vascular Stent demonstrates continued good results\u00a0at\u00a02\u00a0years for endovascular treatment of challenging obstructive superficial femoral artery and popliteal artery disease.", "offsetInBeginSection": 1517, "offsetInEndSection": 1752, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987", "text": "This study therefore investigated the performance of the GORE TIGRIS Vascular Stent at three different centers in France in patients with symptomatic peripheral artery disease.", "offsetInBeginSection": 251, "offsetInEndSection": 427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987", "text": "METHODS This retrospective, single-arm, multicenter cohort study included 215 patients with peripheral artery disease (Rutherford-Becker category 2-6) who were treated with the GORE TIGRIS Vascular Stent, a dual-component stent consisting of a nitinol wire frame combined with a fluoropolymer-interconnecting structure.", "offsetInBeginSection": 430, "offsetInEndSection": 749, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17704480", "text": "The Gore TAG endoprosthesis (W. L. Gore and Associates, Flagstaff, Ariz) was the first to enter clinical trials for the treatment of thoracic aortic aneurysms, confirming its safety and efficacy as well as its short-term advantages over open surgical repair.", "offsetInBeginSection": 104, "offsetInEndSection": 362, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27872317", "text": "METHODS A prospective, single-center pilot study recruited 30 symptomatic patients (mean age 64 years; 18 men) to evaluate the safety and early efficacy of the new Gore balloon-expandable covered endoprosthesis for the treatment of de novo or restenotic common and/or external iliac artery lesions.", "offsetInBeginSection": 115, "offsetInEndSection": 413, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26808286", "text": "BACKGROUND The aim of this study is to assess the safety and the short-term results of endovascular treatment of common iliac artery (CIA) aneurysms using the new GORE EXCLUDER iliac branch endoprosthesis (IBE) device.", "offsetInBeginSection": 0, "offsetInEndSection": 218, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24947948", "text": "The aim of this study is to present our short-terms results in the treatment of laparoscopic paraesophageal hiatal hernia (LPHH) with a synthetic polyglycolic acid:trimethylene carbonate mesh (Gore Bio A(\u00ae)).", "offsetInBeginSection": 317, "offsetInEndSection": 526, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16533688", "text": "Gore TAG endoprosthesis was the first to enter clinical trials in the United States for treatment of descending thoracic aortic aneurysm, and gained the approval of the US Food and Drug Administration for general use in March 2005.", "offsetInBeginSection": 139, "offsetInEndSection": 370, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a760e5583b0d9ea66000018", "body": "Which comparisons demonstrate the applicability of StereoGene in regulatory genomics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29028265", "http://www.ncbi.nlm.nih.gov/pubmed/33327941", "http://www.ncbi.nlm.nih.gov/pubmed/17567996", "http://www.ncbi.nlm.nih.gov/pubmed/15163354", "http://www.ncbi.nlm.nih.gov/pubmed/16407459", "http://www.ncbi.nlm.nih.gov/pubmed/21575713", "http://www.ncbi.nlm.nih.gov/pubmed/35813762", "http://www.ncbi.nlm.nih.gov/pubmed/16179648", "http://www.ncbi.nlm.nih.gov/pubmed/14630651", "http://www.ncbi.nlm.nih.gov/pubmed/15851414"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265", "text": "These analyses provide examples for the broad applicability of StereoGene for regulatory genomics.", "offsetInBeginSection": 1473, "offsetInEndSection": 1571, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265", "text": "We apply our method to numerous comparisons of ChIP-Seq datasets from the Human Epigenome Atlas and FANTOM CAGE to demonstrate its wide applicability.", "offsetInBeginSection": 1062, "offsetInEndSection": 1212, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15814024", "text": "This paper reviews methods of identifying conserved regulatory elements of developmental genes by comparative genomics, including new attempts to detect conserved features beyond simple sequence similarities.", "offsetInBeginSection": 555, "offsetInEndSection": 763, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10207157", "text": "These results demonstrate the utility of genomic sequence comparisons of homologous genes in related species as an effective tool with which to dissect the functional information of complex genes.", "offsetInBeginSection": 821, "offsetInEndSection": 1017, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23175757", "text": "RESULTS We present a framework for reconstructing gene regulatory networks from genetical genomics data where genotype and phenotype correlation measures are used to derive an initial graph which is subsequently reduced by pruning strategies to minimize false positive predictions.", "offsetInBeginSection": 557, "offsetInEndSection": 838, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23175757", "text": "However, although genetical genomics data contain rich information, a clear dissection of causes and effects as required for reconstructing gene regulatory networks is not easily possible.", "offsetInBeginSection": 366, "offsetInEndSection": 554, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23440612", "text": "Its genome has been used in large-scale genome comparisons to locate vertebrate specific regulatory elements and also it has been an excellent model system to test out the predicted DNA sequences for their ability to drive reporter gene expression in vivo.", "offsetInBeginSection": 258, "offsetInEndSection": 514, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23440612", "text": "The sequencing of many vertebrate species over the last decade has opened up the possibility of using comparative genomics as a powerful tool to elucidate regulatory elements in the vertebrate genome.", "offsetInBeginSection": 0, "offsetInEndSection": 200, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567996", "text": "We find that sets of putative transcriptional regulatory sequences, defined by ENCODE experimental data, have a wide span of evolutionary histories, ranging from stringent constraint shown by deep phylogenetic comparisons to recent selection on lineage-specific elements.", "offsetInBeginSection": 201, "offsetInEndSection": 472, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14993210", "text": "CompareProspector outperformed many other computational motif-finding programs, demonstrating the power of comparative genomics-based biased sampling in eukaryotic regulatory element identification.", "offsetInBeginSection": 1375, "offsetInEndSection": 1573, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a72329e2dc08e987e000006", "body": "Falciform ligament sign is characteristic to which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26577973", "http://www.ncbi.nlm.nih.gov/pubmed/23133059", "http://www.ncbi.nlm.nih.gov/pubmed/36188093", "http://www.ncbi.nlm.nih.gov/pubmed/3881894", "http://www.ncbi.nlm.nih.gov/pubmed/26664796", "http://www.ncbi.nlm.nih.gov/pubmed/35047164", "http://www.ncbi.nlm.nih.gov/pubmed/36188082", "http://www.ncbi.nlm.nih.gov/pubmed/29403671", "http://www.ncbi.nlm.nih.gov/pubmed/19184144", "http://www.ncbi.nlm.nih.gov/pubmed/35699804"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059", "text": "Primary tumor of falciform ligament is exceedingly uncommon.", "offsetInBeginSection": 0, "offsetInEndSection": 60, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19716250", "text": "RESULTS All specific air distributions were more frequently present in patients with gastroduodenal perforation than lower GI tract perforation, but only the falciform ligament sign was statistically significant (p<0.05).", "offsetInBeginSection": 1158, "offsetInEndSection": 1379, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19716250", "text": "Regardless of the perforation sites, the falciform ligament sign was present significantly more frequently with an increase in the amount of free air on multiple logistic regression analysis (adjusted odds ratio, 1.29; p<0.001).", "offsetInBeginSection": 1517, "offsetInEndSection": 1745, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26577973", "text": "Pathologies of the falciform ligament are extremely rare entities ranging from cyst and hematoma to abscess and gangrene.", "offsetInBeginSection": 0, "offsetInEndSection": 121, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2003436", "text": "One or more of these signs were present in 26 cases (59%) of pneumoperitoneum, including the right-upper-quadrant gas sign in 18 cases (41%), Rigler's sign in 14 cases (32%), and the falciform ligament and football signs in one case each (2%).", "offsetInBeginSection": 697, "offsetInEndSection": 940, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17322659", "text": "The patient with the falciform ligament disease represents the first reported case of primary torsion and infarction of the falciform ligament, and the patient with the transverse colon epiploica represents the first reported case of vibration-induced appendix epiploica torsion and infarction.", "offsetInBeginSection": 445, "offsetInEndSection": 739, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3881894", "text": "The demonstration of a vessel in the falciform ligament, traditionally presumed to be a reopened umbilical vein, is an important sonographic sign of portal hypertension.", "offsetInBeginSection": 0, "offsetInEndSection": 169, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2910743", "text": "Cullen's sign can be seen to be secondary to the tracking of liberated pancreatic enzymes to the anterior abdominal wall from the inflamed gastrohepatic ligament and across the falciform ligament.", "offsetInBeginSection": 721, "offsetInEndSection": 917, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27938473", "text": "Mesenchymal stem cells (MSCs) were isolated from the liver falciform ligament and abdominal subcutaneous adipose tissue in patients undergoing partial hepatectomy for liver disease.", "offsetInBeginSection": 270, "offsetInEndSection": 451, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27938473", "text": "Falciform ligaments in the liver are surrounded by adipose tissue.", "offsetInBeginSection": 0, "offsetInEndSection": 66, "beginSection": "abstract", "endSection": "abstract"}]}]}